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 Some bicyclam compounds are highly active as HIV inhibitor agents 
with high selectivity for the CXCR4 coreceptor, an important protein 
receptor for the human immunodeficiency virus.  One particular bicyclam, 
AMD3100 (1,1’-(1,4-phenylenebismethylene)-bis-1,4,8,11-tetraazacyclotetra- 
decane, known as xylyl-bicyclam) reached Phase II clinical trials in 2001.  
More recently, it has been relaunched commercially as Mozobil, a stem cell 
mobiliser.  The activity of this macrocycle and configurationally restricted 
analogues as antivirals against HIV, have been shown to increase on 
complexation with zinc.  A range of metals has been studied with varying 
degrees of activity seen, but none show activity comparable with the zinc 
complexes.   
 In order to investigate the chemistry of macrocycles in their role as 
anti-HIV agents, the syntheses of vanadium-cyclam, vanadium-bicyclam and 
zinc constrained cyclam complexes have been carried out.  Of the many 
oxovanadium(IV) cyclam complexes synthesised, those with a sulfate or 
chloride axial ligand trans- to the V=O group were chosen for comparison 
purposes with oxovanadium(IV) bicyclam analogues for both solid state and 
solution analyses.  X-ray crystallography showed that the oxovanadium(IV) 
cyclam complexes crystallised in the thermodynamically stable trans-III 
configuration.  Aqueous solution studies using EPR spectroscopy revealed a 
different behaviour for the oxovanadium(IV) cyclam and bicyclam 
complexes studied.  Results suggested that the 6th axial ligand trans- to the 
V=O group could undergo facile exchange in solution for the cyclam 
complexes but may be retained in the bicyclam complexes.  Antiviral test 
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results for oxovanadium(IV) cyclam complexes revealed these to be 
completely inactive against HIV. 
 Xylyl-bicyclam was synthesised and complexed with vanadium, as 
oxovanadium(IV) sulfate and chloride structures.  EPR spectroscopy results 
suggested that for the bicyclam chloride complex some displacement of the 
6th axial ligand may occur, but the bicyclam sulfate appeared to retain both 
axial ligands.  More importantly, these ligands also appear to have a 
significant effect on the hyperfine coupling constant, A.   
 Antiviral test results for oxovanadium(IV) bicyclam sulfate and 
chloride complexes revealed these to be highly active against HIV, with the 
chloride structure showing similar activity to AMD3100.   
 Possible interactions between the V=O group and the protein 
backbone of CXCR4 were studied using molecular modelling techniques, 
incorporating the X-ray crystal structure obtained for the oxovanadium(IV) 
cyclam sulfate complex.  This revealed the possibility of a weak interaction 
between the oxygen of the V=O group and the proton of the alpha-carbon of 
a tryptophan residue, Trp195.  No metal-carboxylate interaction was seen 
between the vanadium centre and aspartate residue Asp171 in the binding 
site investigated, possibly due to the distance between them being 
unfavourable for formation of a coordination bond (3.4 Å).  Possible 
hydrogen bonding was seen between the carboxylate oxygens of Asp171 and 
the NH protons of the trans-III configured ring.  These studies may 
demonstrate how oxo-metals interfere with the protein backbone in such a 
way as to distort the molecule from an optimum binding geometry.  It may 
also indicate the importance of a second binding site known to support a   
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cis-V configuration of the macrocycle, bearing in mind that vanadium 
bicyclam complexes do show activity as antivirals against HIV.  It is possible 
that one ring of the vanadium bicyclam complexes interacts with the binding 
site for the trans-III configuration in a similar fashion to the cyclam 
complexes and the antiviral activity may result, in this case, from interactions 
formed through binding of the second ring.  The aromatic linker is also 
thought to be important. 
 Cyclams can be constrained by adding bulky substituents and/or 
additional rings to the structure and this has the effect of stabilising one 
configuration.  NMR studies show how a zinc constrained cyclam retains the 
trans-III configuration in solution and also shows high activity against HIV, 
comparable with the vanadium bicyclam sulfate complex.  This emphasises 
how the oxo-vanadium cyclams must be in an unfavourable position and 
unable to form crucial interactions known to be important for antiviral 
activity.  A 4-coordinate zinc constrained macrocycle showed unusual 
binding to three ring nitrogens and may reveal an intermediate species in the 
uptake and release of metals by cyclams.  Further complexation by exchange 
of the axial ligand revealed a 5-coordinate zinc bound to all four nitrogens on 
the ring.   
 This thesis provides the first investigation into the role of                 
oxo-vanadium complexes as antiviral agents against HIV looking at possible 
interactions of the oxo-metal group with the protein backbone of the CXCR4 
receptor.  An investigation into configurational change in solution for zinc 
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1. INTRODUCTION 
1.1.    Bioactivity of macrocycles 
  The biochemistry of organic macrocycles has long been utilised by 
Nature to enable some of the most important processes essential for the 
continuation of life.  Prime examples include i) the transport and storage of 
oxygen in mammalian and other respiratory systems and ii) the mechanism 
of photosynthesis.[1] In these examples structurally related organic 
macrocycles are found as metal complexes. Iron-porphyrin complexes 
involved in the majority of dioxygen binding processes are associated with 
haem proteins and this porphyrin family of natural macrocycles provides a 
chemical ring system upon which many biologically important molecules are 
based.  Much research has been done concerning the synthesis of compounds 
that mimic biological species involved in processes such as dioxygen 
activation and electron transfer.   
 The latter process is associated with photosynthesis, another 
important biochemical mechanism. The chlorophylls form part of the 
structurally related family of chlorin macrocycles that function as 
magnesium complexes in the conversion of light energy to chemical energy 
in green plants.  In chlorins, the porphyrin structure is altered by the 
addition of another 5-membered ring and a long hydrocarbon chain for 
orientation of the molecules during the photosynthetic process.  The same 
tetrapyrrolic structure of porphyrin and chlorin is again employed by Nature 
to produce another important family of macrocycles known as the corrins 
that include vitamin B12.  The corrins are a partially reduced form of 
porphyrin where a meso carbon atom is replaced by a direct C-C bond.  This  
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ring system is found within the group of vitamin B12 cobalt complexes.  The 
cobalt ion is axially bonded to both a heterocyclic nitrogen donor and a 
cyanide ligand, a result of the particular purification process adopted.[2]   
Figure 1.1 shows the structures of the Fe(II) complex haem, 1 and the 
chlorophyll a molecule, 2.  
                                                                                                                      
Figure 1.1      A metal complexed porphyrin structure – haem 1, and the modified 


















































Fe(II)Protoporphyrin 9, 1    
Chlorophyll a, 2    
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It is believed that these ligands are important in Nature because of their 
enhanced kinetic and thermodynamic stabilities arising from the firmly held 
metal ion within the cyclic cavities.  In addition, the planar delocalised 
electronic structure is a key characteristic.  As Nature has chosen to use 
macrocyclic structures for such fundamental processes, it would seem 
reasonable to apply synthetic derivatives for medicinal application in a 
physiological frame.[1]  
1.1.1. Synthetic Macrocycles 
 A large number of macrocyclic compounds with complexed metal 
ions have been prepared and investigated.  Cyclic polyamines in particular 
bind to a wide range of metals and in many cases show configurational 
changes during binding.[3]  For the coordination chemist, macrocyclic ligands 
are usually defined as having at least 3 donor atoms and a minimum of 9 
atoms forming the ring.  The donor atoms can either be integrated within or 
alternatively (although much less common), attached to a cyclic backbone.  
Much of the coordination chemistry is defined by steric and electronic 
considerations associated with the macrocyclic cavity, the size of which plays 
a large part in influencing the properties of resultant metal complexes.  The 
actual hole-size of a cyclic ligand is dependent upon the number of atoms in 
the macrocyclic ring; the nature of the donor atoms possibly playing a role in 
affecting the cavity size.[1]  Many variations of both organic backbone and 
donor atom combinations exist, some of which have proved active in a 
medicinal capacity while others are successful in applications as diverse as 
microelectronic devices and sensors.[4, 5] 
 The chemistry of macrocyclic ligand complexes has important 
implications for many areas of biochemistry with commercial application as 
 
  4 
contrast agents for magnetic resonance imaging (MRI),                 
radionuclide-directing agents within the field of radiopharmaceuticals and 
more recent application as anti-viral compounds and stem cell mobilising 
agents.  In addition, high intensity γ-ray emitters such as 99mTc, 67Ga and β 
emitters such as 89Sr and 153Sm are used in diagnostic imaging and therapy 
respectively.[6, 7]  A highly successful commercial example in the field of 
magnetic resonance imaging (MRI) is a chelated non-radioactive metal ion 
complex known as Gd-DOTA, a Gd(III) complexed 12-membered ring 
1,4,7,10-tetraazacyclododecane (cyclen) shown in Figure 1.2.  For MRI 
procedures the required dose of paramagnetic ion is very high in order to 
obtain a clear image, resulting in high toxicity levels.  Chelation by 
macrocycles not only reduces the acute toxicity but also helps to increase the 
rate of elimination from the body.  As a result, this reduces long-term toxic 
effects and is why macrocyclic complexes have been so successful in this 
field.  Gd(III) is paramagnetic and 8-coordinated to the macrocycle donor 
atoms (4 nitrogen and 4 carboxylate groups) with a 9th inner sphere 
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Figure 1.2      1,4,7,10-tetraazacyclododecane (cyclen) 3, and a tetra-carboxylate 
gadolinium (III) complex (Gd-DOTA), 4  
 
 
 In radiopharmaceutical agents, a macrocycle is often used to bind the 
radionuclide used to kill the cancer cells found in tumours.  A target-specific 
metalloradiopharmaceutical consists of a targeting biomolecule, a linker, a 
BFC (bifunctional chelator) and a metallic radionuclide.  The BFC is an 
intentionally designed polydentate chelator that binds strongly to the 
radionuclide through complexation and through covalent attachment of the 
targeting molecule to its backbone.  This interaction can be through a linker 
molecule, often used to modify the pharmacokinetic properties of the 
radiopharmaceutical, such as a hydrocarbon chain to increase lipophilicity 

























Figure 1.3       Schematic representation of a metalloradiopharmaceutical and                 
           tumour receptor 
 
It is crucial that the BFC forms a stable metal chelate and is kinetically inert at 
physiological pH.  A slow rate of dissociation in solution is essential to avoid 
accumulation of radioactivity in non-targeted organs.  Isotopes such as 67Cu 
and a number of radiolanthanides possess the required therapeutic 
properties while others are more suitable for diagnostic imaging.[9]   
 Cyclic polyethers (crown ethers) form another large family of ligands 
with varying numbers of donor atoms and subsequent ring sizes.  These 
show similar coordination chemistry to that of natural antibiotics like 
nonactin.  These macrocycles can also be structurally altered and numerous 
derivatives with varying degrees of substituent functionality are known.[2] 
Mixed donor atoms within macrocyclic ligands are also widely used, having 
selectivity for metal ion binding and different bonding preferences.  
Combinations include N,O-donor compounds representing a mixture of 
azamacrocycles and crown ethers while others include softer donor atoms 
such as phosphorus, selenium and sulfur.  The latter has been shown to have 
rich coordination chemistry in the form of thiacrown ethers.[2] 
biomolecule linker receptor 
chelate 
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1.2.    HIV and AIDS 
 Acquired Immunodeficiency Syndrome (AIDS) has killed more than 
25 million people since the effect of the Human Immunodeficiency Virus was 
first reported in 1981, making it one of the most destructive epidemics in 
recorded history.[10]  The 2007 AIDS epidemic update by UNAIDS (Joint 
United Nations Program on HIV/AIDS) reports that global estimates for 2007 
are:[10]  
Total number of people living with HIV in 2007:                    33.2 million                                                
[30.6 - 36.1 million] 
Adults living with HIV in 2007:                                                  30.8 million                                         
[28.2 – 33.6 million] 
Women living with HIV in 2007:                                                15.4 million                                         
[13.9 – 16.6 million] 
Children under 15 years living with HIV in 2007:                     2.1 million                       
[1.9 - 2.4 million]         
                     
The disease is caused by the Human Immunodeficiency Virus (HIV) - a 
retrovirus that attacks the immune system.  Retroviruses contain an RNA 
genome that relies on the reverse transcriptase enzyme in order to replicate 
via the host cell DNA.  HIV is classified as belonging to a subgroup of 
retroviruses called lentiviruses, characterised by their long incubation period.  
Other lentiviruses include SIV (Simian Immunodeficiency Virus) and FIV 
(Feline Immunodeficiency Virus).  Infection of a cell requires particular 
surface proteins that act as receptors for specific envelope proteins of the 
retrovirus.   
 
  8 
1.2.1. Polyoxometallates 
 The first polyoxometallate that proved active against HIV (HPA-23 
[(NH4)17Na(NaSb9W21O86).14H2O]) was produced by Rozenbaum et al. in 
1985.[11]  This led to a search for similar compounds with the ability to 
suppress HIV replication without being cytotoxic to the host cells and the 
process of examining hundreds of polyoxometallates began in earnest.  This 
work resulted in examples such as JM1493, 5 and JM2820, 6 in the 1990s 
(Figure 1.4) illustrating the proposed structures of potential anti-HIV agents 
at that time.[11]  These polyoxometallates are seen as globular or spherical 
polyanionic structures with anionic charge arising from peripheral oxygen 
atoms.  
 In the course of treatment of HIV and AIDS a potential anti-viral agent 
may require to be administered over a prolonged period of time.  The 
outcome of such treatment would probably result in deposition of the 
compound in the body, thought to be mainly in the liver.  This led to the 
recommendation that incorporation of metals in an organic macrocycle, not 
dissimilar to those used in nature for fundamental biochemical processes, 





















                                                          JM1493 H4SiW12O40, 5                                                                   












                                              JM2820 [Me3NH]8[Si2W18Nb6O77], 6                                                                                      
                   ( Si – white, W – cyan, Nb – dark blue) 
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1.3.    Existing Drug Treatments 
 The drug treatments used today in the treatment against HIV infection 
and associated AIDS disease are primarily associated with post-infection and 
are classified as follows. 
1.3.1.  Reverse Transcriptase Inhibitors (RTIs) 
 These antiretroviral drugs inhibit the enzyme reverse transcriptase, 
essential for successful replication of HIV.  There are three known types of 
RTI; Nucleoside Analogue Reverse Transcriptase Inhibitors (NARTIs or 
NRTIs), Nucleotide Analogue Reverse Transcriptase Inhibitors (NtARTIs or 
NtRTIs) and Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs).  
Both NRTIs and NtRTIs act in a similar way (via phosphorylation steps) and 
their mechanism of action is through chain termination of viral DNA.[12]  
Three examples are shown in Figure 1.5:  Zidovudine is also known as AZT, 
ZDV and azidothymidine, trading commercially as Retrovir.  Didanosine has 
trade names Videx and Videx EC.  Alcabar, also known as ABC, has the trade 
name Ziagen and is an analogue of guanosine (a nucleoside).  
 
 












Figure 1.5                       Zidovudine, 7;   Didanosine, 8;   Abacavir, 9 
 In contrast, NNRTIs mode of action occurs by blocking the movement 
of protein domains of reverse transcriptase essential for carrying out DNA 
synthesis.  NNRTIs are bound in a hydrophilic pocket close to the catalytic 
site of reverse transcriptase in HIV-1.  The major problem with these 
antivirals is the continual ability of HIV-1 to form resistant strains in vitro 
and in vivo.[13]  These drugs are not incorporated into the viral DNA unlike 
NRTIs.  Figure 1.6 shows some current examples from this class of 
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1.3.2. Protease inhibitors (pharmacology) 
 It is important to distinguish between natural protease inhibitors and 
protease inhibitors associated with antiviral activity.  Natural protease 
inhibitors inhibit the function of peptidases by digesting long protein chains 
into short fragments and are associated with physiological processes.  
Protease inhibitors (pharmacology) are a class of antiretroviral drugs that 
inhibit the function of HIV-1 protease.  HIV-1 protease is an enzyme essential 
to the life-cycle of the virus used to cleave newly synthesised polyproteins.  
Without effective HIV-1 protease new virions remain non-infectious, 
resulting in new virions that are unable to infect new cells. 
 Structural analysis revealed that inhibitor drugs like Darunivir, 15 
interact closely with Asp29 and Asp30 in the active site and these carboxylate 
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1.3.3. Entry inhibitors 
 The biological target of entry inhibitor drugs is specific protein 
receptors expressed on the surface of Helper T-cells (a type of white blood 
cell or leukocyte) found in the immune system.  CD4 (cluster of 
differentiation 4) is a glycoprotein receptor and the primary receptor used by 
HIV-1 to gain entry to host cells.[16-18]  Binding of the virus to CD4 occurs 
through attachment of the viral envelope glycoprotein, gp120 and through 
this association the virus gains access to a very important receptor, CXCR4.  
The interaction with CXCR4 enables the virus to fuse with the cell 
membrane, gaining entry to the cell where it effectively discharges the viral 
RNA, leading to replication and the onset of infection.[12]  CXCR4 is 
associated with HIV infection at later stages of AIDS disease when the 
immune system deteriorates rapidly.  Another cell surface protein used by 
the virus is CCR5 (CC chemokine Receptor 5), found on Helper T-cells and 
macrophages and is associated with the transfer of HIV through body fluids.  
Nomenclature and classification of these chemokine receptors is based on the 
arrangement of four conserved N-terminal cysteine residues that are 
important in determining the protein tertiary structure.[19]  The abbreviation 
CC refers to the proximity of two cysteine residues.  CCR5 has adjacent 
cysteines whereas in CXCR4 they are separated by one amino acid.   
1.3.3.1. Fuzeon 
  T-20 (Enfuvirtide, Fuzeon) was the first of a new class of anti-
HIV drugs known as entry (or fusion) inhibitors, named for their ability to 
prevent the virus binding to and entering the cell.  T-20 is an approved anti-
HIV peptide developed by Trimeris Pharmaceuticals and Roche in 2003.  The 
viral entry process of Human Immunodeficiency Virus type 1 (HIV-1) into 
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target cells is assisted by envelope glycoprotein gp41.[20] Envelope 
glycoproteins gp120 and gp41 of HIV-1 are both involved in viral entry into 
target cells.  GP120 interacts with the cell surface protein receptor CD4 and 
coreceptor CXCR4, after which gp41 enables the fusion of viral and cellular 
membranes.[21]  It is believed that formation of a six-helical bundle structure 
consisting of a gp41 N-terminal heptad repeat (NHR) and C-terminal heptad 
repeat (CHR) facilitates this interaction.[22]  The mechanism of action of T-20 
is thought to be through binding to gp41, preventing fusion with important 
cell surface receptors on Helper T-cells.   
1.3.3.2. Maraviroc 
 Maraviroc is an entry inhibitor that specifically targets the chemokine 
receptor, CCR5.  Importantly, Pfizer’s Celsentri® (maraviroc), is the first new 
oral class of HIV treatment and was licensed by the European Agency for the 
Evaluation of Medicinal Products (EMEA) in September 2007.  Maraviroc 
works by blocking entry of the virus into human immune (CD4) cells, 
preventing HIV from entering and replicating.  It is licensed for treatment of 
patients infected with only CCR5-tropic HIV-1 (in combination with other 
antiretroviral drugs)  Currently, all other available oral HIV medicines target 
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1.3.3.3. AMD3100 
 The small molecular CXCR4 antagonist xylyl-bicyclam, Figure 1.8, 16 
(AMD3100) was the first CXCR4 antagonist to enter clinical trials for 
treatment of HIV infection.[24]  A chance discovery in a contaminated batch of 
cyclam (1,4,8,11-tetraazatetradecane) Figure 1.8, 17 showed distinct anti-HIV 
activity at an EC50 value of ~10 μg per mL.  Typically, polyoxometallates 
showed an EC50 value of ~ 1 μg per mL.  The impurity was identified 
through HPLC analysis as the bicyclam JM1657 Figure 1.8, 18 - a cyclam 
dimer with macrocyclic rings connected through a C-C bond.  Development 
of a linker molecule that would effectively hold the two cyclam rings 
together resulted in AMD3100.  By changing the C-C bond (which proved 
difficult to replicate) to an aromatic bridge, an EC50 value of 0.005 μg per mL  
was obtained and it had one of the highest selectivity indices recorded for 
anti-HIV agents.[11]  At physiological pH, each cyclam ring carries an overall 
2+ charge and can adopt the stable trans-III (RRSS) configuration with respect 
to the four nitrogens.  It is suggested that negatively-charged aspartate 
residues found in the CXCR4 receptor (Asp171, Asp262), may provide crucial 
binding sites for interaction with the positively charged bicyclam rings via 
hydrogen bonding.[25]  Using bovine rhodopsin as a template for CXCR4 
(PDB Code 1HZX), in-silico docking predictions showed that two nitrogens 
of one cyclam ring can interact with two carboxylate oxygens of an aspartate 
residue, Asp262 and two nitrogens of the other cyclam ring with two 
carboxylate oxygens of a glutamate residue, Glu288.[26] 
 Although AMD3100 binds specifically to CXCR4 and is effective as an 
anti-HIV agent, it was withdrawn from Phase II clinical trials in May 2001 
due to cardiotoxicity.  It has been suggested that toxicity may result from 
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metal complexation affecting ring coordination through isomer 
configurational binding.[24]  A particular disadvantage was its lack of oral 
bioavailability.  Several analogues have been prepared retaining the aromatic 
linker while substituting one or both rings by N-containing basic centres 
capable of binding to acidic residues.[24, 27]  Varying levels of activity 
suggested the possibility of spatial importance of the aromatic ring.  
Replacement by a saturated cyclohexane ring rendered the analogues 
completely inactive leading to the conclusion that a central linker with planar 
or near planar geometry is crucial for maintaining activity.[24] 
1.3.3.4. Metal Complexes 
 A study into protein recognition of macrocycles has shown how the 
affinity of bicyclam for CXCR4 is enhanced further by binding to Ni(II) or 
Zn(II).[28]  It can be illustrated that anti-HIV activity is very much dependent 
upon the bound metal and a Zn(II)-bicyclam complex showed slightly higher 
biological activity than the metal-free ligand.  Experiments predict an order 
of activity for the following metals tested:  Zn(II)  >  bicyclam  ~  Ni(II)  >  
Cu(II)  >  Co(III)  >>>  Pd(II).  The Pd(II) complex is shown to be virtually 
inactive.[29-31]  This is discussed further in Section 1.4.2.   
 By exploring the structure of protein-cyclam adducts, structural 
insight into specific hydrophilic and hydrophobic interactions involved in 
the binding of bicyclam to CXCR4 can be gained.  In addition to known 
interactions with aspartate and glutamate residues there is a distinct 
possibility that the hydrocarbon backbone of the bicyclam rings is involved 
in hydrophobic interactions with tryptophan residues, Trp195 and Trp283.[32]  
This particular interaction is comparable to that of the hydrophobic contact 
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of the side-chains of proline with tryptophan found at some protein-protein 
interfaces, commonly described as a Trp-Pro-Trp sandwich.  If these 
macrocycles exist as metal complexes in vivo, then it is pertinent to ask how 
this would affect levels of essential elements in the body and what the long-
term effect may be.  Cyclam has a high affinity for Zn(II) (log K = 15.5) [33] and 
it has been calculated that in the case of AMD3100 nearly all the drug would 
exist as a Zn(II) complex at physiological pH of 7.4.  The kinetics of Zn(II) 
binding with cyclam at pH7 show that uptake is relatively rapid.[34]  
Competitive experiments show that Zn(II) has a higher uptake rate than 
Cu(II) - important information as Cu(II) may be a competitor for bicyclam.  
Cu(II) is shown to have a stronger affinity for cyclam than zinc and so could 
form preferentially in vivo, but the complexes are biologically less active.  The 
ability of Zn(II) to exert kinetic control over the uptake of Cu(II) into specific 
binding sites is shown and a rate for the disappearance of “free” Cu(II) on 
addition to cyclam is determined.[34]  The uptake of Cu(II) appears to be 
markedly slower in the presence of Zn(II) under these particular 
experimental conditions and suggests that Zn(II) binds more rapidly to 
cyclam at physiological pH of 7.4.  Further investigation is therefore required 
in regard to the wider significance in biology for these complexes and their 
interactions with proteins.  
 The selectivity of CXCR4 for bicyclams is well researched and the 
affinity for CXCR4 is enhanced through metal ion binding of an AMD3100 
complex to the aspartate residue, Asp262. [28, 35]  An investigation [36] into the 
structure and dynamics of metallo-macrocycles showed how the CXCR4 
receptor binds preferentially to a zinc complexed bicyclam and that the two 
macrocyclic rings in a perchlorate complex exist as two major configurations, 
trans-I and trans-III (Figure 1.9) in aqueous solution.  Addition of acetate to 
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represent the carboxylate side chains of Asp171 and Asp262 induced a major 
structural change such that the two rings exist in aqueous solution as          
cis-V/trans-I.  A definition of the six possible configurations cyclam can adopt 
on complexing with a metal ion was proposed over 40 years ago[37] and it is 
generally regarded that the trans-III configuration is the most 
thermodynamically stable isomer.  An homology model of CXCR4 was 
produced using the structure of bovine rhodopsin as a template and           
cis-V/trans-I Zn2-bicyclam was docked with the cis-V macrocycle coordinated 
to Asp262 through a Zn(II)-carboxylate interaction, and through double N-H 
H-bonds to the oxygens of Glu288.  The trans-I macrocycle is bound to the 
oxygens of Asp171 through a Zn(II)-carboxylate interaction (Figure 1.10).  It 
is thought that the high anti-HIV activity of Zn(II)-bicyclam may arise 
through retention of the cis-V configuration in one of the macrocycles.[36] 
 Recently, a configurationally restricted bismacrocyclic CXCR4 
receptor antagonist showed increased levels of activity against HIV.[38]  The 
zinc complex of an ethylene bridged analogue of AMD3100 revealed a lower 
EC50 value than AMD3100 and [Zn2-AMD3100]
4+ and showed the highest 


























Figure 1.9  Configurations of metal-cyclam                                                       
   The trans-III configuration is highlighted as the most stable  
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AMD3100 (xylyl-bicyclam, Figure 1.8, 16) has now made an impact in stem 
cell research.  CXCR4 receptors are also expressed in bone marrow and by 
binding to the receptor the drug promotes the release of stem cells from bone 
marrow into the blood stream.  The natural ligand of CXCR4 is stromal cell-
derived factor-1 (SDF-1), responsible for directing migration of 
hematopoietic cells from foetal liver to bone marrow.[40]  Blocking of SDF-1 by 
AMD3100 triggers a rapid movement of stem cells from the bone marrow to 
the circulating blood where they can be easily collected for transplant 
purposes.  Stem cell mobilisation is presently at the forefront of scientific 
research in the pursuit of non-invasive methods to treat the depressed 
immune systems of post-chemotherapy patients.  In fact, any physiological 
tissue or muscle where cells do not normally regenerate after destruction or 
injury could potentially benefit from this type of therapy, such as cardiac 
therapy.  Another major area of interest that would benefit from stem cell 
treatment is brain disease such as Alzheimer’s.  AMD3100 has been re-
launched commercially as Mozobil and is currently undergoing its second set 
of Phase III clinical trials against Hodgkin’s and Non-Hodgkin’s Lymphoma 
as a stem cell mobiliser.  
1.4.   Cyclam and bicyclam 
Macrocycles such as cyclam and bicyclam are highly protonated and bind 
transition ions to form a range of trans (I-V) and cis configurations (Figure 
1.9).  These configurations may be recognised independently by different 
coreceptor proteins.  Reported pKa values for cyclam show a high affinity for 
the first two protonations (average pKa1 11.4, pKa2 10.3).[41-44]  Values of pKa3 
and pKa4 show much weaker affinities (1.6 and 1.9 respectively) due to steric 
restrictions and electrostatic repulsions from the first two protonations.  The 
 

















































restricted geometry may allow the nitrogen lone pairs to overlap, resulting in 
high electron density within the cavity.   
Table 1.1   Protonation values for cyclam 
pKa1 pKa2 pKa3 pKa4 Conditions Ref 
11.49 10.24 1.64 0.86 Unknown 39 
11.585 10.624 1.611 2.415 0.5 M KNO3, 25˚C 40 
11.3 10.23 1.43 2.27 0.1 M NaNO3, 25 ˚C 41 









Figure 1.11                     Protonation steps for cyclam and bicyclam complexes  
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 Macrocyclic amines form stable complexes with almost all transition 
metal ions.[45]  The stability is associated with the “chelate effect” and an 
example of how an increase in the number of chelate rings is related to the 
entropic factor.  Other contributions arise from metal ion size and ring cavity 
area.  Cu(II)-cyclam is more stable (log K = 30.5) than the equivalent             
15-membered macrocycle complex (log K = 24.4).[45]  The stability of these 
complexes reveals why cyclam is not used in selective metal extraction.   
1.4.1. Configurational isomers and transition metal complexes 
 It is expected that particular ring configurations play a crucial part in 
determining the antiviral activity of macrocyclic complexes.  Metallo-
complexes of cyclam and bicyclam in solution give rise to several different 
configurational isomers, each dependent on the chirality of the 4 ring 
nitrogens.[3]  Metal coordination to cyclam (or bicyclam) gives rise to 5 
possible ring configurations, the stereochemistry of the NH protons 
described as RSRS, RSRR, SSRR, RSSR and RRRR.  These five configurations 
are designated trans-I to trans-V respectively.  Two trans- isomers show NH 
protons across the macrocycle cavity diagonal pointing in the same direction 
(trans-I and trans-V).[36]  It is expected in this instance that the macrocycle is 
able to fold across such a diagonal leading to the isomers, cis-I and cis-V 
(Figure 1.9).  Research has shown that trans-I, II, III and cis-V configurations 
are significant for potential bioactivity in metallo-macrocyclic antiviral 
compounds.[36, 38, 46]  Antiviral activity of cyclam and its derivatives is thought 
to be significantly influenced by metal complexation and subsequent binding 
with carboxylate oxygens of acidic amino acid residues in the binding site of 
CXCR4.   
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Transition metal complexes favouring square planar geometries are found 
predominantly in the trans-I configuration while octahedral complexes 
favour trans-III.  Analysis of all nickel(II) cyclam complexes in the Cambridge 
Structural Database (CSD) shows the most common configuration to be  
trans-III, so deemed the most stable configuration.  Less than 23% of 
octahedral nickel(II) complexes with a 1,4,8,11-substituted cyclam backbone 
adopted the trans-I configuration compared with more than 75% preferring 
trans-III.[47]  This situation is reversed for square-planar, square-pyramidal 
and trigonal-bipyramidal complexes with less than 30% adopting trans-III 
and the majority showing a preference for the trans-I configuration.  
Repeated analyses for copper(II) complexes resulted in similar findings.[48]  
Different metal complexes show varying levels of anti-HIV activity revealing 
a relationship between the metal-cyclam geometry and the number of 
binding site interactions possible.   
 Studies undertaken[49] also assume the biological target to be the 
coreceptor protein CXCR4 and experimental work employed the use of 
acetate ligands to represent carboxylate oxygens.  Pd(II)-cyclam retains a 
trans-III configuration in both solid state and solution.[49]  Varying the 
counterion had no effect on ring configuration and addition of acetate did 
not induce any configurational change in the bicyclam analogue.  Ni(II)-
cyclam  adopted the thermodynamically stable trans-III configuration in the 
solid state with axial counterions, but in solution produced both a 
diamagnetic square-planar trans-I configuration in addition to a 
paramagnetic isomer.  The bicyclam analogue contained a mixture of 
paramagnetic-paramagnetic, paramagnetic-diamagnetic and diamagnetic-
diamagnetic species with different configurations for each combination.  
Both Cu(II)-cyclam and bicyclam were  found to be trans-III in the solid state 
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(H2O axial ligands, acetate counter ion) and in solution.  Co(III)-cyclam 
adopted the trans-III configuration in the solid state (acetate axial ligands), 
but solution studies showed the existence of three different configurations 
(trans-III, trans-I and a further unidentified trans- configuration).  The 
bicyclam analogue formed intermediate species on reacting with acetate that 
equilibrated to the trans-III isomer with time.[49]  All complexes showed a 
marked contrast to results found for Zn(II)-cyclam and bicyclam where 
addition of excess acetate produced a higher proportion of the cis-V isomer.  
Zn(II)-bicyclam has been shown to exist in three configurations in solution, 
trans-I, trans-II and cis-V and formation of the cis-V configuration is driven by 
addition of excess acetate.[36]  
1.4.2. Constrained Cyclam Complexes  
 Various analogues of cyclam have been prepared using a range of 
substituent functional groups and examples include dioxocyclams and  
cross-bridged cyclams.[3]  The constraining bridge is of particular interest as a 
means of retaining a rigid structure in one configuration, as cyclam is known 
to exist as several isomers in solution (Figure 1.9).  It has been suggested[34] 
that studies using configurationally-restrained cyclams may provide some 
insights into the mechanism of action of (apo) cyclam drugs in vivo and the 
role of metal complexation.   
 Some tetraaza macrocyclic ligands containing pendant arms with 
varying organic groups have been synthesised.[50]  The rate of metal complex 
formation of these compounds is shown to be retarded due to the steric 
congestion around the macrocycle by the introduction of pyridylmethyl or 
phenylmethyl pendant arms.  A zinc complex of a constrained cyclam 
bearing two cyclohexane rings and two methyl groups shows an unusual 
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crystal structure in that the Zn(II) ion is found in an axially-elongated 
octahedral environment with two trans- water molecules and four equatorial 
nitrogen atoms from the macrocycle.[51]  This contrasts with previous work on 
mononuclear complexes of macrocyclic polyamines where coordination 
environments are usually found to be distorted tetrahedron or square 
pyramidal with only one water molecule bound to zinc(II) ions.[45, 52, 53] 
 In bicyclam, addition of an ethylene bridge between adjacent 
nitrogens results in formation of a piperazine ring on each macrocycle.[38]  
The induced steric restriction keeps the ring configuration as trans-II on 
metal complexation.  Studies have shown how such a restriction may favour 
a five-coordinate Cu(II) species on protein binding, in contrast to a distorted 
octahedral zinc(II) species for the same ligand.[54]  Solution studies analysed 
by NMR spectroscopy showed that the zinc complex was present in a single 
configuration and showed the highest recorded activity to date against HIV.  
The mechanism of antiviral activity is expected to be the same as for the 
bicyclams, through binding interactions with CXCR4.[38]  The trigonal 
bypyramidal geometry of the Cu(II) complex provides an interesting 
perspective on expected protein binding interactions and this study 
correlates antiviral activity with associated binding strength of carboxylates. 
 Configurational restriction of the macrocycle in some cases appears to 
increase antiviral activity[54] and may even provide increased kinetic stability 
in vivo.[55, 56]  This led to the idea explored in this thesis that it would be 
interesting to study cis-V constrained macrocycles in this context due to the 
high antiviral activity recorded for this predominant configuration in        
Zn2-bicyclam.  
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1.4.3. Proposed mechanism of antiviral activity 
 It is suggested that viral gp120 (the glycoprotein envelope) is an 
indirect target of bicyclam compounds.  Using time-of-addition experiments, 
results indicate that bicyclams interact with an early post-adsorption stage in 
the replication cycle of the virus and that the mode of action is through entry 
inhibition of HIV into the cell.[11]  No viral DNA was detected in PCR 
(polymerase chain reaction) experiments after infection of cells with HIV in 
the presence of AMD3100.  The inhibitory effect was                   
concentration-dependent, leading to possible viral uncoating as the target.  
However, this step cannot be assayed directly and so studies have been 
directed toward the binding and fusion of the virus.[57]  It is well documented 
that one mode of entry for HIV into the cell is through interaction with a 
specific receptor expressed on the surface of white blood cells (Helper          
T-cells) and explains why HIV affects the immune system.   
 Bicyclams are targeted at CXCR4, the coreceptor for T-tropic HIV-1 
and HIV-2 strains and competitive binding experiments between the 
bicyclam AMD3100 and monoclonal antibody 12G5 mAb that reacts 
specifically with CXCR4 have been carried out.[58]  By blocking the interaction 
with CXCR4, the virus is denied access to the cell preventing the onset of 
infection.  At 25 μg/mL, AMD3100 completely inhibits the binding of the 
12G5 mAb by binding directly and specifically to CXCR4.[58]  At a 
concentration of 0.2 μg/mL AMD3100 still affects the binding of 12G5 mAb to 
CXCR4.  The specificity of AMD3100 for the CXCR4 receptor has been 
determined acting on the premise that the compound should only be active 
against viruses that use CXCR4 as a coreceptor to enter the target cells.  
AMD3100 is active against T-tropic viruses (IC50 between 0.003 and            
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0.01 μg/mL) but not active against M-tropic viruses (IC50 > 25 μg/mL).          
M-tropic viruses are known to preferentially use the CCR5 receptor, 
although some can also use CCR2 and/or CCR3 (but not CXCR4) to enter 
cells.  It has also been shown that there is no interaction of AMD3100 with 
any of the chemokine receptors CXCR1 through CXCR3, or CCR1 through 
CCR9.[19]  It is interesting to note that no reports in the literature give any 
indication of whether AMD3100 could be involved in binding to other 
receptors from the same superfamily of proteins; the 7-helix transmembrane 
family, for example D6 (CCPB2). 
1.4.4. Metalloporphyrins 
 Porphyrins are macrocycles comprised of four pyrroles linked by four 
methine bridges.  Although metalloporphyrins exhibited potential as anti-
HIV agents, in terms of potency and selectivity they were analogous to 
polyoxometallates[11], somewhat less than that of the serendipitously 
discovered macrocycle, bicyclam.   
 There are several reported accounts of particular porphyrins that 
display antiviral activity against HIV infection, with results obtained using 
viral replication inhibition assays.[59, 60]  One investigation involved the 
possible antiviral activity of natural porphyrins related to protoporphyrin 
and other associated structures.  None of the compounds tested met the 
criteria for successful inhibition of HIV infection.[61]  Metalloderivatives were 
subsequently evaluated; compounds with no axial ligands were more 
effective at preventing infection.  A possible mechanism for activity may 
involve porphyrin binding to the V3 loop of viral envelope glycoprotein 
gp120, thereby blocking access to the CD4 receptor.  It would appear that the 
axial ligands are involved in steric restrictions with the biological target. 
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 Expanded porphyrins are mimics of natural porphyrins, designed in 
such a way as to incorporate an array of metal ions.  These ligands have such 
a large degree of structural freedom that they are able to accommodate all 
sizes of metal ion, including small ions like vanadium(V).[62]  Such            
high-oxidation state vanadium compounds are thought to hold promising 
medicinal properties, including anticancer, antiviral and insulin-mimetic 
activity.[63-67] 
1.5.   Vanadium as a bioactive metal 
1.5.1. Vanadium 
 Vanadium was named after Vanadis, the Norse goddess of beauty, 
due to its tendency to form compounds and solutions with a wide variety of 
colours.  Although a range of oxidation states from -1 to +5 exist, biologically 
relevant oxidation states are limited to +3 to +5.  Table 1.2 shows the 
reduction potentials of vanadium in aqueous solution.[68]  
Table 1.2    Reduction potentials in aqueous solution [68] 
Reduction reaction                                                    E˚ (V vs. NHE) 
O2 + 4H
+ + 4e-                 2H2O                                             1.229 
VO2
+ + 2H+ + e-                          VO2+ + H2O                                   0.991 
VO2+ + 2H+ + e-                          V3+ + H2O                                      0.337 
V3+ + e-                             V2+                                                                                   -0.225 
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 Vanadium is known to be of essential importance in some biological 
processes and described as an essential mineral or trace element in human 
physiology.  Haloperoxidases are enzymes that catalyze the oxidation of 
halides (iodide, bromide and chloride) by hydrogen peroxide, resulting in 
halogenation of organic substrates.  Two classes of haloperoxidases are 
known, the vanadium- and Fe-heme-containing enzymes.  Within the class of 
vanadium-haloperoxidase enzymes, both vanadium bromoperoxidases      
(V-BrPO) and vanadium chloroperoxidases (V-ClPO) have been identified.[69]   
Ascidians (sea-squirts) accumulate vanadium from the surrounding sea and 
concentrate it 103 to 106-fold.  Vanadium is as abundant as zinc in the earth’s 
crust (0.015%).  More importantly, a high concentration of vanadium(V) is 
found in sea water in the form of contact ion pairs Na+H2VO4
- in an average 
concentration of 30 nM.[63]  It is reduced from V(V) to V(III) possibly by 
tunichromes (peptide pigments consisting of hydroxy-dopa units) for storage 
in blood vacuoles at very acidic pH values.[63, 70, 71]  Vanadium-binding 
metallo-proteins (vanabins) found in the blood of such creatures are assumed 
to be involved in the transport of oxygen but no scientific evidence is 
available to substantiate this.  At present there is no real understanding of 
why vanadium is collected and accumulated in this manner and no 
biological explanation is available.  The Amanita mushroom is another 
example of an organism containing unusually high levels of vanadium with 
concentrations of nearly 400 ppm being observed in some species.[68]  This 
particular vanadium compound was isolated in 1972 and given the name 
amavadin (or amavadine).[68]  Identification of the organic ligand present in 
amavadin was revealed through IR and EPR analysis, although initially an 
absorption in the IR spectrum at 980 cm-1 was wrongly identified as a V=O 
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stretching frequency.  This led to the proposed structure shown as Figure 








Figure 1.12         Structure of amavadin:   originally proposed structure 19, and the                                   
experimentally determined and revised structure, 20 
 
Again, the role is unknown but thought perhaps to be associated with a 
defence mechanism.  The discovery of the role of vanadium as an insulin 
mimic in 1979 increased scientific interest in the coordination chemistry and 
reactivity of this Group 5 transition metal.[72]  Pioneering work by many 
groups[73] has made a significant contribution to the understanding of the 
solution chemistry, coordination chemistry and bioinorganic chemistry of 
vanadium.  An insulin mimic is a substance that alleviates some or all of the 
symptoms of diabetes.  The ability of vanadate to act as a phosphate 
analogue may be the reason why such coordination complexes are so 
successful as insulin mimics, although it is not certain whether V(V) or V(IV) 
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1.5.2. Vanadium in macrocycles 
 Recently, macrocycles in the form of expanded porphyrins have been 
used to accommodate vanadium[62], the coordination chemistry of which is a 
relatively unexplored area.  In these complexes, the dioxovanadium(V) 
cation VO2
+
,  is coordinated to three pyrrolic nitrogens.  
 Vanadium(IV) porphyrins have been shown to be physiologically 
stable as a new class of anti-HIV agents and demonstrate solution stability 
against glutathione reduction.[74]  As potential therapeutics, vanadium 
complexes are possible anticancer and antidiabetic agents, and there is 
growing awareness in their antiviral properties.  It is found[74] that 
macrocyclic dianionic porphyrinato ligands stabilise the vanadium ion by 
providing a rigid square planar scaffold.  No demetallation resulting in free 
porphyrin ligand was observed.  
 Vanadium macrocycles offer new possibilities for design of antivirals 
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1.6.   Aims of thesis 
 Xylyl-bicyclam is a CXCR4 receptor antagonist.  Antiviral activity has 
been linked to the existence of particular isomers in solution and is thought 
to be associated with metal complexation in the body.  Several metal 
complexes have been characterised that display varying levels of activity and 
different ring configurations.  It is suggested that cardiac toxicity may be 
linked to complexation with particular metals.  The aim of this study is to 
investigate oxo-vanadium complexes of cyclam and bicyclam and their 
possible interaction with the CXCR4 receptor.  Another aspect of the project 
is to investigate the antiviral activity of constrained macrocycles that may 
retain a particular configuration in solution.  Specific aims are as follows. 
 1. To synthesise and characterise the organic macrocyclic ligand,                  
xylyl-bicyclam (1-1’-[1,4-phenylenebis(methylene)]-bis(1,4,8,11-tetraaza 
cyclotetradecane)). 
 2. To synthesise and characterise vanadium complexes of xylyl-bicyclam 
and cyclam (1,4,8,11-tetraazacyclotetradecane) with substitution of the axial 
ligand trans- to the oxygen of the V=O group by biologically relevant ligands 
Examples include thiocyanate (prevalent in plasma in the lungs of smokers) 
and cyclic GMP (guanosine monophosphate), a cyclic nucleotide.  EPR 
spectroscopy will be used to investigate the behaviour of cyclams and 
bicyclams in aqueous solution and solution studies will be used to 
investigate the binding strength of the axial ligand.  Investigations using IR 
with resonance Raman spectroscopy, X-ray crystallography and 
EXAFS/XANES will be used to give information on the solid state.  
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 3. To synthesise and characterise zinc complexes of the constrained 
analogues of 1,4,8,11-tetraazacyclotetradecane. Solution studies using 2D 
NMR spectroscopy will allow ring configurations to be assigned and 
compared to those in the solid state.  The role of both zinc and the ring 
nitrogens in the binding of axial ligands will be investigated. 
4. To investigate the binding of xylyl-bicyclam and related complexes to 
7-helix transmembrane G-protein coupled receptors such as CXCR4 and D6, 
using molecular modelling.  In-silico docking of complexes known to be 
either active or inactive may reveal the existence or alternatively the absence 
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2. MATERIALS AND METHODS 
2.1   Chemicals and instruments 
2.1.1 Chemicals 
 Cyclam (1,4,8,11-tetraazacyclotetradecane), α-α’-dibromo-p-xylene, 
ethyl trifluoroacetate, triethylamine, zinc acetate dihydrate, zinc chloride, 
barium chloride, vanadyl sulfate hydrate, vanadyl acetylacetonate, sodium 
bromide, potassium iodide, sodium thiocyanate, sodium ammonium 
phosphate tetrahydrate, silver hexafluorophosphate, guanosine                     
5’-monophosphate disodium salt hydrate (from yeast) guanosine 3’,5-cyclic 
monophosphate sodium salt and NMR solvents, deuterium oxide (99.9%) 
and chloroform-d (99.9%) were purchased from Aldrich Chemical Co., and 
were reagent grade unless otherwise stated.   
 
2.1.2 I R spectroscopy 
 Infrared spectra were recorded as KBr pellets in the range               
4000 – 400 cm-1 on a Perkin-Elmer Paragon 1000 Fourier-transform 
spectrometer.  Solution IR spectra were recorded on a Perkin-Elmer 100 
Fourier-transform spectrometer and data were analysed using Spectrum 
software.  Calibration for solution IR studies was carried out using a solution 
(275 mM) of MgSO4 as a standard.  All solutions for standard and complexes 
were made using double distilled water.  
 
2.1.3 Conductivity measurements 
Electrical conductivity was measured using the JENWAY Ltd Model 
4310 conductivity meter with an electrode of surface area 1 cm2.  Calibration 
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of the instrument was acquired with the Hanna conductivity standard 1413 
µS / cm prior to measurement of the sample.  Solutions were prepared from 
double distilled water and recorded at ambient temperature. 
 
2.1.4 Resonance Raman spectroscopy 
 Raman spectra were collected using a Labram 300 (Horiba Jobin Yvon, 
Stanmore, Middlesex, UK) 20mW HeNe laser with 632.817 nm wavelength, 
filter 0.1 – 100%, hole 500 micron, slit 300 micron, grating 1800 lateral (XY),     
spatial resolution < 1 mm, spectral resolution about 2.5 cm-1 and 
magnification 100 (numerical aperture about 0.95, Olympus UK, London, 
UK).  Data were processed using LabSpec (Horiba Jobin Yvon) software, 
version 4.18. 
 
2.1.5 NMR spectroscopy 
 NMR spectra were recorded either on a Bruker AVA 600 MHz 
spectrometer using a 5 mm RT (room temperature) TXI (triple resonance 
inverse) [1H, 13C, 15N] probe equipped with xyz gradients, a Bruker Bio600 
MHz spectrometer using a 5 mm TXI [1H, 13C, 15N]  cryo-probe equipped 
with z gradients, or a DMX500 MHz equipped with a TBI [1H, 13C, 15N]         
z-gradient probe.  All spectra were acquired at 298 K unless otherwise stated 
using standard pulse sequences for samples in 5 mm NMR tubes.  1H shifts 
for D2O solutions were referenced to 1,4-dioxane (3.75 ppm) and 1H NMR 
signals for CDCl3 solutions were referenced to the residual solvent peak, δ 
7.27 ppm (chloroform).  All spectra were recorded at 298 K and processed 
using XWIN-NMR (Version 3.6 Bruker UK Ltd) and TOPSPIN (Version 3.1 
Bruker UK Ltd) software. 
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2.1.6 X-ray crystallography 
 X-ray crystallographic studies were carried out on a Bruker     
SMART-APEX CCD diffractometer equipped with an Oxford Cryosystems 
low-temperature device by Prof Simon Parsons, University of Edinburgh, 
UK.  Crystal structure determination was also carried out by the ESPRC 
National Crystallographic Service, University of Southampton, UK. 
 
2.1.7 CHNS analysis 
 CHNS analyses were carried out by University of St. Andrews,          
St. Andrews, UK, using a CE Instruments EA1110 CHNS analyser. 
 
2.1.8 Electrospray ionisation-mass spectrometry (ESI-MS) 
 Positive-ion electrospray ionisation mass spectra were obtained on a 
Micromass Platform II mass spectrometer and solutions were infused 
directly at 10 µL/min.  The capillary voltage was 3.5kV and the cone voltage 
was typically varied between 5 and 45 V.  The source temperature was 
dependent on the solvent used.  Data were processed using Masslynx (v3.5) 
Windows XP PC data systems. 
 
2.1.9 Ultraviolet and visible spectroscopy (UV-Vis) 
 UV-Vis absorption spectra were acquired on a Varian Cary 50 Bio 
spectrometer using 1 cm pathlength quartz cuvettes.  Spectra were acquired 
at room temperature, processed using Cary WinUV version 3.0 software and 
referenced to the solvent alone. 
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2.1.10 pH measurements 
 All pH values of solutions were determined using a Corning 145 pH 
meter equipped with a micro combination electrode and calibrated with 
Aldrich buffer solutions at pH 4, 7 and 10.   
 
2.1.11 EPR spectroscopy 
 EPR spectra were recorded on an X-band Bruker ER200D-SCR 
spectrometer connected to a Datalink 486DX PC with EPR Acquisition 
System, version 2.42 software with the help of Dr Neil Robertson, University 
of Edinburgh, UK.  Data were simulated using Bruker WINEPR Simphonia 
version 1.26 software by the National EPR Centre, University of Manchester, 
UK and corrected as for the DPPH standard.[1]   
 
2.1.12 Absorption Near Edge Structure (XANES) and                                      
 Extended X-ray Absorption Fine Structure (EXAFS)  
2.1.12.1  V K Edge XANES/EXAFS 
 All data were collected and recorded by Danielle Covelli, University 
of British Columbia, Canada.  X-ray absorption spectra were recorded at 
Stanford Synchrotron Radiation Laboratory (SSRL) on the 20-pole wiggler 
beam line 7-3, under ring operating conditions of 80-100 mA and 3 GeV.  
Data was collected using a Si (220) phi = 0˚ double crystal monochromator 
and the signal was detected using a 30 element Ge detector array.  All 
samples were prepared by lightly grinding 5 mg of vanadium complex with 
boron nitride in a mortar and pestle until a fine uniform powder was formed.  
Vanadium metal reference foil was used for energy calibration.   
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 XAS data were collected in the energy range from 5235-6485 eV using 
XAS Collect software.  Ten scans of each compound were obtained at the V K 
edge, to ensure reproducibility.  Energy calibration was performed using the 
V K-edge spectrum of a vanadium metal foil, assuming the lowest energy 
peak to be 5465 eV.  Data processing, including averaging scans, energy 
calibration, background subtraction and normalisation was performed in 
SixPACK (Sam Webb, Stanford Synchrotron Radiation Laboratory).  EXAFS 
analysis was carried out using Artemis (Bruce Ravel, Argonne National 
Laboratory). 
 Portions of this research were carried out at the Stanford Synchrotron 
Radiation Laboratory, a national user facility operated by Stanford 
University on behalf of the U.S. Department of Energy, Office of Basic 
Energy Sciences.  The SSRL Structural Molecular Biology Program is 
supported by the Department of Energy, Office of Biological and 
Environmental Research and by the National Institutes of Health, National 
Centre for Research Resources, Biomedical Technology Program. 
 
 Some of the techniques in this section were used extensively 
throughout the project.  These are discussed in more detail in the next 
section. 
  
2.2   IR spectroscopy [2, 3] 
   Infrared (IR) absorption spectra provide a quick and simple means of 
confirming the presence or absence of a functional group in a molecule or 
compound.  This technique is used routinely by vanadium chemists to look 
at the characteristic vibrational stretch of the V(IV)=O group, found to be in 
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the range 980 ± 50 cm-1[4] and both solid state and solution IR have proved to 
have been invaluable in this work.  IR is one of the few techniques available 
for acquiring informative structural data for paramagnetic vanadium 
compounds such as those synthesised in this thesis.  Coordination of groups 
like acetate can take place with a metal in three different modes (unidentate, 
bidentate or bridging) and these modes may be identified through a 
comparison of frequencies with ionic acetate complexes.  The technique has 
been used for both vanadium and zinc work in this thesis.  
 Spectra can be recorded in transmission or absorption mode and 
identifications made are unique to a particular molecule’s structure.  There 
are two types of fundamental vibrations in molecules and for each to be seen 
in an IR spectrum there must be a change in the electric dipole of the 
molecule.  A stretch is a vibration between two atoms on the same bond axis 
and the distance between them can increase or decrease.  A bend occurs 
when the position of the atoms change relative to the bond axis.   
 In a simple diatomic molecule both atoms are bonded by the overlap 
of a number of orbitals.  At a particular internuclear distance a balance is met 
between attractive bonding forces and repulsive interaction between the 
remaining electrons of both atoms.  This equilibrium bond distance (re) can 
be changed by applying energy and the system vibrates at a certain 
frequency, ώ defined by: 
                                  where µ is the reduced mass of the two   
             objects. 
   
The vibrational frequency will depend on the mass of the two atoms at either 
end of the bond and the strength of the bond, or force constant, holding them 
µ =  (m1*m2) (m1+m2) 
 2π 
1 ώ = k          
µ √ 
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together.  Heavier atoms held by weaker bonds should vibrate at lower 
frequencies than lighter atoms and those held by multiple bonds.  The 
vibrational frequency also alters with charge on a molecule.  As the number 
of electrons changes, the occupation of the bonding and nonbonding 
molecular orbitals varies.  An increase of bond order and strength leads to an 
observed increase in vibrational frequency. 
 
2.3   Resonance Raman spectroscopy [2, 5] 
   Resonance Raman and infrared spectroscopies are complimentary 
techniques.  Polar bonds result in a large dipole and absorb strongly in the 
infrared, whereas more easily polarised covalent bonds absorb strongly in 
Raman spectra.  These techniques can be used together to determine the 
presence or absence of a centre of symmetry in a molecule.  Compounds with 
a centre of symmetry will not display any common peaks in their Raman and 
infrared spectra and this is described by the mutual exclusion principle.  For 
solution studies, the choice of solvent is important in vibrational 
spectroscopy.  As water is a poor Raman scatterer, aqueous solutions are 
more amenable to study by Raman than infrared spectroscopy. 
  Raman spectra originate in the electronic polarisation caused by 
ultraviolet or visible light.  When light of energy less than that required to 
promote a molecule into an excited electronic state is absorbed by a molecule 




v = 1 
v = 0 
virtual excited state 
Figure2.1   Energy levels involved in Raman spectroscopy 
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The lifetime of this virtual state is very short and the majority of the light is 
re-emitted over 360˚ at the same energy.  This re-emitted light is known as 
Rayleigh scattering.  A small proportion of this re-emitted light differs in 
energy from the incident radiation (ν0) by energy gaps that correspond to 
some of the vibrational modes.  The probability for a ground state molecule 
to be excited into a vibrationally excited state is high due to the population 
density of the ground state.  This leads to peaks with high intensity being 
observed at a lower frequency than the incident radiation (Stokes lines).  
Peaks derived from excited vibrational states at higher energy are called  
anti-Stokes lines and will be much lower in intensity as a result of the much 
smaller population density. 
 The selection rule for Raman spectroscopy differs from that of 
infrared.  Raman activity is determined by a change in polarisability of the 
molecule during a vibration.  The polarisability is a measure of the ease with 
which the electron cloud may be distorted, or polarised. 
 
2.4   NMR spectroscopy [6-9]  
   Some atomic nuclei have a nuclear spin (I) that results in observed 
behaviour not unlike that of bar magnets.  When a magnetic field is applied, 
these magnets can orient themselves in 2I + 1 different ways.  The most 
important nuclei for NMR analysis are 1H and 13C with spins of ½ and these 
nuclei adopt one of two possible orientations.  The low energy orientation is 
aligned with the magnetic field and the high energy orientation is aligned 
against the applied field.  The difference in energy is given by 
    ΔE = hγB0/2π 
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where γ = gyromagnetic ratio (a proportionality constant that measures the 
strength of the nuclear magnets).  This constant is different for each nucleus. 
B0 is the strength of the applied field and the number of nuclei in the low 
energy state (Nα) and in the high energy state (Nβ), will differ by an amount 
determined by the Boltzmann distribution: 
    Nβ/Nα = exp(-ΔE/kT) 
Nuclear spins of 1/2, 3/2, or 5/2, ….., etc. belong to nuclei with an odd mass 
number.   
 








ratio, γ        







1H ½  4.84 26.75 99.99 1.000 
13C ½ 1.22 6.73 1.11 0.016 
15N ½ 0.49 -2.71 0.37 0.001 
*51V 
7/2 5.1514 7.0453 99.76 0.382 
*
51V not studied by NMR in this thesis, but relevant to EPR studies 
 
2.4.1 Nuclear spin and chemical shift 
 The spin quantum number of NMR active nuclei must be equal to, or 
greater than ½ for the nucleus to possess a magnetic moment, generated by 
the spinning of the nucleus.  The magnitude of the magnetic moment varies 
between atoms and is defined as 
     µ = γh/2πI 
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where h = Planck’s constant.  The spin states of nuclei are characterised by 
magnetic quantum numbers mI = I, I-1, I-2, …., -I.  In the presence of a 
magnetic field the orientation of the magnetic moment µ, to the field 
direction (z-axis) is quantised and depends on I such that 
     µz = γh/2πmI 
where mI has 2I + 1 values.  The energy of a transition is dependent upon the 
strength of the magnetic field and the magnetogyric ratio, γ.  The frequency 
ν, of such a transition is given by 
     ν0 = γB0/2π 
In the absence of a magnetic field, all 2I + 1 orientations of a spin-I nucleus 
have the same energy.  This degeneracy is removed on the application of B0.   
 The position of the chemical shift describes the chemical environment 
of a nucleus.  In a molecule, the magnetic field B, experienced by a nucleus 
differs from B0 due to a small magnetic field B’, induced by the electrons of 
the molecule circulating in the direction of the magnetic field.  The motion of 
B opposes B0 shielding the nucleus to some extent such that 
    B = B0 – B’ 
A definition of the chemical shift δ, is given in terms of the difference in 
resonance frequencies between the nucleus being studied (ν) and a reference 
nucleus (νref). 
    δ = 106 [(ν – νref)/νref] 
The term δ is quoted in parts per million to scale the numerical value to a 
convenient size.  The signals for deshielded nuclei are seen on the left hand 
side of the spectrum due to a larger ν and δ.  Deshielding effects can be seen 
as a result of hydrogen bonding and, in particular, intramolecular hydrogen 
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bonds can shift a signal to a higher chemical shift than its expected 
resonance. 
 
2.4.2 Spin-spin coupling and quadrupolar relaxation 
 Interactions between the spins of neighbouring nuclei result in the 
splitting of the NMR signal, the pattern of which is characteristic of the 
nuclear environment under investigation.  Spin-spin coupling is measured 
using the coupling constant, J (Hz) and is observable up to 4 bond lengths (W 
coupling).  This is seen in aromatic systems where the planarity of the ring 
allows specific nuclei to “see” each other across a further distance than 
usually observed in an NMR spectrum.  These spectra show splitting 
patterns characterised by the presence of weak couplings.  Normally, J (Hz) 
is only observable up to 3 bond lengths between nuclear centres.   
 Coupling constant values are affected by interbond angles and 
increase with increasing angles.  In the case of olefinic cis- and                  
trans- coupling, for two-bond coupling a trans- coupling is normally 
observed with a larger J(Hz) value than a corresponding cis- coupling.  For 
three-bond coupling, the dihedral angle φ, is important between planes 
containing coupling nuclei and bonds associated with them.  The dihedral 
angle can be derived from the Karplus equation 
    3J = Ccos2φ + Bcosφ + A 
 Quadrupolar relaxation is electric rather than magnetic in origin.  In 
contrast to nuclei with values of I = ½ where the charge distribution is 
spherical, nuclei with a quadrupole moment are ellipsoidal in charge 
distribution (I > ½).  An electric field is generated from the motion of an 
unsymmetrical field for these species, creating a fluctuating electric field or 
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electric quadrupole.  If a quadrupole moment is large enough, it can 
influence both its own nucleus and adjacent nuclei.  Line broadening is seen 
for nuclei attached to atoms with larger relative electric quadrupole 
moments.  Often, NH protons cannot be observed (or are very broad) due to 
the quadrupole effect.  Relaxation refers to the processes that allow nuclear 
spins to lose energy and drop from the excited state to the ground state 
without emitting an NMR signal. 
 
2.4.3 Paramagnetic effects in NMR spectra [10] 
 The unpaired electrons in paramagnetic compounds such as high spin 
Fe(II), Fe(III), Co(II), Ni(II), Cu(II) and Ru(III) have a severe effect on 
chemical shift and linewidths of signals observed in spectra of biomolecules 
that contain one or more paramagnetic transition metals.  The extent of line 
broadening observed, as seen with NH protons, is a major drawback for 
analysis using high-resolution NMR spectroscopy.  In some compounds the 
extent of delocalisation of an unpaired electron is such that severe line 
broadening results in no signal being seen.  Relaxation of the unpaired 
electron(s) is the main cause of line-broadening effects seen in solution 
spectra due to a dipolar or contact coupling with the resonating nucleus i.e. 
through-space or through-bond.  No NMR analysis was possible for the 
vanadium complexes in this thesis as paramagnetic signals were too broad to 
detect. 
  
2.4.4 2D NMR spectroscopy 
 In 2D NMR, a second dimension is introduced that allows for more 
detailed structural determination.  The most important benefit is that 
individual chemical shifts and all coupling constants can be measured 
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without ambiguity, even when multiplets are overlapping.  2D NMR data is 
especially valuable to completely assign the signals of a compound for which 
the structure is already known.  There are now several two-dimensional 
experiments available for molecular structural studies and those used in this 
thesis are listed in Table 2.2. 
 
Table 2.2   2D NMR experiments used in this thesis 








assignments from that 
of known carbons, or 
vice versa 
[1H,13C] HSQC 




2.4.4.1 COrrelation SpectroscopY (COSY) and TOtal Correlation    
 SpectroscopY (TOCSY) 
       Most 2D experiments can be divided into auto-correlated or         
cross-correlated types.  Auto-correlated experiments refer to homonuclear 
spin systems where a magnetisation (or coherence) transfer occurs.  A 
common auto-correlation experiment is [1H, 1H] COSY that produces          
off-diagonal correlation peaks.  In cross-correlation experiments the 
magnetisation of one nucleus is modified by the coupling effects of other 
nuclei.  The 2D peaks appear at the intersection of f1 and f2, i.e. both axes are 
in frequency units which may be converted to ppm. 
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 In [1H, 1H] COSY experiments, signals from couplings are viewed as 
cross-peaks between the two frequency domains and are dominated by 
geminal and vicinal coupling.  In [1H, 1H] TOCSY experiments, all mutually 
coupled proton spins can be grouped from the cross-peaks present.  This 
experiment contains much more information than the [1H, 1H] COSY as 
correlations between protons up to seven bonds are possible.  The transfer of 
magnetisation occurs from Ha to Hb, from Hb to Hc and so on until all 
mutually coupled protons have been connected.  Relationships can be 
established between protons that are actually far removed.  An advantage of 
this experiment is the ability to identify the number of isomers or different 
products in a sample.     
 
Information    Groups  Experiments 
Vicinal proton connectivities     [1H, 1H] COSY 
 
 
All proton connectivities in     [1H, 1H] TOCSY 
one spin system 
 
 
2.4.4.2 Heteronuclear Single-Quantum Correlation (HSQC) 
       These experiments enable identification of protons directly 
coupled to other NMR active nuclei (H-X).  Examples include [1H, 13C] and 
[1H, 15N] HSQC experiments.  Proton resonances may also be more spread 
out depending on the chemical shifts of coupled heteronuclei.  This allows 
assignment of protons that may be overlapping in 1D or 2D proton spectra.  
H    H 
      C     C 
C     C     C     C 
H    H     H    H 
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A useful practice for [1H, 13C] HSQC is the identification of NH protons 
through their absence in the spectrum.  Broadened NH peaks that show up 
in a 1D spectrum can be verified in this way, leading to easier identification 
of the remainder of the molecule by acquiring this as a starting point for 
assignment of the peaks.   
 
2.4.4.3 15N NMR spectroscopy [9] 
       Proton resonances have been detected from NH protons with 14N 
present in natural abundance (99.6 %) but they are often broadened as 14N is 
a quadrupolar nucleus (I=1) and quadrupolar relaxation occurs.  For aqueous 
experiments, D2O is usually unsuitable due to NH/ND exchange and it is 
often necessary to work in H2O.  Despite the low natural abundance of 15N 
(0.37 %), it has spin ½ and can be utilised in experiments using polarisation 
transfer from 1H.  This leads to an intensity increase in signal, given by the 
ratio of magnetogyric ratios, γH/γX.  For 15N, a gain of 9.8 (γH/γX) in signal 
intensity is achievable by such a polarisation transfer. 
 
2.5   EPR spectroscopy [11-17] 
   EPR (Electron Paramagnetic Resonance) or ESR (Electron Spin 
Resonance) is a magnetic resonance method used to characterise and 
investigate properties of paramagnetic materials, those containing unpaired 
electrons.  Materials such as free radicals, donor and acceptor impurities in 
semiconductors, metal ions in crystals and inorganic metal complexes can be 
studied using this method.  The fundamental physical concepts are related to 
that of nuclear magnetic resonance (NMR), the main contrast being that the 
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excited spins are those of electrons rather than nuclear spins.  Information on 
the structure and environment of radicals can be gained from important 
parameters such as g-factors, hyperfine (hf) splitting (electron-nucleus 
coupling) and zero field splitting.  Investigations at different temperatures 
can provide information on the dynamics of a system.   
 
2.5.1 Spin-lattice relaxation 
 Magnetic energy is absorbed by the paramagnetic ion and transferred 
to the lattice.  Lattice motions result in a fluctuating magnetic field to which 
the spin magnetic moment of the electron couples, and magnetic energy is 
emitted.  This simple loss of energy means that a particular spin spends less 
time in the excited state resulting in a broadened resonance line.  Line-widths 
are predicted from spin-lattice relaxation (2πT1)-1, where T1 is the relaxation 
time for the transfer of energy from the spin system to the lattice.  T1 is 
particularly sensitive to temperature and the presence of nearby electronic 
excited states.  A decrease in temperature reduces molecular tumbling and 
interatomic motion, resulting in longer relaxation times and subsequent 
narrower lines.  Nearby electronic excited states (~ 100 cm-1) result in short 
relaxation times and lower temperatures are required to reduce the width of 
the lines.   
 
2.5.2 Hyperfine splitting 
 Magnetic interactions that occur between electron spins and nuclear 
spins in a molecule give rise to a specific number of lines in the EPR 
spectrum.  This arrangement is the hyperfine structure of the spectrum.  From 
the number of lines and relative intensities, interpretation of the number and 
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spins of the nuclei that interact with an unpaired electron can be made.  The 
strength of the interaction and the magnetic moments of the nuclei give rise 
to the separations between the lines.  The hyperfine separation can be used to 
describe the number of equivalent nuclei in the molecule.   
 
2.5.3 Line widths and intensities 
 The line width is a result of magnetic interactions between the electron 
spin and the environment in the sample.  As electrons can interact 
magnetically with their environment in the sample, the resultant magnetic 
field experienced by a population of electron spins is not evenly distributed.  
The resonance absorption line obtained for a given value of this resultant 
field is obtained over a range of values of the applied field.  This results in a 
finite line width from which information regarding the spin environment can 
be obtained.  One such example of these effects is the ability to make an 
order of magnitude estimate of the distance between paramagnetic centres 
and chemical exchange between a paramagnetic molecule and its 
surroundings.   
 Several parameters affect the intensity of a signal which is the total 
area under the resonance curve.  A combination of frequency (usually         
9.5 GHz), concentration of paramagnetic sample and temperature all 
determine the intensity of the observed signal.  The intensity can be used to 
determine the concentration of paramagnetic centres in the sample. 
 
2.5.4 Magnetic moment and g-factor 
 The fundamental properties of an electron are its mass, charge, 
intrinsic angular momentum (also known as the spin) and its magnetic 
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moment.  The magnetic moment µ, can be thought of as arising from the 
spinning motion of the electron’s charge and has the spin quantum number s 
= ½ with magnetic components ms = +½  and ms = -½.  The magnetic moment 
of the electron is aligned either parallel (ms = +½) or antiparallel (ms = -½) to 
the magnetic field (B0) and different energies apply to each.  A lower energy 
is associated with the anti-parallel alignment and the energy difference 
between the two states is given by: 
     ΔE = geµBB0 









Equations of ΔE with hν gives a resonance condition that is satisfied through 
irradiation with photons.  Transitions are subsequently induced between the 







B0 = 0 
Magnetic field, B0 
∆E = E +½ - E -½   
ms = +½  
ms = -½  
Figure 2.3   Splitting of energy levels is directly proportional to strength of 
magnetic field 
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in which n+ and n- represent populations of upper and lower level energy 
states, respectively.  It is this population difference caused by the energy 
separation that is detected as an absorption.  An EPR spectrometer achieves 
resonance using a fixed frequency ν, while sweeping the magnetic field.  
Experiments typically employ microwave frequencies of approximately         
9 GHz in X-band spectrometers and spectra are commonly presented as first 
or second derivatives.  Higher field W-band spectrometers operate at 95 GHz 
and the improved spectral resolution can reveal small couplings not seen 
with X-band analysis.  Recent developments have resulted in spectrometers 
operating up to THz (very high frequency (VHF) EPR) and are most 
prominently used in structural biology.[18] 
 The g-factor represented by ge, is a physical property of the electron 
and a proportionality constant between the magnetic moment and the 
angular momentum where ge = 2.002319 for unpaired electrons.  Different 
metal ions have varying g-values and published values for some examples of 
d1 Ti3+, Zr3+, Nb4+, Cr5+, Mo5+ and W5+ ions are listed in Table 2.4.  Published 
values for some examples of d1 V4+ ions are listed in Table 2.5.  In addition to 
its spin, an electron can have additional angular momentum as it moves not 
only around its own axis but also in an orbit and is called orbital angular 
momentum.  Orbital angular momentum also has a magnetic moment 
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Table 2.4   Listed g-values for d1 metal ions [19] 
Metal ion giso g║ g┴ 















2-   
           
1.991      
1.989   
1.869           





                   
-                  
-          
1.923       
2.008    
1.96     
2.090 
1.804 
1.940            
                  
-                
-         







Table 2.5   Listed g-values for d1 V4+ ions [19] 
Metal ion giso g║ g┴ 
VO2+                                    
in KNO3                               
in CsNO3   
V(NEt2)4        
VOSO4                          
in H2O        
VO(acac)2             
in CH3OH   
VO(picolinate)2  
VOTPP                  
in CHCl3 
           
1.966      
1.964   
1.976           
           
1.961       
           
1.969  
1.970             
 
1.979 
         
1.9352  
1.919  
1.946          
                  
-              
                  
-                
-                
-             
1.966 
          
1.974         
1.984  
1.991         
 
-              
                  
-                   
-                
-             
1.985 
 
2.5.5 EPR of V4+ and VO2+ 
 51V has a natural abundance of 99.8% and a nuclear spin I = 7/2.  In 
solution, eight hyperfine lines are observed and couplings are usually large 
(~ 100 gauss).  As almost all vanadium compounds have symmetry less than 
Oh and Td, EPR signals are easily observed due to a longer relaxation time.[19]  
At room temperature there is free rotation of the vanadyl group (V=O) 
resulting in an isotropic spectrum. At lower temperatures anisotropy 
becomes apparent and axial or rhombic spectra can be identified.  Lower Aiso 
values are seen with increasing basicity due to greater delocalisation of the 
unpaired electron and vanadium systems are sensitive to solvation.  The 
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decrease in Aiso with basicity of any 6th axial solvent ligand can be compared 
with the same decrease in stretching frequency of the V=O group as the 
basicity of the 6th axial ligand increases.  Higher Aiso (51V) values are 
associated with greater localisation of the electron on the metal when ligands 
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3. OXOVANADIUM(IV) CYCLAM COMPLEXES 
           This chapter describes the syntheses of oxovanadium(IV) cyclam 
complexes, 21-29.  Numbers in bold after compound names refer to 
experimental data in Chapter 7.  Two complexes, oxovanadium(IV) cyclam 
sulfate 21 and chloride 22 were investigated further with bicyclam analogues, 
oxovanadium(IV)-xylyl-bicyclam sulfate 30 and chloride 31 (Chapter 4) to 
explore the chemistry of oxovanadium(IV) in macrocycles.  
 Cyclam exhibits high thermodynamic and kinetic stability on 
complexation with a variety of cations, including transition metals.[1]  The 
particular macrocycle ring configurations of isomers in solution are 
dependent upon the geometry of the complex in question.  The 
stereochemistry is dictated by the chirality of the ring nitrogens giving rise to 








Figure 3.1(b)   Some major configurations of metallo-cyclam complexes.  
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Square planar complexes prefer to adopt the trans-I configuration while 
octahedral complexes show a preference for trans-III.[2, 3]  It is thought that 
trans-I and trans-III configurations may interconvert in solution due to the 
flexibility of the ring and investigation of the relative strain energies reveals 
that the trans-III isomer is the most stable.[3, 4]  Configurational isomers 
thought to exhibit antiviral activity against HIV include trans-I/trans-III, 
trans-II and cis-V, shown in Figure 3.1(b). 
3.1.   Experimental 
    Oxovanadium(IV) cyclam complexes were synthesised as shown in 















Scheme 3.2   General preparative route to oxovanadium(IV) macrocycle complexes 
where X = Br (24), I (25), NCS (26), HOPO3 (27), GMP (28) and cGMP(29) 
(experimental details are found in Chapter 7). 
VOSO4.xH2O 
MeOH, Δ 
BaCl2 (1 mol. equiv.) 




















AgPF6 (2 mol. equiv.) 









Addition of X (axial ligand exchange) 
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3.2.   Materials 
    Starting materials were purchased from Sigma-Aldrich as detailed in 
Chapter 2.  The solvent used for all synthetic work was anhydrous quality 
methanol from Sigma-Aldrich.  HPLC Grade methanol and reagent grade 
diethyl ether were used for crystallisations.   
3.3.   Results 
3.3.1. Magnetic measurements 
 Bulk magnetic properties can be analysed by measuring the magnetic 
polarisation M, in an applied magnetic field, H.  The sensitivity of M to H is 
defined as the magnetic susceptibility Χ, where Χ = dM/dH which in low 
fields can be approximated to M/H, and values of Χ are comprised of two 
components.  The parameter Χ consists of a diamagnetic component which is 
very small resulting from paired electrons and a paramagnetic component 
which is much larger and results from unpaired electrons.  The small 
diamagnetic component is subtracted to give a net susceptibility such that 
Χpara = Χtotal – Χdia.  In subsequent discussion, Χ will be taken to mean Χpara.  
The parameter Χpara holds the most useful information of the sample, and 
significantly, above any bulk magnetic ordering temperature can be 
generally represented by the equation: 
 
where µo = 1 in c.g.s. units (permeability), NA/3kB = 1/8 in c.g.s. units and      
µB = the Bohr Magneton.  The magnetic moment, µeff = g√(S(S+1))µB such that 
Xpara can be described as:  













Χ =  is known as the Curie Law. and 
 
  66 
 Data from paramagnetic compounds with no interacting magnetic 
moments will therefore give a straight line plot for 1/Χ vs T.  The slope of the 
line gives the Curie constant from which the g-value is derived.  This Law is 
further refined to include the parameter Θ, the Weiss constant, where             
Χ  =            is referred to as the Curie-Weiss Law.  Dominant ferromagnetic 
interactions will generally lead to Θ > 0 and anti-ferromagnetic interactions 
which are much more common will lead to Θ < 0.  Data can be presented in 
different forms dependent upon the parameter used for the y-axis.  In Figure 
3.3(a) a plot of Χ vs T shows how the data fit well to the Curie Law for the 
cyclam chloride complex 22.  The same fit can also be made for the cyclam 
sulfate complex 21 and parameter values of g, C and Θ for both complexes 
are listed in Table 3.4.  An alternative representation of the data would be to 
show a straight line plot using 1/Χ on the y-axis, where Θ = 0 would pass 
through the origin, Θ < 0 would give a negative intercept and Θ > 0, a 
positive intercept on the x-axis.  Data for complex 22 in this format is 
displayed in Figure 3.3(b). 








Figure 3.3   Plots of Curie Law fits for vacuum dried single crystals of 
oxovanadium(IV) cyclam chloride 22, in powder form.  Graph (a) shows Χ vs T and 
graph (b) shows the reciprocal plot, 1/Χ vs T. 

























 Linear Fit of RecipChi
Equation y = a + b*x
Adj. R-Square 0.99967
Value Standard Error
RecipChi Intercept 6.92164 0.4786
RecipChi Slope 2.65143 0.00327
1/Χ             ■                              
linear fit  
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The good fit of the data for both complexes 21 and 22 to the Curie Law 
confirms the presence of an oxovanadium(IV) metal centre with negligible 
interactions between vanadium centres.  
Table 3.4   Magnetic parameters for oxovanadium(IV) cyclam complexes, sulfate 21 and 
chloride 22  
Complex g C Θ µeff 
sulfate, 21 1.927 0.348 -0.05 1.67 
chloride, 22 2.005 0.377 -2.61 1.73 
 
 
3.3.2. X-ray crystallography 
 Four X-ray crystal structures of oxovanadium(IV) cyclam complexes 
were achieved in this work.  Three structures were determined at 150 K 
(complexes 21, 22 and 26) and complex 25 was determined at 120 K.  Data for 
the latter was collected by the EPSRC National Crystallography Service, 
University of Southampton, UK.  All structures show the cyclam ring in the 
trans-III configuration.  Selected bond lengths and angles are detailed in 
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Table 3.5   Selected bond lengths (Å) and angles (˚) for oxovanadium(IV) cyclam complexes.  
Italics apply to complex 25, where atom numbering different for comparison of identical 
bonds/angles.  
Axial ligand trans- to V=O 









V-N            
bond lengths 
N(1)-V(15)   
N(4)-V(15)   
N(8)-V(15)  









2.097(2)      (N1-V1)    
2.093(2)         (N5-V1)      
2.111(2)      (N8-V1) 






V=O            
bond lengths 
V(15)-O(16) 1.6093(17) 1.599(3) 1.6009(19) 1.6004(16) 
V-L*           
bond lengths 
 2.1359(16) 
V(15)-O(17)          
2.6501(12) 
V(15)-Cl(17)   
2.6044(7) 
V(15)-Cl   
2.2053(19)  
V(15)-N(17) 
N(1)-V-N(11)   95.98(8) 95.67(16) 95.95(8)  (N8-V-N12) 92.14(8) 
N(4)-V-N(1)  84.27(9) 83.91(15) 84.14(8)  (N12-V-N1) 84.18(7) 
N(4)-V-N(8)   92.92(8) 92.12(15) 93.11(8)  (N1-V-N5) 95.97(7) 
N(8)-V-N(1)   166.88(7) 165.46(16) 168.51(8)(N5-V-N12) 166.46(7) 
N(1)-V-L*    93.92(9) 83.39(12) 85.67(6)  (N12-V-L*) 82.69(7) 
Bond angles 
 
L-V=O 177.83(9) 176.99(12) 176.91(7) 178.74(8) 
* L = bonding atom of axial ligand trans- to V=O.   
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Table 3.6   X-ray crystallographic data for oxovanadium(IV) cyclam complexes 
Axial ligand          
trans- to 
V=O 
Sulfate        
(SO42-), 21 
Chloride         
(Cl-), 22 
Iodide               
(I-), 25 
Thiocyanate     
(NCS-), 26 
Formula C34H84N12O19S3V3 C11H31Cl2N4O3.5V1 C10H24Cl1I1N4O1V1 C11H24F6N5O1P1S1V1 
Formula 
weight 
1214.13 397.24 429.62 470.31 
Crystal 
system 
Trigonal Monoclinic Monoclinic Monoclinic 
Space group R 3 c C 1 c 1 P 1 21/n 1 P 1 21/n 1 
a / Å 25.2262(2) 15.3070(6) 10.0293(4) 9.4176(10) 
b / Å 25.2262(2) 13.2387(6) 10.3318(4) 19.597(2) 
c / Å 15.1963(3) 18.7031(8) 15.9990(5) 10.9379(12) 
α / ˚ 90 90 90 90 
β / ˚ 90 101.165(2) 90.704(3) 111.405(4) 
γ / ˚ 120 90 90 90 
Cell vol. / Å3 8374.76(19) 3718.4(3) 1657.70(11) 1879.4(4) 
Z 6 8 4 4 
Density 
(Calc) mg/m3 
1.444 1.419 1.721 1.662 
Abs. coeff. 
mm-1 
0.680 0.838 2.618 0.792 
Reflections 
collected 
55545 8887 23623 19947 
Independent 
reflections 
5575 [R(int) = 
0.037] 
8887  [R(int) = 
0.048] 
3800  [R(int) = 
0.0432] 




0.0292       [3992 
data] 
0.0543       [8478 
data] 
0.0277       [3250 
data] 




0.0849 0.1491 0.0724 0.1078 
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[V(IV)O(cyclam)SO4]·1.33CH3OH], 21 
 Complex 21 crystallised as the trans-III 
isomer, the most thermodynamically stable ring 
configuration (Figure 3.7).  The geometry is 
distorted octahedral and one of the methanol 
molecules of crystallisation is disordered (Figure 3.8).  Complex 21 is neutral 
and the sulfate group 
coordinates as a 
monodentate ligand.  
Two of the remaining 
sulfate oxygens form 
hydrogen bonds to two 
NH protons of the 
cyclam ring.  The oxo-
vanadium(IV) bond 
length is short 
(1.6093(19) Å) and 
comparable with the 
V=O bond in the square pyramidal oxovanadium(IV) complex [V(IV)O(acac)2] 
(1.58 Å).[5]  The V-O(sulfate) bond length of 2.1359(16) Å, is slightly longer 




Figure 3.7   V(IV)O(cyclam) sulfate, 21 
 










Figure 3.8   Crystal packing of [V(IV)O(cyclam)SO4·1.33 CH3OH] 21, projected along the c axis of the unit cell.  Hydrogen bonds are shown (cyan) between methanol, sulfate 
and NH groups, leading to stabilisation of the trans-III configuration.  Methanol molecules with 100% carbon occupancy and disordered oxygens are highlighted in boxes. 
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[V(IV)O(cyclam)Cl]·CH3OH·1.5H2O]Cl, 22 
 Complex 22 crystallised as the trans-III isomer, in a distorted 
octahedral geometry 
(Figure 3.9).  There are 
two molecules in the 
asymmetric unit and the 
V-Cl bond is significantly 
longer than published 
examples for octahedral 
vanadium(IV) complexes 
of chloride ligands trans- 
to V=O[6, 7]     (2.465 Å, 
2.468 Å).  Hydrogen 
bonds exist between 
chloride atoms, ring 
protons and solvent molecules, adding to the stability of the trans-III 
configuration (Figure 3.10).  The angle Cl-V=O (176.99(12) Å) is significantly 
smaller than the corresponding O3SO-V=O angle in the sulfate complex, 21 
(177.83(9) Å).  The N(1)-V(15)-N(8) angle (165.46(16) Å) is also significantly 
smaller than the corresponding angle in complex 21 (166.88(7) Å).  
 
Figure 3.9   V(IV)O(cyclam) chloride, 22 
 







Figure 3.10   Crystal packing of [V(IV)O(cyclam)Cl]+·CH3OH·1.5H2O]Cl, 22 showing  networks of hydrogen bonding between chloride groups, NH groups, methanol 
and water.  These interactions provide extra stability for the trans-III configuration. 
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[V(IV)O(cyclam)Cl]I, 25 
Complex 25 crystallised as the trans-III isomer, in a distorted octahedral 
geometry.  The axial chloride and counter ion iodide ions were refined 
isotropically and are drawn as 
spheres instead of ellipsoids. 
During recrystallisation, the 
iodide ligand appears to have 
exchanged with the chloride.  
A small amount of chloride ion 
must have been present in the 
recrystallisation powder and 
shows an interesting preference of vanadium as a hard metal centre for a 
hard ligand.  Mass spectrometry gave the molecular ion as m/z = 394.1 [M]+ 
for [VO(cyclam)I]+ which shows the iodide is bound.  The iodide ion is seen 
as the counter ion in the crystal structure and it may be that the crystal 
chosen for X-ray analysis was part of a mixture of crystals with both chloride 
and iodide axial ligands.  The V-Cl bond length (2.6044(7) Å) of 25 is 
significantly shorter than the V-Cl bond length of 22 (2.6501(12) Å).  
Distances were measured between axial chlorides of one molecule and the 
ring NH protons of a neighbouring molecule in complex 22 and compared 
with 25.  The former shows calculated distances of 2.491 Å and 2.590 Å, while 
the latter displays a much longer distance of 2.736 Å.  There is no hydrogen 
bonding seen in complex 25 and the angle N-V-N is correspondingly larger 
than that seen for complex 22.  The angle Cl-V=O (176.91(7) Å) is comparable 
with that of complex 22 (176.99(12) Å).   
 
Figure 3.11    V(IV)O(cyclam) iodide, 25 
 











Figure 3.12   Crystal packing of [V(IV)O(cyclam)Cl]I, 25.  No hydrogen bonds exist between molecules and only short contacts (sum of van der waals radii) are 
seen between chlorides groups, NH groups and iodide counter ions.   
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[V(IV)O(cyclam)NCS]PF6, 26 
Complex 26 crystallised as the trans-III isomer, in a distorted octahedral 
geometry.  This complex crystallised with one cyclam ring in the asymmetric 
unit and PF6 as the 
counter ion for 
charge balance.  
No hydrogen 
bonding is seen 
between the axial 
sulfur atom of the 
thiocyanate ligand 
and NH protons of 
the ring, or 
between the ring 
and the counter 
ion.  The SCN-V=O angle (178.74(8) Å) is significantly larger than that of any 
other crystal structure in this chapter and vanadium shows an expected 
preference for the harder nitrogen ligand than the softer sulfur. 
 
Figure 3.13   VO(cyclam) thiocyanate, 26 
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Figure 3.14   Crystal packing of [V(IV)O(cyclam)NCS]PF6, 25.  No hydrogen bonds exist between molecules and only short contacts (sum of van der waals radii) 
are seen between thiocyanate groups, NH groups and PF6 counter ions.   
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3.3.3. FTIR and resonance Raman spectroscopy 
 All complexes were analysed by solid state and solution IR and 
selected complexes by resonance Raman spectroscopy.  The shift of the 
V(IV)=O vibrational stretch, a characteristic probe for the axial ligand trans- 
to V=O[8, 9] was recorded for each complex and data are listed in Table 3.16.  
The vibrational stretches of NH groups are listed and found to be consistent 
for all complexes.  Solution IR was carried out by the Department of 
Chemistry, University of Warwick, Gibbet Hill Road, Coventry, UK, for 
oxovanadium(IV) cyclam sulfate 21 and chloride 22, to investigate 
displacement of the axial ligand in an aqueous environment.   
 Raman spectra are shown in Figure 3.15.  Problems were encountered 
using single crystals for Raman analysis as the red laser (632 nm) charred the 
sample extensively.  Cracking and scarring were observed and the damage to 
the crystal is shown in Figure 3.17.  Replacement of the laser light with one of 
lower absorption wavelength (blue laser, 432 nm) resulted in the same 
damage to the crystal, only to a lesser degree.  This made analysis difficult as 
scans were required to be collected very quickly.  The nature of the technique 
often requires several scans for good data collection and samples became 
charred before enough data could be collected.  Spectra were acquired using 
a 0.1 % laser filter aperture for the first collection of data points, increasing to 
100 % for each complex to see which bands could be found.  Not all of the 
complexes were suitable for analysis as varying degrees of damage to the 
structures was incurred through absorption of the laser light.  The samples 
were moved around on the microscope slide so that the laser was focused on 
a fresh part of the sample each time the filter aperture was increased, 
ensuring spectra were not acquired from a previously damaged portion.   
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Figure 3.15   Selected Raman spectra of (a) VO(cyclam)sulfate 21, 10% laser filter aperture;                     
(b) VO(cyclam)sulfate 21, 100% laser filter aperture; (c) VO(cyclam)chloride 22, 100% laser filter 














Table 3.16   Infrared and Raman absorptions for powder samples of oxovanadium(IV) 

























V=O  974, 
974  
(w, br) 
988,    
988 (w) 





















PO43-  - - - - - - 1093 1095 1092 
C=O# - - - - - - - 1693 1698 
S042-  
ν3              
-          
-       
ν4             
- 
      
1106   
1064 
1028            
619  
598 
- - - - - - - - 
N=C - - - - - 2084 - - - 
V-N 445 445 445 445 445 - 445 - 445 






* L = bonding atom of axial ligand trans- to V=O group.  Values in bold represent Raman absorptions        










 Solution IR revealed a change in the V=O stretch for complexes 21    
(957 cm-1) and 22 (980 cm-1) and spectra are shown in Figure 3.18.  Using 
MgSO4 (275 mM solution, 10 µL drop, 1024 scans) the resonant frequency for 
the ν3 vibration of free sulfate was found to be 1102 cm-1.  This was repeated 
after several hours to check the consistency of the data.  The spectrum 
remained unchanged in this time.  Solutions of the MgSO4 standard and 
complexes 21 (275 mM) and 22 (296 mM) were made using double distilled 
water.  The solutions for complexes 21 and 22 were made by dissolving 3 mg 
of the complex in 30 µL of double distilled water. The spectra remained 




green block single 
crystals of 21 
Red laser        
λ 632 nm 
Blue laser        
λ 432 nm 
New position for laser 

































Figure 3.18   Solution IR spectra for (a) MgSO4 (standard) and oxovanadium(IV) cyclam 









3.3.4. Conductivity Measurements 
Electrical conductivity was measured using the JENWAY Ltd Model 
4310 conductivity meter with an electrode of surface area 1 cm2.  Calibration 
of the instrument was acquired with the Hanna conductivity standard      
1413 µS / cm prior to measurement of the sample.  Solutions (1 mM) of 
complexes 21 and 22 were prepared from double distilled water and 
recorded at ambient temperature. 
 Published experimental values for conductivity measurements of 
electrolytes in water are given in Table 3.19[10] and provide an indication of 
ranges that may be expected from different ratios of electrolytes in solution.   
Table 3.19   Expected Molar Conductance (ΛM) Rangesa for 2, 3, 4 and 5 Ion Electrolytes   
(~10-3 M) at 298 K  
Electrolyte Types           
Solvent 
             
Dielectric 
Constant 
1:1 2:1 3:1 4:1 
Water [11] 78.4 118-131 235-273 408-435 ~560 
a  Units on all molar conductivities are Ω-1 cm2 mol-1 
An example of the order of magnitude expected for neutral complexes is 
described in the literature as 5-6 Ω-1 cm2 mol-1 for mixed-ligand complexes    
(1 x 10-3 M) of formula [M(bpy)(cbdca)] where M is Pd(II) or Pt(II).[12]  Values 
for complexes 21 and 22 are listed in Table 3.20.  Conductivity is directly 
linked to the concentration of ions in solution and the values show an 
increase in conductivity for solutions of the order: complex 22 > MgSO4 ~ 
NaCl > complex 21.  
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                   Table 3.20   Conductivity measurements for oxovanadium(IV)                                   
      cyclam complexes (21, 22) and standards 
 1 mM 0.1 mM 
NaCl                             
t = zero                        
t = 24 h                        
t = 60 h                        
t = 84 h 
                                
135    (135)                    
139    (139)                    
140    (140)                    
138    (138) 
                                
160    (16)                
150    (15)                
160    (16)                
160    (16) 
MgSO4                        
t = zero                        
t = 24 h 
                                
186    (186)                    
182    (182) 
                                     
-                                    
- 
21                                 
t = zero                        
t = 24 h 
                                                
61      (61)                         
61      (61) 
                          
150    (15)                   
150    (15) 
22                                 
t = zero                        
t = 24 h 
                                
247    (247)                      
247    (247) 
                                     
-                                    
- 
                    Units on all molar conductivities are Ω-1 cm2 mol-1  and values                          
       in brackets represent measured conductivities, κ. 
 
3.3.5. EPR spectroscopy 
 EPR spectroscopy revealed 8-line spectra for the 51V (I = 7/2, 99.76% 
natural abundance) quadropolar nucleus, 3d1 complexes (no. lines = 2nI+1).  
All calculated A and g-values for 298 K and 77 K spectra are shown in Tables 
3.22 and 3.23 respectively.  Spectra representative of all the cyclam complexes 
are shown in Figure 3.21 for room temperature analyses (water and 
methanol) and for frozen samples.  Data were simulated using Bruker 
WINEPR Simphonia version 1.26 software by the National EPR Centre, 
University of Manchester, UK and corrected as for the DPPH standard.[13]  
Spectra were compared with a reference complex 23 where the 6th axial 
ligand trans- to the V=O group is expected to be a solvent molecule, 
synthesised by abstraction of the chloride from complex 22 using AgPF6.  All 



















Figure 3.21   Representative spectra of all oxovanadium(IV) cyclam complexes 21-29 showing 
(a) solution spectrum in water, 298 K and (b) frozen spectrum in methanol, 77 K. 
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              Table 3.23   EPR parameters A(G) and g-values calculated for all complexes in methanol 
Axial ligand 





H2O, 23 Bromide 
(Br-), 24 




GMP, 28 cGMP, 29 
Aiso (G), 298 K 88 88 88 88 88 88 88 88 
A┴ (G), 77 K 53               xx 
53               yy 
53             xx 
53            yy 
53             xx 
53            yy 
53             xx 
53            yy 
53          xx 
53         yy 
53            xx  
53               yy 
53            xx  
53               yy 
53          xx  
53               yy 
A║ (G), 77 K 167              zz 167           zz 167           zz 167           zz 167        zz 167              zz 167              zz 167              zz 
g-value, 298 K 1.972 1.972 1.972 1.972 1.972 1.972 1.972 1.972 
g-value, 77 K 1.983          xx 
1.983       yy 
1.968           zz 
1.983        xx 
1.983       yy 
1.968        zz 
1.983        xx 
1.983       yy 
1.968        zz 
1.983        xx 
1.983       yy 
1.968        zz 
1.983     xx 
1.983    yy 
1.968     zz 
1.983        xx 
1.983       yy 
1.968           zz 
1.983        xx 
1.983       yy 
1.968           zz 
1.983        xx 
1.983       yy 
1.968           zz 
Axial ligand 





H2O, 23 Bromide 
(Br-), 24 




GMP, 28 cGMP, 29 
Aiso (G), 298 K 88 88 88 88 88 88 88 88 
g-value, 298 K 1.972 1.972 1.972 1.972 1.972 1.972 1.972 1.972 
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3.3.6. EXAFS/XANES 
 Spectra were obtained by Danielle Covelli, University of British 
Columbia at the Stanford Synchrotron Radiation Laboratory, for 
oxovanadium(IV) cyclam complexes 21 (sulfate) and 22 (chloride) and 
compared with the bicyclam analogues 30 (sulfate) and 31 (chloride) having 
identical axial ligands trans- to the V=O group.  The data for 30 and 31 are 
shown in Chapter 4.  Vanadium K-edge EXAFS data for cyclam complexes 21 
and 22 are shown in Figure 3.24.  EXAFS parameters obtained from R-space 
fits for 21 (k3, Δk = 2-13 Å-1, Δr = 0.7-2.5 Å) and 22 (k3, Δk = 1.7-12.5 Å-1, Δr = 
0.7-2.5 Å) are listed in Table 3.25 and statistical parameters from best R-space 
fits are given in Table 3.26.  The XANES spectrum is shown in Figure 3.27 
and includes data for the bicyclam analogues 30 and 31.   
 These spectra will not be discussed in any detail in this chapter as they 
will be included with the EXAFS and XANES data for the bicyclams and 







Figure 3.24   R-space (non-phase shift corrected) with calculated fits                             
EXAFS data for (a) VO(cyclam)sulfate 21 and (c) VO(cyclam)chloride, 22.                                  
( Figures (b) and (d )not shown relate to the bicyclam data in Chapter 4). 
V=O 
V-N V=O V-N 
V-Cl 
R (Å) R (Å) 
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Table 3.25   EXAFS parameters for oxovanadium(IV) complexes 21 (sulfate) and 22 (chloride) 















































Definitions from Table 3.25 
aN = path degeneracy, R = distance in Å, σ2 = bond variance (related to Debye-Waller factor), 
SO2 = amplitude reduction parameter and ΔEo = internal reference energy. 
b These parameters were fixed during the fitting procedures. 
c  Estimated coordination number for each path, where CN = N*SO2*(GSO2) 
d Global SO2 (GSO2) is defined as a global amplitude reduction factor (equivalent for all 
paths).  GSO2 was adjusted in cases where CN for V-O deviated significantly from 1.   
 
Table 3.26   Statistical parameters obtained from the best R-space fits given in Table 3.25 for 
complexes 21 and 22 








21 12 34.5 85.4 0.0027 





Figure 3.27   XANES pre-edge data for (top) oxovanadium(IV) cyclam (21) and bicyclam (30) 
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3.3.7. Antiviral HIV Tests 
 Anti-HIV activity tests on complexes 21 (sulfate) and 22 (chloride) 
were carried out by Professor Dr Erik De Clercq, Rega Institute, Katholieke 
Universiteit Leuven, Minderbroedersstraat 10, B-3000 Leuven, Belgium.  Both 
cyclam complexes were found to be completely inactive against both HIV-1 
and HIV-2.  Results from the antiviral and cytotoxicity evaluations are 
detailed in Table 3.28.  The complexes were tested against a range of virus 
strains in addition to HIV and found to be completely inactive against all cell 
lines.  Results from these evaluations are detailed in Tables 3.29 – 3.32. 
Table 3.28   Anti-HIV and cytotoxicity evaluation in IIIB and ROD cell cultures 












21 IIIB > 340  > 340   x1 5 1    
  > 340  > 340  x1 4 1 > 340       > 340  x1 
 ROD > 340  > 340  x1 27 2    
  > 340  > 340   x1 24 2 > 340       > 340  x1 
22 IIIB > 360  > 360   x1 4 1    
  > 360  > 360   x1 7 1 > 360    > 360  x1 
 ROD > 360  > 360   x1 14 2    
  > 360  > 360   x1 14 2 > 360       > 360  x1 
 
Table 3.29   Cytotoxicity and antiviral activity in HeLa cell cultures 












21 > 100 > 100 > 100 > 100 
22 > 100 > 100 > 100 > 100 
a Required to cause a microscopically detectable alteration of normal cell morphology                            
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Table 3.30   Cytotoxicity and antiviral activity in Vero cell cultures 
















21 > 100 > 100 > 100 > 100 > 100 > 100 
22 > 100 > 100 > 100 > 100 > 100 > 100 
a Required to cause a microscopically detectable alteration of normal cell morphology                            
b Required to reduce virus-induced cytopathogenicity by 50% 
 
Table 3.31   Anti-Feline Corona Virus (FIPV) and anti-Feline Herpes Virus activity and 
cytotoxicity  in CRFK cell cultures 
EC50b (µM) Compound CC50a (µM) 
Feline corona virus 
(FIPV) 
Feline Herpes virus 
21 > 100 > 100 > 100 
22 > 100 > 100 > 100 
a 50% cytotoxic concentration, as determined by measuring cell viability with the colorometric 
formazan-based MTS assay                                                                                                                        
b 50% effective concentration, or concentration producing 50% inhibition of virus-induced  cytopathic 
effect, as determined by measuring the cell viability with the colorometric formazan-based MTS assay.                                                                                                        
CRFK cells: Crandell-Rees Feline kidney cells 
 
Table 3.32   Cytotoxicity and antiviral activity in HEL cell cultures 























21 > 100 > 100 > 100 > 100 > 100 > 100 
22 > 100 > 100 > 100 > 100 > 100 > 100 
a Required to cause a microscopically detectable alteration of normal cell morphology                            
b Required to reduce virus-induced cytopathogenicity by 50% 
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 Oxovanadium(IV) cyclam complexes were also tested for CXCR4 
binding activity using an alternative assay.  An investigation was carried out 
using antibody competition binding tests for complexes 23 
(oxovanadium(IV) cyclam aqua) and 29 (oxovanadium(IV) cyclam cGMP) as 
an indirect measure of the amount of complex successfully bound to CXCR4.  
The extent of binding was detected by fluorescence and these experiments 
were carried out by Dr Steve Archibald, Departments of Chemistry and 
Biological Sciences, University of Hull, Hull, UK.   
 Details are listed in Table 3.33 and Figure 3.35 shows the plot obtained 
for complex 29 which is representative of both complexes tested.  It is of 
course possible that, in solution, complex 29 is the same as complex 23 as the 
EPR results would suggest.  The plot shows the fluorescence lies in the 
region of the positive control suggesting that none of the complex was found 
to be strongly bound to CXCR4.  This suggests that binding of the complexes 
to CXCR4 is weak, and that the natural antibody is largely favoured and may 
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Table 3.33   Antibody competition binding studies    
Compound Antibody inhibition (%) 
Saturated with 20 µM  Duplicate 1 Duplicate 2 
23 2.93 0 
29 5.67 3.15 












Figure 3.35   Fluorescence plot from antibody competition binding studies 
Key Name Parameter Gate
- control.001 FL1-H No Gate
ARVC(cGMP-2).011 FL1-H No Gate
+ control.019 FL1-H No Gate
102 101 100 
FL1-H 
Key Name Parameter Gate
- control.001 FL1-H No Gate 
ARVC(cGMP), 29 FL1-H No Gate 
+ control.019 FL1-H No Gate 
100 
  80 
  60 
  40 
  20 
   0 
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3.3.8. In-silico docking of metallomacrocycles with bovine rhodopsin 
 template 
 Until recently[14, 15] the only 7-helix transmembrane G-protein coupled 
receptor for which the crystal structure is 
known is bovine rhodopsin, a 
photoreceptor of the vertebrate visual 
system, and has typically been used as a 
template for all known 7-helix 
transmembrane GPCRs.  The seven 
transmembrane alpha helices are linked 
together sequentially by extracellular and 
cytoplasmic loops.[16]  A molecule of the 
chromophore retinal (retinylidene) is 
represented by red spheres and located in 
the binding site, found closer to the 
extracellular section.[17] The rhodopsin 
structure is commonly used to model 7-helix transmembrane proteins such 
as CXCR4, the coreceptor for HIV.   
 A model was achieved using Modeller release version 8 and version 2 
and this work was carried out with the help of Dr Dinesh C Soares, 
Department of Medical Genetics, Western General Hospital, Edinburgh.  
CXCR4 shows 33% sequence alignment identity with bovine rhodopsin and 
from the model it is possible to manually dock an antagonist molecule in the 
relevant binding site.  This method can be used to study possible binding 
interactions between the functional groups of amino acid residues and that of 
the antagonist molecule, gaining some insight into how a particular 
antagonist shows anti-HIV activity in vivo.  Figure 3.37 shows a modelled 
Figure 3.36   X-ray crystal 
structure of bovine rhodopsin [17]  
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representation of the CXCR4 coreceptor and the relevant amino acid residues 
thought to be associated with the binding of zinc(II)-(xylyl-bicyclam)[18] are 
highlighted.  Complex 21 (sulfate) was chosen as the antagonist for potential 











 Manual docking of this compound was performed under SYBYL 
version 6.9 (Tripos Associates, St. Louis, MO, USA).  Complex 21 was first 
superimposed onto one ring of the previously docked [Zn2-xylyl-bicyclam]-
CXCR4 protein receptor interaction[18] using all equivalent Cα atoms.  This 




Figure 3.37   Representation of CXCR4 and antagonist binding sites 
(carboxylate residues are shown as red spheres) 
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with respect to CXCR4 (cf. [Zn2-xylyl-bicyclam]).  The vanadium cyclam 
compound was then merged with the CXCR4 protein model into a separate 
MOL2 file using SYBYL v6.9.   
 Expected clashes were observed between Asp171 and the sulfate 
group, which was subsequently removed to free the axial 6th position of the 
octahedral geometry.  The EPR data from Section 3.3.5 suggest that the 6th 
ligand is labile and may be exchanged in water and this assumption is used 
in the modelling exercise.  Parameters were set with a view to investigate the 
possibility of metal-carboxylate interactions with Asp171 in the binding site.  
In this case, the vanadium centre was fixed relative to the receptor.  A 
distance restraint (1.609 Å) was set between V=O to maintain the bond length 
and prevent stretching during the minimisation process.  Bad contacts and 
geometries were then relieved by energy minimising the region of the 
CXCR4 receptor surrounding the oxovanadium(IV) cyclam complex 21, (all 
amino acid residues 5Å from the cyclam ligand).   
 Figure 3.38 shows a model of one of the known binding sites for 
CXCR4, highlighting how an oxovanadium(IV) cyclam complex might bind 
to the site.   
 











 A weak interaction between the oxygen atom of the V=O group and 
the proton of the α-carbon of a tryptophan residue (Trp195) is seen in 
addition to a hydrophobic interaction with the hydrocarbon backbone of the 
cyclam ring.  Hydrogen bonding may also be possible between carboxylate 
oxygens of an aspartate residue (Asp171) and NH protons of the macrocycle 
which is in the trans-III configuration.  This provides a suitable geometry for 
hydrogen bonding due to the downward oriented protons.  A distance of   
3.4 Å is measured between the vanadium metal centre and carboxylate 














Figure 3.38   Model of an oxovanadium(IV) complex in one of the CXCR4 binding 
sites   
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3.4.   Discussion 
3.4.1. Oxovanadium(IV) cyclam complexes in the solid state 
3.4.1.1. Magnetic measurements 
 Analysis by SQUID (Superconducting Quantum Interference Device) 
provided magnetic measurements for complexes 21 (sulfate) and 22 
(chloride) and reveal the complexes to be dominated by antiferromagnetic 
interactions in each case.  Magnetic susceptibility has been measured in the 
temperature range 0-300 K and calculated µeff values (Table 3.4) confirm the 
presence of one vanadium centre for each complex.  The g values for V(IV) 
are expected to be slightly less than 2 and calculated values are consistent 
with this, although the sulfate complex is slightly lower than the chloride.  
This lower value most likely arises from either a slight impurity or perhaps a 
small amount of water or other solvent not accounted for in the molecular 
weight.  Theta values for both complexes are small and for sulfate it is 
essentially zero indicating negligible intermolecular interactions. For the 
chloride complex, the interactions look to be small and antiferromagnetic. 
3.4.1.2. X-ray crystallography 
X-ray crystallography shows all 4 oxovanadium(IV) cyclams 
crystallise with the thermodynamically stable trans-III ring configuration.  
The vanadium centre sits outwith the plane of the 4 ring nitrogen atoms and 
the angle N-V-N differs between complexes.  This difference appears to be 
dependent upon the extent of both intra- and intermolecular hydrogen 
bonding between the axial ligand, NH protons and solvent molecules.  
Significant differences are also seen between bond lengths of the axial ligand 
and V=O groups and angles (L-V=O).  Table 3.39 lists the values found.   
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Table 3.39   X-ray crystal structures of oxovanadium(IV) cyclams in order of increasing 










21                2.1359(16) 4 177.83(9) 2 166.88(7) 2 
22               2.6501(12) 1 176.99(12) 3 165.46(16) 3 
25                    2.6044(7) 2 176.91(7) 3 168.51(8) 1 
26                   2.2053(19) 3 178.74(8) 1 166.46(7) 2 
  
The values show that the V-Cl bond length of complex 22 is 
significantly longer than any of the other complexes.  The complex also 
exhibits the smallest angles for L-V=O and N-V-N.  In comparison with 
complex 25 where the axial ligand is also chloride, the values show that 
changing the counter ion affects the N-V-N angle.  The larger iodide ion 
keeps the molecules sufficiently far enough apart that no hydrogen bonding 
takes place between the chloride axial ligand and NH protons of adjacent 
molecules.  This particular hydrogen bond is seen extensively in complex 22 
(Figure 3.10) and results in a significant decrease of the N-V-N angle from 
the non-hydrogen-bonded analogue, 25.  The axial ligands of complexes 21 
and 26 are bonded to the vanadium metal through atoms with similar 
electronegativity values.  Complex 21 (O3SO-V) exhibits both intra- and  
inter-molecular hydrogen bonding between the sulfate, NH protons and 
solvent molecules, and has a smaller L-V=O bond angle than that of complex 
26 (SCN-V) which shows no hydrogen bonding in the crystal matrix.  There 
appear to be no previous reports of 6-coordinate oxovanadium(IV) structures 
of cyclam in the CSD[19], nor for any other oxidation state of vanadium in 
cyclams.  A    5-coordinate square pyramidal oxo-vanadium(IV) cyclam has 
been reported[20] but no crystal structure is available for comparison of V-N 
bond lengths.  It would be interesting to compare how the bond length of 
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V=O may be affected by this geometry.  Attempts to crystallise complex 23 
which may also be a 5-coordinate structure have not been successful so far. 
3.4.1.3. Infrared and Resonance Raman spectroscopy 
 For all complexes, the strong V(IV)=O vibrational stretch was found to 
lie in the range 933 – 988 cm-1, in good agreement with literature values of 
985 ± 50 cm-1.[21]  NH stretches were compared and found to be within 
expected values of 3000 – 3500 cm-1 with small variations between the 
complexes.[22]  It would not be expected that the axial ligand trans- to the V=O 
group would affect the strength of the NH bonds nor the subsequent V-N 
bond as the electronic structure of the vanadium(IV) metal centre does not 
change with alternating axial ligand.  Complex 21 shows the characteristic 
V(IV)=O vibrational stretch at 974 cm-1, unusually high for a 6-coordinate 
complex and would indicate the sulfate binds weakly.  Complex 22 shows 
the V(IV)=O stretch at 988 cm-1 suggesting that the chloride ligand is also 
weakly bound and this is borne out by the long V-Cl bond length   
(2.6501(12) Å) found in the X-ray structure.  
 Raman spectroscopy revealed additional signals on increasing the 
percentage of laser light allowed through the filter.  The V=O stretch was 
seen only for the sulfate 21 and chloride 22 complexes and weak signals in 
the region 950-980 cm-1 are in good agreement with the strong infrared 
absorption values for this group.  Assignments were made for vibrations of 
bonds between the oxovanadium(IV) atom with the nitrogens of the 
macrocycle ring (V-N) at 445 cm-1.[23]  It is documented for V(0) and V(II) 
compounds that the V-N stretch occurs between 385 – 370 cm-1.[24]  V(0) and 
V(II) compounds have d5 and d3 electronic structures respectively.  An 
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increase in oxidation state from 0 to II gives a slight increase in the V-N 
stretch from 371 cm-1 to 385 cm-1.  Further oxidation to V(IV), with a d1 
configuration, may be expected to show a more significant change in 
frequency due to the higher concentration of charge on the vanadium having 
a stronger electron-withdrawing effect on the nitrogen lone pair, resulting in 
a stronger bond.  Raman signals were also seen in the range 350–250 cm-1 for 
two of the complexes and these have been assigned to the   
oxovanadium(IV)-axial ligand bond, trans- to the V=O group.  These signals 
were seen only for complexes 21 (V-O, 295 cm-1) and 22 (V-Cl, 300 cm-1) when 
applying the 100% filter.  The assigned V-O and V-Cl signals became 
apparent on increasing the filter aperture of the laser from 10% to 100%, but 
the result was decomposition of the complex.  This was confirmed by visual 
inspection which revealed charring in addition to a new signal circa. ~1000 
cm-1 and cannot be assigned to any functional group within the complexes.   
3.4.1.4. EXAFS 
 EXAFS data were Fourier-transformed over a k-range varying from 
1.6-13 Å-1.  The data shows two main first-coordination shells for the sulfate 
complex 21 and the scattering pathways are assigned as V=O and V-N.  No 
signal is seen for V-O of the sulfate complex and it is thought to be hidden 
under the large signal for V-N.  The data clearly shows three main first-
coordination shells for the chloride complex 22 and the scattering pathways 
are assigned as V=O, V-N and V-Cl respectively.  These data will be 
discussed more fully in Chapter 4 when discussion of the bicyclam EXAFS 
and XANES data are used to compare the electronic structures of the 
oxovanadium(IV) sulfate and chloride bicyclams with the cyclam analogues 
of this chapter. 
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3.4.2. Oxovanadium(IV) cyclam complexes in solution 
3.4.2.1. Infrared spectroscopy 
Solution infrared spectroscopy was used to investigate the possibility 
of displacement of the axial ligand.  Comparison of the vibrational stretch for 
the V=O group with that of the solid state values may show differences in 
terms of binding strength of the axial ligands.  For complex 21, exchange of 
the sulfate group with water can be investigated through the vibrational 
modes related to the symmetry of the sulfate group.  The free sulfate ion 
belongs to the high-symmetry point group Td and of the four fundamentals, 
only v3 and v4 are infrared active. [24, 25]  If the symmetry of the ion is lowered 
by complex formation, the degenerate vibrations split and Raman-active 
modes appear in the infrared spectrum.[24]  In complex 21, the symmetry of 
the sulfate ion belongs to the C3v point group in the solid state, confirmed by 





 The spectrum acquired for complex 21 revealed that the ν3 vibration 
mode was split into two signals at 1119 and 1043 cm-1 in addition to a signal 
at 1095 cm-1  assigned to free sulfate.  The free sulfate signal appears to be 











Unidentate complex (C3v) 
Figure 3.40   Sulfate coordination environments for free and bound ions 
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bidentate structure of C2v symmetry would split the v3 vibration into 3 
separate bands, but the range is outwith that seen for complex 21.  The ν4 
vibration is unchanged at 600 cm-1 from that of the free sulfate.  This would 
also be split into three bands if the structure was bidentate or bridged 
bidentate.  The V=O stretch at 957 cm-1 occurs at a lower wavenumber than 
the solid state sample (974 cm-1).  For a mixture of bound and unbound 
sulfate species in solution, a second signal for V=O would be expected.  This 
would be likely to occur at a higher wavenumber (VOSO4 = > 1000 cm-1) and 
is suspected to be hidden beneath the broad signal for free sulfate at         
1095 cm-1.  The spectrum acquired for complex 22 also shows a decrease in 
the V=O stretch at 980 cm-1 from the solid state sample (988 cm-1), although 
much smaller than that seen for the sulfate complex, 21.  The strong band at 
1100 cm-1 is assigned to the C-Oas stretch of methanol. 
3.4.2.2. Conductivity measurements 
The binding strength of axial ligands for complexes 21 and 22 was 
investigated by analysing the concentration of ions in an aqueous solution to 
see if the vanadium-axial ligand bond strength could be correlated with the 
extent of ligand displacement.  Three different concentrations of NaCl were 
used to standardise the experiment and readings were recorded over several 
hours to ensure the solution had stabilised.  For a 1 mM concentration, values 
for NaCl and MgSO4 show that both salts fully dissociate to give 1:1 
electrolytes in solution.  These values lie slightly outwith the 1:1 range 
quoted in Table 3.19 and show that the ranges given can only provide an 
indication of expected values as both NaCl and MgSO4 are 1:1 electrolytes.  
The experimental result for 21 suggests that the complex may be partially 
hydrolysed.  The dilution factor is significant as a change in concentration 
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should result in a large difference in conductivity for weak (partially 
dissociated) electrolytes.  The value of 61 Ω-1 cm2 mol-1 is too low for a 1:1 
electrolyte/complex (full hydrolysis) in solution and too high for a neutral 
complex (no hydrolysis) according to the value ranges expected for these two 
possibilities.  The value for complex 22 suggests that full hydrolysis has 
taken place, as 247 Ω-1 cm2 mol-1 is in the correct range for a 2:1 
electrolyte/complex according to the published values listed in Table 3.21.  
As there are two chloride atoms (axial ligand and counter ion) in this 
structure, a 2:1 ratio would be expected if the complex is fully hydrolysed. 
3.4.2.3. EPR spectroscopy 
EPR spectroscopy revealed 8-line spectra due to coupling of the 
unpaired electron with the 51V (I = 7/2, 99.76% natural abundance) 
quadropolar nucleus, 3d1 complexes (no. lines = 2nI+1).  Spectra for all 
complexes show the g-values are close to 2 in all cases as expected, as the 
unpaired electron is in a non-degenerate orbital.  In addition, there should 
also be negligible mixing in of an orbital component from excited states 
through spin-orbital coupling.  The unpaired electron is in the d(xy) orbital 
and oriented between the N atoms in the cyclam plane.  As d(xy) is 
essentially non-bonding, any interaction with the nitrogen orbitals is very 
small and no resolved coupling to nitrogen is seen.  Any orbital angular 
momentum is subsequently quenched resulting in a “spin-only” system.  In 
both methanol and water the cyclam complexes 21, 22 and 24-29 show 
identical spectra to the reference complex 23, in which the 6th axial position is 
thought to be filled by a solvent molecule.  This suggests that the 6th ligand 
for the complexes has been replaced by solvent and appears to be in 
agreement with X-ray crystal structure data (Table 3.5) where bond lengths 
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of the axial ligand trans- to the V=O group indicate that this ligand is weakly 
bound.  It is of course possible that the ligand may still be attached and this 
can neither be discounted nor proved from X-band EPR analysis.   
3.4.3. Oxovanadium(IV) cyclam complexes in-silico  
 There are two known strains of the HIV virus (HIV-1 and HIV-2). 
Although twelve different chemokine receptors are known to function as 
HIV coreceptors in cultured cells, only two are known to play an active part 
in vivo.[26]  The first of these two receptors, CCR5, binds macrophage-tropic 
viruses associated with mucosal and intravenous transmission of HIV.  The 
second, CXCR4, is active in the binding of T-cell-tropic viruses, often found 
in the later stages of disease.  The CXCR4 coreceptor plays a crucial role in 
allowing the HIV virus to enter into the cell’s cytoplasm where it discharges 
its DNA, effectively turning the cell into an HIV factory.  The family of 
proteins to which both CCR5 and CXCR4 belong are known as 7-helix 
transmembrane proteins and these proteins characteristically span the lipid 











Cytoplasm      
Figure 3.41   Representation of a 7-helix transmembrane protein  
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The literature shows that the bicyclam AMD3100 is most active as a zinc(II) 
complex[26] and in solution under physiological conditions the two 
macrocyclic rings exist in different configurations.  One ring remains in the 
cis-V configuration found in the solid state crystal structure, but the other is 
thought to exist as trans-I (or possibly trans-III resulting from flexibility of the 
ring) in solution.  Binding is through the zinc atom with carboxylate oxygen 
atoms of aspartate residues (Asp 171, Asp 262) and hydrogen bonding 
between the N-H protons of the cis-V configured macrocycle and carboxylate 
group of the glutamate residue (Glu 288).  These interactions are shown 







 Molecular modelling can offer a representation of possible binding 
interactions in the CXCR4 active site.  Previous studies show that activity 
may result from binding in an analogous fashion to zinc bicyclam[18], through 
important metal-carboxylate interactions with aspartate residues, Asp171 
and Asp272, found in two separate binding sites.  Complex 21 (sulfate) was 
used as a model to represent oxovanadium(IV) cyclam complexes 21-29, 
Figure 3.42   Proposed interactions between Zn(II)-bicyclam and the          
CXCR4 binding sites[16] 
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irrespective of the axial ligand trans- to V=O based on the assumption made 
from the results of the solution studies that the axial ligand undergoes either 
part or full exchange in an aqueous environment.  Modelling of the complex 
is in a binding site thought to accommodate the trans-I configuration.  The 
configurations trans-I and trans-III are likely to be interconvertible due to the 
flexibility of the ring and so the structure chosen (trans-III) was deemed to be 
a satisfactory model.   
 Potential hydrogen bonds were observed between carboxylate oxygen 
atoms of Asp171 with two NH protons of the cyclam ring (~2.0 Å and 2.7 Å) 
and a weak interaction observed between V=O---H (2.2 Å) of the α-carbon 
proton from Trp195 in the CXCR4 protein backbone.  Trp195 was previously 
implicated in a putative stacking interaction with Zn2-bicyclam and thought 
to provide hydrophobic interactions with the hydrocarbon backbone of the 
cyclam ring.[27]   
 The antiviral test results indicate that the oxovanadium(IV) complexes 
may not bind (or bind weakly) to the carboxylates of Asp171 in the CXCR4 
binding site and the model indicates that the proposed weak interaction 
between the V=O group and the proton attached to the α-carbon of Trp195 
could be anchoring the ring in an unfavourable position for successful 
binding of the axial ligand trans- to V=O.  The distance between the 
vanadium centre and carboxylate oxygens of Asp171 (3.4Å) was found to be 
incompatible for formation of a coordination bond and this may be only one 
of a number of possible reasons for the inactivity of the oxovanadium(IV) 
cyclam complexes.  
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3.5.   Conclusion 
     Infrared and Raman spectroscopy, EXAFS, magnetic measurements 
and X-ray crystallography were used to study oxovanadium(IV) complexes 
in the solid state and the presence of the oxovanadium(IV) ion is confirmed 
for all complexes.  As seen in the recrystallisation of the iodide complex 25 
(chloride axial ligand) and the binding of thiocyanate through the nitrogen 
atom of complex 26, vanadium as a hard metal centre shows an interesting 
preference for hard ligands and all complexes form the trans-III configuration 
irrespective of ligand or counter ion.   
 The ring configuration is known to be of importance for antiviral 
activity of metallocyclam complexes, as seen for previously studied zinc 
complexes where interconversion between configurations is often facile.[18]  
Zinc complexes show higher antiviral activity than any other transition metal 
studied to date.  The paramagnetic nature of the oxovanadium(IV) 
complexes has presented challenges for identification of the ring 
configurations in solution as NMR analysis has not been possible.  It would 
seem that no other analytical technique available at this time can provide 
such information and at this point it is unknown whether the 
oxovanadium(IV) cyclams exhibit any interconversion of ring configuration 
in solution.   
 As antiviral activity is greatly influenced by metal complexation, it is 
of paramount importance to understand the factors that influence 
interactions between the coreceptor protein CXCR4 and metallocyclam 
complexes.  Molecular modelling suggests that one possible reason for the 
inactivity of the cyclam complexes may be due to the unfavourable position 
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of the macrocycle in the binding site as a consequence of weak interactions 
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4. OXOVANADIUM(IV) BICYCLAM COMPLEXES 
 This chapter describes the synthesis and characterisation of 
oxovanadium(IV) bicyclam and cyclam complexes with aromatic pendant 
arm substituents.  Numbers in bold after compound names refer to 
experimental data in Chapter 7.   
 In the late 1980’s, the serendipitous discovery of an impurity in a 
batch of cyclam resulted in a compound that showed high antiviral activity 
against HIV.[1]  The compound was characterised as the bicyclam JM1657 (18) 
and the structure was found to display a carbon-carbon bridge between two 
cyclam rings creating two chiral centres.  This proved an obstacle in attempts 
to reproduce the compound due to the difficulty in forming the carbon-
carbon bond between the two macrocycles.  Alternative strategies were 
adopted and the synthesis of various linker molecules was attempted in an 
effort to find an improved or equally active product.  This led to the 
discovery of JM2763, a bicyclam constructed of two cyclam rings joined by an 
aliphatic linker bridge consisting of 3 methylene groups.  The compound 
showed similar antiviral activity to JM1657 (18).   
 Many derivatives were synthesised in an attempt to improve the 
activity of bicyclam and the most significant result came when an aromatic 
linker bridge was used.  This work led to synthesis of the compound JM3100, 
later renamed AMD3100 (16) when a company called AnorMED (AMD) took 
over the development of the compound from Johnson Matthey (JM) and 
referred to as xylyl-bicyclam throughout this thesis. AMD3100 was 
successful as an entry inhibitor against HIV, reaching Phase II clinical trials 
but was not pursued further in light of cardiac problems experienced by two 
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patients.[2]  An unexpected observation made during pharmacokinetic studies 
revealed highly elevated levels of white blood cells in patients, even with low 
doses of the compound AMD3100 (40 to 80 µg per kg).  This led to an 
investigation into the particular type of white blood cells involved and it was 
revealed that AMD3100 showed a synergistic relationship with peg-
filgrastim in mobilising stem cells from the bone marrow into the blood 
stream.[1]  In 2006 the product was acquired by Genzyme and has since been 
relaunched commercially under the name of Mozobil, recently completing its 
second set of Phase III clinical trials as a stem cell mobiliser.  Both studies 
successfully met the primary and secondary endpoints and marketing 
applications have been submitted in the United States with expected 
approval by the end of the year.  European approval is expected in 2009 with 
subsequent global applications in up to 60 countries.[3]  Approximately 55,000 
stem cell transplants are performed each year for multiple myeloma, 
Hodgkin's and non-Hodgkin's lymphoma.[1] 




4.1.   Experimental 
4.1.1. Materials 
 Starting materials were purchased from Sigma-Aldrich as detailed in 









Figure 4.1   Xylyl-bicyclam, 16 
 
  113 
from Sigma-Aldrich.  HPLC Grade methanol and reagent grade diethyl ether 
were used for crystallisations.  Reagent grade ethyl acetate and hexane were 
used as eluents for flash column chromatography.  HPLC Grade methanol 
was used as the eluent for Sephadex column chromatography. 
4.1.2 Synthesis of Xylyl-bicyclam, 16 
 Xylyl-bicyclam 16, was synthesised from cyclam 17 using the route 
shown in Scheme 4.2.[4]  Trifluoroacetate was used as protecting groups for 
three of the four amines and deprotection was carried out using 10% sodium 
hydroxide. 
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4.1.3 Syntheses of oxovanadium(IV) cyclam complexes with aromatic 
 pendant arm substituents 
 Compounds 30 and 31 were synthesised from xylyl-bicyclam 16, 
shown in Scheme 4.3.  Compound 34 was synthesised from the         
naphthyl-substituted cyclam 33 by Dr S J Paisey, University of Edinburgh 
and is shown in Scheme 4.4. 
4.1.3.1     Synthesis of oxovanadium(IV) bicyclam complexes 












 The preparation of the bicyclam complexes was difficult and synthesis 
of only two products, 30 and 31, were achieved in sufficient purity for 































Scheme 4.3   General method used to prepare oxovanadium(IV) bicyclam sulfate 30 (L = sulfate) and 
chloride 31 (L’ = chloride). 
2Cl- 






















L = sulfate 
VOSO4.xH2O 
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comparison with the oxovanadium(IV) cyclam analogues 21 (sulfate) and 22 
(chloride) to investigate the chemistry of the oxovanadium(IV) group in 
macrocycles.  Methanol was used as the reaction solvent and formation of 
these oxovanadium(IV) complexes appeared to be in competition with either 
a polymerisation of the oxovanadium(IV) groups or, alternatively, the 
formation of a bridged species.  This by-product was insoluble in any of the 
organic solvents tested.  On recrystallisation of the complexes after 
purification using Sephadex column chromatography, the products then 
tended to react with the recrystallisation solvent system resulting in 
precipitation of insoluble solids.  This resulted in low yields of pure 
compound.  Scaling up the synthetic process resulted in a higher percentage 
of the by-product and several small syntheses were required to provide 
suitable amounts of the intended product.  Crystallisation of complexes 30 
and 31 suitable for X-ray purposes was unsuccessful.  Due to the 
paramagnetic nature of the oxovanadium(IV) metal centre, X-ray crystal 
structures would seem to be the best means of determining the configuration 
of the rings in the solid state.   
 Many syntheses were attempted in order to produce sufficient 
amounts of the complexes in this chapter necessary for analytical 
investigation, but not all gave good yields and in many cases the target 
compound was not achieved.  Two alternative vanadium bicyclam 
complexes were attempted by exchanging the chloride ligands from complex 
31.  The same methods and procedures used for ligand exchange syntheses of 
the cyclam complexes in Chapter 3 for thiocyanate (26) and cyclic GMP (29) 
were adopted.  These two ligands were chosen due to their biological 
significance and the syntheses proceeded without any obvious problems.  
Unfortunately, mass spectrometry did not confirm the intended products 
 
  116 
and the decision was taken to investigate a different macrocycle also bearing 
an aromatic pendant arm.   
4.1.3.2     Synthesis of oxovanadium(IV) naphthyl cyclam complexes 
 A cyclam with a naphthyl pendant arm (33) was used to complex 
vanadium.  Using the method adopted in Scheme 4.4, complexation was 








 On addition of VO(acac)2 to a solution of cyclam, it was observed that 
the initial green solution did not change colour during the reaction time of  
16 h.  No insoluble by-product was formed using this salt and mass 
spectrometry confirmed the presence of two major fragments and the 
molecular ion.  It was hoped that formation of single crystals for X-ray 
purposes would prove easier than for the bicyclam complexes, in an attempt 
to uncover information regarding ring configurations for oxovanadium(IV) 
























Scheme 4.4   Synthetic route for complexing naphthylated cyclam 
33 34 
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extrapolated to the bicyclam complexes 30 and 31 to help to explain the 
antiviral activity/inactivity of oxovanadium(IV) complexes associated with 
CXCR4 binding.  Several crystallisations were attempted using the same 
method that afforded crystals of the cyclam complexes i.e. diffusion of ether 
into a methanolic solution of the compound but no crystals had formed at the 
time of writing. 
4.1.4 FTIR and resonance Raman spectroscopy 
 Infrared absorptions for the V=O group were recorded for each 
complex and details are found in Table 4.5.  A Raman signal is seen at        
450 cm-1 for all complexes investigated in this chapter and is assigned to the 
V-N bond.  Signals found in the frequency range 350-250 cm-1 are assigned to 
V-L bonds, where L = 6th axial ligand trans- to the V=O group.  Selected 
spectra are shown in Figure 4.6. 
Table 4.5   Infrared V=O and NH vibrations with Raman signals for V-N bonds 
Complex V=O (cm-1) NH (cm-1) V-N (cm-1)  
30 (sulfate) 945 3278 (br), 3125 (br) 450 
31 (chloride) 964 3230 (w), 3107 (br) 450 
34 (acac) 995 3220 (br)  450 
  
 Raman spectra for complex 31 are shown for both 10% and 100% laser 
filter apertures.  Signals for the V=O group were not seen for the bicyclam 
complexes but a strong signal was present at 995 cm-1 for the             
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naphthyl-cyclam complex 34 in both the infrared and Raman spectra.  There 
was no variation in frequency for V-N in any of the complexes studied as 
expected. 
  







Figure 4.6   (a) Fingerprint region of Raman spectrum with 10% laser filter aperture of         











Figure 4.6   Raman spectra with 100% laser filter aperture of (c) oxovanadium(IV) bicyclam 
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4.1.5 UV-Vis spectroscopy 
 The reaction of 30 with an excess of acetate was monitored over time.  
A 10 mM solution of 30 was prepared and the absorbance detected at 690 nm 
and 450 nm.  Unfortunately, the complex precipitated from solution so the 
true concentration is unknown and no binding constants or extinction 
coefficients were determined.  An excess of ammonium acetate (3M) was 
added to the solution to mimic potential carboxylate binding in the CXCR4 
receptor site and to induce any observable spectral change.  An isosbestic 
point was seen at 350 nm shown in Figure 4.8, but from these data we can 
only tentatively suggest that binding to acetate occurs.  As millimolar 
concentrations were required to study these complexes, it was not possible to 
investigate acetate binding for the chloride sample, or to use UV-Vis 












Figure 4.7   Aqueous solution of oxovanadium(IV) bicyclam, 30  at 298 K. 
 
t = 0 
Figure 4.8   Addition of 3M ammonium acetate (0.5 mL) to an aqueous solution of              
oxovanadium(IV) bicyclam, 30 (0.5 mL) at 298 K. 
t = 0 
t = 15 h 
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4.1.6 EPR spectroscopy 
  EPR spectroscopy revealed 8-line spectra for the 51V (I = 7/2, 99.76% 
natural abundance) quadropolar nucleus, 3d1 complexes (no. lines = 2nI+1).  
All calculated A and g-values for 298 K and 77 K spectra are shown in Tables 
4.9 and 4.11 respectively.  Spectra for the bicyclam complexes 30 and 31 are 
shown in Figure 4.10 for room temperature analyses and in Figure 4.12 for 
frozen samples.  Data were simulated using Bruker WINEPR Simphonia 
version 1.26 software by the National EPR Centre, University of Manchester 
and corrected as for the DPPH standard.[5]  Room temperature spectra were 
obtained in water and methanol and compared to a reference complex 32, 
synthesised by abstraction of the chloride from complex 31 using AgPF6, 
where the 6th axial ligand trans- to the V=O group is expected to be a solvent 
molecule.  Sufficient amounts were only available for analysis in water and 
composition of the reference compound (analogous to the cyclam complex, 
23) was confirmed by mass spectrometry as oxovanadium(IV) bicyclam, m/z 
637.2 [M-2H2O]+.   
 
Ligand T (K) Aiso 
(G) 
giso Ligand T (K) Aiso 
(G) 
giso 
solvent (H2O) 298   88 1.974 solvent 
(MeOH) 
- - - 
sulfate, 30 298   84 
  95 
1.974 
1.972 
sulfate, 30 298 90 1.967 
chloride, 31 298 
298 





chloride, 31 298 90 1.973 
 
 
Table 4.9   EPR parameters of oxovanadium(IV)-xylyl-bicyclam complexes                                                
(a) water, 298 K                                                                  (b) methanol, 298 K 
 
 


















Aiso = 87 
Aiso = 115 
2 sets of signals for chloride species (c): 
Key: 
2 sets of signals for sulfate species (b): 
Aiso = 95 G 
Aiso = 84 G 
Figure 4.10   EPR spectra for oxovanadium xylyl-bicyclam complexes in water at room temperature.  
The axial ligand trans- to the V=O group is (a) H2O 32, (b) sulfate 30 and (c) chloride 31. 
(b) (a) 
Field (Gauss) B  
(c) 
Field (Gauss) B 
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 Two sets of separate signals are clearly seen in the room temperature 
spectrum in water for the bicyclam chloride complex, 31.  Simulation of the 
data gave rise to the values shown in Table 4.9 and suggests there may be 
evidence of solvent exchange (Aiso = 87 G) and a different environment for 
the vanadium centre (Aiso = 115 G).  Two sets of values were also found for 
the sulfate complex 30 and may suggest that each ring could be in a different 
configuration.  No evidence of solvent exchange for the sulfate complex was 
apparent from the values obtained (Aiso = 84, 95 G). 
Table 4.11   EPR parameters of frozen oxovanadium(IV) xylyl-bicyclam complexes in 
methanol 
Ligand T (K) A║ (G) A┴ (G) g║ g┴ 
(a) sulfate, 30             (A1) 77 167        zz 53          xx 
53         yy 
1.957     zz  1.972     xx 
1.972    yy 
(b) chloride, 31          (A1) 77 
 
167        zz  
          
53          xx 
53         yy  
1.957     zz 1.971     xx 
1.971    yy 
                                     (A2) 77 174        zz 53          xx 
53         yy 
1.950    zz 1.971    xx 
1.971   yy 
 
 Spectra for frozen solutions of complexes 30 and 31 show differences 
between the two.  Only a single set of A║ values can be extracted for the 
sulfate complex 30 with a corresponding A┴ value and simulated values are 
in good agreement with manual calculations.  The values are shown as (A1) 
on Table 4.11.  The chloride complex 31 shows two separate sets of peaks for 
A║ values and this is confirmed by the simulated data.  Values for this 
second set of peaks listed as (A2) in Table 4.11 may relate to either a different 
configuration for one of the rings of the macrocycle, or an exchange of the 
chloride ligand by solvent.  Due to the agreement in g-values, A║ and A┴ 
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(A1) with the sulfate complex 30, the nature of the bound ligands that give 
rise to these values may be similar.  
 An additivity relationship allows for the hyperfine coupling constant 
A║ to be correlated to the number and types of ligands present in the 
equatorial plane, with the most donating ligands contributing least to the 
hyperfine coupling.[6, 7]  The formula, devised by Wüthrich[8] and refined later 
by Chasteen[6] unfortunately cannot be applied to the complexes in this work 
as all 4 equatorial ligands are identical, thereby making the same 
contribution.   
 Simulated spectra are listed in Appendix 1 for the data from frozen 
and room temperature samples.  Simulation graphs for the bicyclam sulfate 
30 and chloride 31 represent all sets of signals in the aqueous experiment 
overlaid in one averaged spectrum.  This is also repeated for data for the 
frozen samples. 
    
 
  125 
                  
     
            
 






Figure 4.12   EPR frozen  spectra for oxovanadium xylyl-bicyclam complexes in methanol.  The axial ligand trans- to the V=O group is (a) sulfate 30 and (b) chloride 31.  




 A║ (A1)  
A┴   
Key: 




  126 
4.1.7 EXAFS/XANES 
 Spectra were obtained by Danielle Covelli, University of British 
Columbia at the Stanford Synchrotron Radiation Laboratory, for 
oxovanadium(IV) bicyclam complexes 30 (sulfate) and 31 (chloride) and 
compared with the cyclam analogues 21 (sulfate) and 22 (chloride) having 
identical axial ligands trans- to the V=O group.  The data for 21 and 22 are 
also shown in Chapter 3.   
 Vanadium K-edge EXAFS data for bicyclam complexes 30 and 31 are 
shown in Figure 4.12.  EXAFS parameters obtained from R-space fits for 21 
(k3, ∆k = 2-13 Å-1, ∆r = 0.7-2.5 Å), 22 (k3, ∆k = 1.6-12.5 Å-1, ∆r = 0.5-2.6 Å), 30 
(k3, ∆k = 1.7-12.5 Å-1, ∆r = 0.7-2.5 Å) and for 31 (k3, ∆k = 2-13 Å-1,                     
∆r = 0.7-2.5 Å) are listed in Table 4.13 and statistical parameters from best R-
space fits for all four complexes are given in Table 4.14.  All k-space data for 
the four complexes are given in Appendix 2.  The XANES spectrum is shown 
in Figure 4.15 and includes data for all four complexes.   
 These spectra will be used to discuss the comparison between 
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Figure 4.12   R-space (non-phase shift corrected) with calculated fits                                              
EXAFS data for (a)  VO(cyclam)sulfate 21, (b) VO(bicyclam)sulfate 30,                                                 
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Table 4.13   EXAFS parameters for oxovanadium(IV) cyclam complexes 21 (sulfate) and 22 
(chloride) and bicyclam complexes 30 (sulfate) and 31 (chloride) 

















































































































aN = path degeneracy, R = distance in Å, σ2 = bond variance (related to Debye-Waller factor), 
SO2 = amplitude reduction parameter and ΔEo = internal reference energy. 
b These parameters were fixed during the fitting procedures. 
c  Estimated coordination number for each path, where CN = N*SO2*(GSO2) 
d  Global SO2 (GSO2) is defined as a global amplitude reduction factor (equivalent for all 
paths).  GSO2 was adjusted in cases where CN for V-O deviated significantly from 1.              
* Note the ∆Eo is large for this sample; however, this provided the best possible fit. 
 
Table 4.14   Statistical parameters obtained from the best R-space fits given in Table 4.13 for 
complexes 21, 22, 30 and 31 








21 12 34.5 85.4 0.0027 
22 12 49.2 22.4     0.0031 
3 10 217.1 99.7 0.0011 
4 (Fit 1) 12 23.9 59.1 0.0037 
4 (Fit 2) 11 27.1 19.3 0.0042 
 
Definitions from Table 4.13 
 














Figure 4.15  XANES spectra of the four complexes studied:  (top) VO(cyclam)sulfate 21, 
VO(bicyclam)sulfate 30 and (bottom) VO(cyclam)chloride 22, VO(bicyclam)chloride 31.  
 
 
 The normalised XANES spectra of the four complexes are shown in 
Figure 4.15 with the emphasis on the pre-edge region.  All four compounds 
show a very pronounced pre-edge feature.  The pre-edge features result from 
a formally quadrupole-allowed dipole-forbidden 1s  3d transition which is 
normally extremely weak.  Due to the short V=O bond in these complexes a 
loss of centrosymmetry in the complex occurs and the pre-edge intensity 
increases.[9] 
Energy (eV) 
22      
31 
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4.1.8 Anti-HIV activity 
 Complexes 30 and 31 were tested by Professor Dr Erik De Clercq, 
Rega Institute, Katholieke Universiteit Leuven, Minderbroedersstraat 10,     
B-3000 Leuven, Belgium for anti-HIV activity.  Both xylyl-bicyclam 
complexes were found to be highly active against HIV.  Information and 
results of the anti-HIV and cytotoxicity tests are detailed in Table 4.12 and a 
graphical representation of the data is set out in Figure 4.13.  This bar chart 
compares levels of antiviral activity of the oxovanadium(IV) complexes with 
AMD3100 and the zinc form of AMD3100. 
Table 4.12   Anti-HIV and cytotoxicity evaluation in IIIB and ROD cell cultures 














30 IIIB  1.149   
(0.951) 
 > 151            
(> 125) 
> 131 101    
   1.57       
(1.3) 
 > 151            
(> 125) 
> 96 95  1.365 
(1.13) 
 > 151            
(> 125) 
> 111 
 ROD  4.457    
(3.69) 
 > 151               
(> 125) 
> 34 83    
   2.138      
(1.77) 
  > 151         
(> 125) 
> 71 92  3.297     
(2.73) 
 > 151    
(> 125) 
> 46 
31 IIIB  0.119 
(0.0925) 
 > 161            
(> 125) 
> 1351 102    
   0.117 
(0.0906) 
 > 161         
(> 125) 
> 1379 125  0.116      
(0.09) 
 > 161            
(> 125) 
> 1365 
 ROD  0.236  
(0.183) 
 > 161         
(> 125) 
> 683 88    
   0.142    
(0.11) 
 > 161           
(> 125) 
> 1139 96  0.193 
(0.15) 







* av. IC50 highlighted in red shows concentration of compound required to effect 50% 
inhibition of virus.   
 








Figure 4.13   Bar chart representation of antiviral test results from Table 4.12.  Higher bars 
for IC50 concentrations represent higher activity, higher bars for CC50 concentrations 
represent higher toxicity.  As cytotoxic concentration is determined to be < 40 µM, all 
complexes show high activity and low levels of toxicity to cells.  The y-axis is purely 







 Figure 4.14   3D representation of a possible configuration for the bicyclam chloride complex, 31.  
The macrocycle should be able to adopt the cis-V configuration from this geometry. 
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 In light of the results from the EPR investigation, a 3D representation 
of a possible configuration for the bicyclam complexes is shown in Figure 
4.14 using the bicyclam chloride 31 structure as an example.  The trans-V 
configuration shows how the chloride may be in a good position for 
hydrogen bonding with two NH protons of the ring and from this geometry 
it would be possible for the ring to adopt the more stable cis-V configuration, 
an important configuration for binding to carboxylates in the CXCR4 active 
site.   
 Due to the positive antiviral test results, it might be expected that at 
least one of the rings would be able to form the cis-V configuration based on 
previous results.[10] 
4.2  Discussion 
    Strong vibrational stretches are seen in the infrared assigned to the 
V=O group for both complexes 30 (945 cm-1) and 31 (964 cm-1).  No band for 
V=O is seen for either complex 30 or 31 in the Raman, but the naphthyl-
cyclam 34 gave rise to both infrared and Raman signals for the V=O group.  
NH stretches were compared and found to be within expected values of 3000 
– 3500 cm-1 with small variations between the complexes.[11]  As reported for 
the cyclam complexes in Chapter 3, it would not be expected that the axial 
ligand trans- to the V=O group would affect the strength of the NH bonds 
nor the subsequent V-N bond as the electronic structure of the vanadium(IV) 
metal centre does not change with alternating axial ligand.  Resonance 
Raman assignments were made for all three complexes for bonds between 
the oxovanadium(IV) metal centre with the nitrogen atoms of the macrocycle 
rings (V-N) at 450 cm-1.[12]  The V-N stretching frequency is documented for 
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V(0) and V(II) compounds and occurs between 385 – 370 cm-1.[13]  V(0) and 
V(II) compounds have d5 and d3 electronic structure respectively.  An 
increase in oxidation state from 0 to II gives a slight increase in the V-N 
stretch from 371 cm-1 to 385 cm-1.  Further oxidation to V(IV), with a d1 
configuration, may be expected to show a more significant change in 
frequency due to the higher concentration of charge on the vanadium having 
a stronger electron-withdrawing effect on the nitrogen lone pair, resulting in 
a stronger bond.  Raman signals were also seen in the range 350–250 cm-1 for 
two of the complexes and these have been assigned to the   
oxovanadium(IV)-axial ligand bond, trans- to the V=O group.  They are 
evident for complexes 31 (V-Cl, 350 cm-1) and 34 (V-O, 295 cm-1).  The 
assigned V-Cl signal became apparent on increasing the filter aperture of the 
laser from 10% to 100%, but the result of this was decomposition of the 
complex.  This was confirmed by visual inspection which revealed charring 
in addition to a new signal circa. ~900 cm-1, that cannot be assigned to the 
complex.  This decomposition of the sample had already been seen for the 
cyclam complexes in Chapter 3, in particular complex 21 when a crystal was 
used for this type of analysis.   
 Analysis of room temperature data acquired by electron paramagnetic 
resonance spectroscopy revealed different behaviour in solution for bicyclam 
complexes 30 (sulfate) and 31 (chloride) from that of cyclam complexes with 
comparable axial ligands, 21 (sulfate) and 22 (chloride).  The g-values are 
close to 2 in all cases as expected as the unpaired electron is in a non-
degenerate orbital.  In addition, there should also be negligible mixing in of 
an orbital component from excited states through spin-orbit coupling.[14, 15]  
The unpaired electron is in the d(xy) orbital and oriented between the N 
atoms in the cyclam plane.[16]  As d(xy) is essentially non-bonding, any 
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interaction with the nitrogen orbitals is very small and no resolved coupling 
to nitrogen is seen.  Any orbital angular momentum is subsequently 
quenched resulting in a “spin-only” system.[17] 
 In the sulfate 30 and chloride 31 complexes, significant differences are 
observed.  Neither set of peaks for the bicyclam sulfate complex 30 show 
similar calculated values to the reference complex where the 6th axial ligand 
is H2O and suggests there is no substitution of the 6th ligand by solvent, 
unlike that proposed for the cyclam complexes in Chapter 3.  The low Aiso 
value of 84 (G) is at the lower end of that reported for other vanadium(IV) 
species with O-donor ligands (85 to 110 G), although not the lowest reported 
(71 G).[7, 18, 19]  The values of giso (1.985, 1.983) fall within reported ranges. [7, 19]  
The separate set of signals observed and confirmed by simulation may also 
suggest that each vanadium centre is in a different environment, indicating 
that the macrocyclic rings could be in different configurations.  The 
possibility of greater delocalisation onto the sulfate ligand may also result in 
the observed low Aiso value.  Complex 31 (Figure 4.10c) clearly shows two 
sets of peaks for the room temperature spectrum.  Some degree of partial 
substitution of the ligand by water is indicated by the g-value and Aiso = 87 
(G) shown in Table 4.9.  A larger Aiso value was calculated for the second set 
of peaks found for complex 31, (Aiso = 115 G) and infers a stronger interaction 
exists between the unpaired electron and the vanadium centre.  As the A-
value is the hyperfine coupling constant and related to the unpaired electron 
density at the vanadium centre it may be that for this particular 
configuration the unpaired electron is more localised on the vanadium than 
for the other configuration where Aiso = 87 G.  An interesting observation is 
that the average g and A values (energy units of cm-1) used to describe the 
frozen solution spectra should approximate to the isotropic g and A values 
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(cm-1) used to describe the fluid solution spectra.  There are some differences 
between these values in the complexes described which may be explained by  
different solvent interactions of the complexes with water and methanol, or 
may indicate that certain configurations are being ' frozen out'  in the frozen 
solution spectra.  Large deviations from square-pyramidal geometry and also 
the nature of the 6th ligand can influence the A-value and pi bonding with 
electron donation to the d(xy) orbital can have a large effect.  In light of these 
observations, it would appear that for the bicyclam complexes there is a 6th 
ligand affecting A. 
 EXAFS data for the two bicyclam complexes 30 and 31 were compared 
with that of the cyclam analogues, 21 and 22.  A comparison of the R-space 
EXAFS for the four complexes with both data and calculated fits is shown in 
Figure 4.12 and data were Fourier-transformed over a k-range varying from 
1.6-13 Å-1 depending on the compound.  For the sulfate complexes 21 and 30, 
two main first-coordination shells are clearly observed and are assigned as 
V=O and V-N.  It is suspected that the signal for V-O is hidden under the 
large peak for V-N.  For the chloride complexes 22 and 31, three main first-
coordination shells are clearly observed in the data, assigned as the V=O,     
V-N and V-Cl scattering pathways, respectively.  A drastic change in the 
intensity of the V-Cl feature from the cyclam 22 to the bicyclam 31 is seen 
with an increase in the V-Cl bond distance from 2.58Å to 2.63Å, respectively.  
Such a large drop in intensity suggests that there may be loss of a chloride 
ligand in the solid state structure of 31, or a large increase in disorder of the 
chloride ligand.  To explore these two possibilities, different fits to the 
EXAFS data were attempted.  The best fit to the first coordination sphere 
yields a coordination environment consistent with VON4Cl0.5 relating to the 
loss of one of the two axial chloride ligands in the bicyclam complex.  
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Enforcing the anticipated VON4Cl coordination environment for each ring 
yields a significantly poorer fit with a concomitant doubling of σ2 for the     
V-Cl pathway (Table 4.13).  Although disorder of a chloride site cannot be 
discounted, the data does appear to support the VON4Cl0.5 fit.  This could 
indicate either partial occupancy or, more probably, the presence of bridging 
chloride ligands creating oligomeric species in the solid state.  This 
assumption is supported when considering how difficult the bicyclam 
complexes were to recrystallise.  Problems were experienced during the 
synthetic work-up and recrystallisation process with precipitation of 
insoluble products, thought to be due to the formation of polymeric or 
bridged species.   
 Antiviral test results reveal that both bicyclam complexes are active 
against HIV, although less active than the zinc form of xylyl-bicyclam.  The 
sulfate complex is active at a concentration of 1.36 µM and the chloride 
complex shows the highest activity of the two at a concentration of 0.12 µM.  
The result for the chloride complex is comparable with the anti-HIV activity 
of AMD3100, i.e. nanomolar concentrations are found to initiate an effect in 
the inhibitory process of blocking the virus via the CXCR4 receptor.  It is 
difficult to postulate the factors involved in the mechanism of antiviral 
activity of these oxovanadium(IV) bicyclams.  The EPR data suggests partial 
exchange of the axial chloride ligand may occur with H2O and if so, may 
result in one ring adopting an unfavourable geometry as suggested for the 
oxovanadium(IV) cyclams in Chapter 3.  Molecular modelling showed that 
on removing the 6th axial ligand it was possible for the macrocycle to be 
bound in such a way that the distance required for coordination bond 
formation between the metal and carboxylates in the binding site was not 
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possible.  As the bicyclams are highly active, it is likely that the aromatic 
linker plays a very important part.   
4.3  Conclusion 
    The starting material xylyl-bicyclam (16) was synthesised 
successfully and characterised by mass spectrometry and 1H NMR 
spectroscopy, with assignments listed in the Experimental Section, Chapter 7.  
Two oxovanadium(IV) xylyl-bicyclam complexes were synthesised and have 
shown high activity against HIV as potential entry inhibitor drugs.  In terms 
of determining the configuration of the rings, the mode of action of the 
antiviral activity is difficult to investigate due to the paramagnetic nature of 
the vanadium centre.  Successful formation of single crystals may provide 
the only means of identifying the configurations of the macrocyclic rings, 
and potential binding interactions between the complexes and the CXCR4 
receptor using techniques such as molecular modelling could then be 
applied.  
 Infrared and Raman spectroscopies in conjunction with electron 
paramagnetic resonance spectroscopy provided a useful insight into the 
electronic character of oxovanadium(IV) bicyclam complexes.  The 
vibrational stretch of the V=O group is characteristic of vanadium in the 4+ 
oxidation state and ligands trans- to the V=O group may influence the 
resonant frequency in accordance with bond strength to the vanadium centre 
and possible geometry of the ring.  Information gained through EPR revealed 
different behaviour in water for the bicyclam chloride complex 31 than for 
the bicyclam sulfate complex 30 and the data suggest that the axial ligand in 
both cases remains bound to vanadium.  This may be crucial for directing the 
configuration of the rings in terms of binding with the CXCR4 receptor.   
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 UV-visible spectroscopy provided only qualitative data due to 
problems with precipitation in solution but it was seen that binding to 
acetate occurs with time and induces a change in the complex.  This could be 
indicative of a change in configuration to one with a preferred geometry for 
binding to carboxylates in the CXCR4 binding site.  It is unknown which 
configuration this induced change represents and in light of the positive 
antiviral results it may be possible that the cis-V configuration could form in 
solution.  There are of course other configurations such as trans-II that are 
thought to show activity against HIV, although these tend to be more 
predominant in constrained systems where the bicyclam rings are held rigid 
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5. ZINC(II) CONSTRAINED CYCLAMS 
 This chapter describes the synthesis and characterisation of zinc(II) 
complexes of constrained cyclams.  Numbers in bold after compound names 
refer to experimental data in Chapter 7.   
  The cyclam (1,4,8,11-tetraazacyclotetradecane) ligand with C- and/or 
N-alkyl groups and the resulting complexes have received considerable 
attention because their structural and chemical properties may be quite 
different from those of the unsubstituted parent cyclam                        
(1,4,8,11-tetraazacyclotetradecane) macrocycle.[1]  In this chapter, two 
constrained cyclams (35 and 39) and their zinc complexes (36-38, 40-42) are 
characterised and compared (Scheme 5.3).  The constrained ligand, HMC 
(5,16-dimethyl-2,6,13,17-tetraazatricyclo-(14,4,01.18,07.12)docosane) 35, bearing 
an additional two cyclohexane rings and two methyl groups on the 
macrocycle has often shown different coordination behaviour from transition 
metal complexes with cyclam.[2-4]  The macrocyclic 14-membered cyclam 
derivatives are moderately flexible structures and can adopt any of six 
















































































 There are several examples in the literature on the effect of ligand 
constraints of macrocyclic complexes.[5-11]  For example, complexes of copper 
polythiaethers such as [14]aneS4 are difficult to synthesise due to the 
unfavourable enthalpic contributions from the uncomplexed ligand.  The exo 
conformation of the ligand results in the lone pairs of the sulfur donor atoms 
being oriented away from the ligand cavity.  On addition of ring substituents 
such as benzene or cyclohexane rings, the sulfur donor atoms are expected to 
show a preference toward an endo conformation, placing the lone pairs 
toward the ligand cavity.[5]  N-functionalised derivatives of cyclam that 
exhibit a novel cross-bridge linking symmetrical nitrogens of the ring show 
increased in-vivo stability in radiolabelled complexes when compared with 
an analogue with no cross-bridge.[12, 13]  Similarly, a side-bridged macrocycle 
incorporating a coordinating acetate pendant arm displays only trans-II or 
trans-IV configurations showing how constraining substituents affect the 
preferred geometry of the ring.[6]  It is of paramount importance to 
understand the metabolic fate of radio-metal labelled complexes in their 
application in areas of diagnostic imaging and targeted radiotherapy.  
Copper radioisotopes used in conjunction with current bifunctional chelators 
show successful inhibition of tumour growth, but retention of activity is also 
seen in organs such as the blood, liver and bone marrow.  This observation 
suggests that the radio-isotope (e.g. 64Cu) may dissociate from the complex 
and further bind to proteins such as superoxide dismutase in the liver.[14]  
Reducing the flexibility of the ring through the addition of constraining 
substituents may result in a potential increase in kinetic stability, an 
important advance when addressing the problem of increased kinetic lability 
in vivo of existing bifunctional radiopharmaceutical chelators.   
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 An investigation into the effect on stability constants in complexes 
with comparable constraining substituents was made.  Using the [14]aneS4 
macrocycle, cyclohexanediyl and cyclopentanediyl ring substituents showed 
that although stability constants for Cu(II)L increased upon the introduction 
of cis-cycloalkyl groups, a decrease in stability of approximately 10-fold is 
seen on the introduction of the trans-cyclopentanediyl substituent.  The  
trans-cyclohexanediyl showed the same effect as the cis-cyclohexanediyl 
derivative.  The cyclopentane substituent is less flexible than the cyclohexane 
rings and the trans-cyclopentane rings appear to orient the donor atoms of 
the macrocycle causing internal strain on attempted coordination with 
Cu(II).[7]   
 The effect of constraining substituents continues to be investigated in 
this work, in particular the effect of adding substituents that may result in a 
single isomer in solution.   
 Acetate is a ligand that can coordinate with a metal ion via one or two 
O atoms (unidentate, chelating bidentate and bridging bidentate).  Acetate 
can also adopt two different bridging conformations, the syn-syn mode and 
the syn-anti mode allowing coordination to a metal in one of the various 




























 Zinc(II) complexes of both cyclam and xylyl-bicyclam greatly enhance 
the anti-HIV activity in comparison to the macrocycles alone[17] and it is 
suggested that the carboxylate groups of aspartate residues Asp171 and 
Asp262 of the CXCR4 chemokine receptor play key roles in the recognition of 
cyclams.[18, 19]  The understanding of binding affinity and configuration 
between carboxylate groups and zinc(II)-constrained cyclams has become 
extremely important in the improved design and development of new highly 
effective anti-HIV drugs that specifically target alternative events in the HIV 
replicative cycle.   
5.1.   Experimental  
    Zinc(II) complexes of constrained cyclams were synthesised as 








 Scheme 5.3   General preparative route to zinc(II) macrocycle complexes where L = acetate, chloride 











1.  Zn(OAc)2·H2O, 1 mol. equiv. 
2.  ZnCl2, 1 mol. equiv. 
CH3CN, Δ 



























1.  Zn(OAc)2·H2O, 1 mol. equiv. 
2.  ZnCl2, 1 mol. equiv. 























 Cyclam ligands, HMC (Hexyl-Me2-cyclam) 35 and NHMC   
(Naphthyl-hexyl-Me2-cyclam) 39, were synthesised adopting a previously 
published method,[2, 20] by Professor Jong-Ha Choi, Department of Chemistry, 
Andong National University, Andong 760-749, South Korea and were very 
kindly donated.  All other starting materials were purchased from Sigma-
Aldrich as detailed in Chapter 2.  Solvents used for synthetic work were 
HPLC grade methanol and ultra-dry acetonitrile from Sigma-Aldrich.  HPLC 
grade methanol and reagent grade diethyl ether were used for 
recrystallisations.   
5.2.   Results 
5.2.1. Infrared spectroscopy 
 The infrared spectrum of Zn(II)-hexyl-Me2-cyclam(diacetate) 36, was 
recorded at room temperature as a KBr disc and shows three weak 
absorption bands (546, 526, 488 cm-1) in the 400-600 cm-1 region, indicating a 
trans- arrangement of the unidentate ligand.[15]  The cis- complex would be 
expected to show more bands and more splitting in this region due to lower 
symmetry.  The infrared spectral data of this complex appear to be consistent 
with the trans- configuration.  The spectrum obtained for the chloride 
complex 37 also shows three bands in this region, although the second band 
at 528 cm-1 is very weak.  These bands are not seen for the phosphate 
complex 38 as the ν4 strong O-P-O stretch found in this region splits into two 
bands at 482 cm-1 and 559 cm-1 and masks any weak signals.  The splitting of 
the band indicates a reduction in symmetry from the free phosphate ion and 
suggests the phosphate is coordinated.  Absorption bands for all three 
complexes are listed in Table 5.4.  Spectra obtained for the                       
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Zn(II)-naphthyl-hexyl-Me2-cyclam(diacetate) complex 40 also shows three 
weak absorption bands in the 400-600 cm-1 region that may infer              
trans- geometry of the acetate ligands.  The chloride species gives similar 
results and the phosphate analogue revealed a strong O-P-O vibrational 
stretch that may overlap weak signals found in this region.  Absorption 
bands for each complex are listed in Table 5.5. 
Table 5.4   Infrared absorption bands in 400-600 cm-1 region for Zn(II)-hexyl-Me2-cyclams 
Complex Band 1 (cm-1) Band 2 (cm-1) Band 3 (cm-1) 
36 546 526 488 
37 546 528 490 
38      (O-P-O) 559 - 482 
 
Table 5.5   Infrared absorption bands in 400-600 cm-1 region for                                           
Zn(II)-naphthyl-hexyl-Me2-cyclams 
Complex Band 1 (cm-1) Band 2 (cm-1) Band 3 (cm-1) 
40 479 508 561 
41 486 507 559 
42      (O-P-O) 557 - 480 
 
5.2.2. X-ray crystallography 
 Three X-ray crystal structures of zinc(II) constrained cyclam 
complexes were achieved in this work.  All three structures were determined 
at 150 K (Figures 5.8, 5.10 and 5.12).  Selected bond lengths and angles are 
detailed in Table 5.6 with supporting crystallographic data in Table 5.7.  
Complex 36 crystallised in the trans-III configuration with axial acetate 
ligands.  Complex 38 crystallised as 2 separate 5-coordinate zinc macrocycles, 
bound to a shared phosphate through zinc-oxygen bonds.  Complex 41 
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crystallised in a trans-I configuration containing a 4-coordinate tetrahedral 
zinc centre to three of the ring nitrogen atoms.  For complex 38, only cell 
dimensions are available and these are listed in Table 5.7. 
 
Table 5.6   Selected bond lengths (Å) and angles (˚) for zinc(II) constrained cyclam complexes 
Axial ligand  and complex 
identification                                  
Acetate          
(36)           
150 K 
Chloride 
(41)             
150 K 
Zn-N bond lengths       
Zn(1)-N(1) #1                 
Zn(1)-N(8) #1  
        
HMC                             
        
2.1368(8)    
2.0660(8)                
                       
-                      
-
Zn(1)-N(3)                      
Zn(1)-N(7) 




Zn-L* bond lengths      
Zn(1)-O(1) #1 
        
HMC 
        
2.2940(7) 
                       
- 
Zn(1)-Cl(2) NHMC - 2.1949(14) 
L* bond lengths (acetate) 
C(102)-O(1)                   
C(102)-O(2) 
        
HMC 
       
1.2715(12)  
1.2459(13) 
                       
-                     
- 
L*-Zn-N bond angles      
O(1)-Zn(1)-N(1)              
O(1)-Zn(1)-N(8) 
        
HMC 
          
81.64(3)   
88.49(3)             
                       
-                      
- 
Cl(2)-Zn(1)-N(3)            
Cl(2)-Zn(1)-N(7) 




N-Zn-N bond angles      
N(1)-Zn(1)-N(1)                        
N(8)-Zn(1)-N(8)               
N(1)-Zn(1)-N(8) 
        
HMC 
           
179.995              
179.994          
83.36(3) 
                       
-                        
-                     
- 
N(3)-Zn(1)-N(7)              
N(3)-Zn(1)-N(10)            
N(7)-Zn(1)-N(10) 
NHMC -                     
-                     
- 
99.51(17) 
104.30(17)                                    
87.28(18) 
 
                    
               
* L = bonding atom of axial ligands                
HMC = Hexyl-Me2-cyclam complexes            




Table 5.7   X-ray crystallographic data for zinc(II) constrained cyclam complexes 
Axial ligands 
and complex 
identification       
Acetate (36) Phosphate (38) Chloride (41) 
Formula C24H46N4O4Zn1 C48H92N8O4P1Zn2 C42H54Cl1N4Zn1 
Formula weight 520.03 - 715.75 
Crystal system Monoclinic - Monoclinic 
Space group P 1 21/n 1 - C 1 2/c 1 
a / Å 9.2392(3) 21.2436(14) 24.5797(11) 
b / Å 10.5922(3) 16.3400(11) 29.3304(12) 
c / Å 13.2643(4) 17.2105(12) 13.1572(6) 
α / ˚ 90 90 90 
β / ˚ 105.727(2) 108.902(4) 95.597(3) 
γ / ˚ 90 90 90 
Cell vol. / Å3 1249.50(7) A^3 5652.0(8) 9440.2(7) 
Z 2 - 8 
Density (Calc) 
mg/m3 
1.382 - 1.007 
Abs. coeff. mm-1 1.020 - 0.604 
Reflections 
collected 
22930 - 33746 
Independent 
reflections 
3647 [R(int) = 0.037] - 9733 [R(int) = 
0.088] 









 The molecular structure of complex 36 was determined by           
single-crystal X-ray diffraction and structure determination was carried out 
at 150 K.  The structure with atomic numbering scheme is shown in Figure 
5.8.  The complex adopts the 
thermodynamically stable 
trans-III configuration.  The 
constrained cyclam ring is 
trans-III and the acetate is 
axially coordinated forming 
hydrogen bonds to one of 
two NH groups resulting in 
additional stabilisation.  The 
bond angles of five- and   
six-membered chelate rings around the zinc(II) are 83.36(3)˚ and 96.64(3)˚ 
respectively.  The crystals are held together by hydrogen bonds between 
secondary NH groups of the constrained cyclam and acetate groups. The 
proton bonded to N8 forms a strong intramolecular hydrogen bond with the 
non-coordinating oxygen atom O2 of acetate (1.985 Å).  This value is 
comparable with typical hydrogen bonds found in H2O (1.97 Å) and these 























Figure 5.9   Crystal packing of Zn(II) hexyl-Me2-cyclam(diacetate), 38.  Hydrogen bonding is seen between NH protons and oxygen atoms of axial acetates.  The 




 The molecular structure of complex 38 was determined by           
single-crystal X-ray diffraction and structure determination was carried out 
at 150 K.  Complex 38 did not crystallise in the expected structure and is 
shown in Figure 5.10.  
Mass spectrometry 
identified the molecular 
ion as the diphosphate 
structure 38, (m/z: 497.2, 
[M]+), but crystals 
formed of the dimer 
(labelled as 38a) with a 
shared phosphate group 
between two zinc                   
5-coordinate centres.  Problems were encountered with refinement of the 
structure thought to be due to the presence of a disordered zinc atom.  The 
structure exhibits a peak close to one of the Zn atoms which suggests that the 
Zn is positionally disordered over two sites, one (the major occupancy) 
where it is coordinated to the phosphate, and the other (minor occupancy) 
when it is coordinated to a chloride.  The chloride site is similarly disordered.  
The chloride must be acting as either a 6th ligand or counter ion for charge 
balance.  As complex 38 was synthesised from complex 37, the presence of 
chloride suggests that not all chloride was removed prior to addition of 
phosphate. 




 The molecular structure of complex 41 was determined by           
single-crystal X-ray diffraction and structure determination was carried out 
at 150 K (Figure 5.11).  Initially, problems were encountered with data 
collection as the crystal cracked before all data was accumulated.  A second 
set of data revealed a different unit cell and the possibility of polymorphism 
was suspected.   
 Differential Scanning Calorimetry (DSC) analysis was used to find the 
temperature at which any phase transition occurred, but results showed 
none was present.  Data collection was eventually successful at 150 K using 
different crystals.  It is noted that the chloride counter ion is not seen in the 
data and is suspected to be moving rapidly in the large solvent channels that 
exist between molecules.  These channels can be seen in the packing diagram 
shown as Figure 5.12. 
 Complex 41 crystallised as a 4-coordinate zinc centre, bound to three 
nitrogens of the macrocycle with a fourth bond to a chloride ligand.  The zinc 
centre is tetrahedral and the NH protons of the ring align in the same 
direction across the diagonal indicating that the ring is in the trans-I 










Figure 5.11   Zn(II)-naphthyl-hexyl-Me2-cyclam, 41(a)                                                                
















Figure 5.12   Crystal packing of Zn(II)-naphthyl-Me2-cyclam, 41(a) projected along the c axis of the unit cell and rotated by 90˚.  Hydrogen bonds are shown 
(cyan) between an unbound nitrogen and a protonated nitrogen of the macrocycle.  Short contacts (yellow) are seen between chloride ligands of one 
macrocycle and methylene protons of the naphthyl of a neighbouring macrocycle.  Short contacts also form between protons of the hexyl rings with carbon 
atoms of the aryl rings. 
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5.2.3. Comparison of bond lengths and angles of constrained       
  metallomacrocycles  
5.2.3.1. Zinc-oxygen bond length comparison (Zn(II)-HMC, 36) 
 Zn-O bond lengths of Zn(II)-hexyl-Me2-cyclam(diacetate)           
(Zn(II)-HMC), 36 were compared with those of three zinc(II) cyclams 
reported in the literature, labelled as [Zn(II)(cyclam)(H2O)2](OAc)2, A[21], 
[Zn(II)(cyclam)(OClO3)2], B[22] and a zinc(II) constrained cyclam             
[Zn(II)-hexyl-Me2-cyclam(H2O)2]Cl2, C.[23]  Details are listed in Table 5.13.  
Comparing the two cyclam structures A and B, the perchlorate ligand of B 
has a significantly longer Zn-O bond length than A (bound water).  The two 
constrained cyclams (36, C) also show a significant difference in Zn-O bond 
lengths with the bound water ligand of C longer than the acetate ligand of 
36.  Bond lengths of Zn-O between B (cyclam-perchlorate ligand) and C 
(constrained cyclam-bound water ligand) are comparable.  Comparing the 
two complexes with bound water ligands A, C reveals the Zn-O bond length 
of C (constrained cyclam) is significantly longer than in A (cyclam).   
5.2.3.2. Zinc-nitrogen bond length comparison (Zn(II)-HMC, 36) 
 Zn-N bond lengths of complex 36 were also compared with 
compounds A, B and C.  The bond length for the longer of the two Zn-N 
bonds (Zn-Na) in complex 36 is significantly longer than in any of the other 
three comparison compounds.  The bond length for the shorter of the two 
Zn-N bonds (Zn-Nb) in complex 36 is significantly shorter than in any of the 





Table 5.13   Comparison of Zn-N and Zn-O bond lengths (Å) and bond angles (deg) in zinc 
cyclam and constrained cyclams (italics refer to actual numbering scheme used in literature 
for identical bonds/angles being compared). 
Axial ligand and complex 
identification 
H2O             
(A)[21] 
OClO3
-                
(B)[22] 
H2O             
(C)[23] 
CH3COO
-          
(36) 
Bond lengths, Å                                   
Zn-O                                          
Zn-Na                                         
Zn-Nb                                     
        
2.2719(14) 
2.1198(15)(N1) 
2.0809(15)(N4)   
         
2.380(2)  
2.086(2)(N1) 
2.090(2)(N4)     
           
2.388(3)  
2.084(2) (N1)    
2.113(2) (N2)                                        
         
2.2940(7)  
2.1368(8)(N1)      
2.0660(8)(N8)
Bond angles, ˚                         
O-Zn-Na                                  
O-Zn-Nb                                   
                            
-                        
-                      
           
86.0(1)  (N1) 
89.0(1)  (N4)      
          
90.70(1) (N1)         
85.80(1) (N2)                                  
           




 Bond angles between the oxygen of the axial bound ligand, zinc and 
the shortest Zn-N bond (O-Zn-Nb) were compared between complex 36 and 
comparison compounds B and C.  Data for A are not available in the 
literature.  For complex 36, this angle is intermediate between values for 
compounds B and C, being significantly larger than C but smaller than B.  
Bond angles were also compared between the oxygen of the axial bound 
ligand and the zinc centre with the longest Zn-N bond (O-Zn-Na).  For 
complex 36, this angle is significantly smaller than either B or C and C is 




5.2.3.3. Zinc-chloride bond length comparison (Zn(II)-NHMC, 41) 
 The Zn-Cl bond length of complex 41 (Zn(II)-NHMC), was compared 
with 3 crystal structures found in the Cambridge Structural Database for 
tetrahedral zinc bound to 3 nitrogens and one chloride.  Complex D is an 
aliphatic, tripodal ligand.  Complex E is a [12]aneN3 ligand and compound F 
is a constrained cyclam.  The complexes are named as below.      
D [(N,N-bis(3-aminopropyl)-N-3-hydroxypropylamine)ZnCl]Cl [24] 
E [ZnCl(C12H27N3)]PF6 [25] 
F [Zn-hexyl-Me2-cyclam(dihydroxypropyl)Cl]ClO4.H2O [26] 
 
 Bond lengths are compared between the zinc and the chloride ligand, 
and between zinc and nitrogen atoms of the rings.  Details are listed in Table 
5.14.  For complex 41, the zinc chloride bond length is significantly shorter 
than the corresponding bond in complex D, also with a chloride counter ion.  
It is marginally shorter than the Zn-Cl bond in E and comparable with the 
constrained cyclam, F.   
5.2.3.4. Zinc-nitrogen bond length comparison (Zn(II)-NHMC, 41) 
 All Zn-N bond lengths for complex 41 are comparable, but complex D 
(chloride counter ion) has one Zn-N bond length which is significantly longer 
than the other two, and longer than those for complex 41.  Complexes E and 
F show comparable bond lengths with complex 41.  Bond angles were 
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compared and are comparable between complexes 41, E and F.  In particular, 
bond angles are in good agreement between complex 41 and complex F. 
 
Table 5.14   Comparison of Zn-Cl and Zn-N bond lengths (Å) and bond angles (deg)                                  
in Zn-3N bound complexes.  Italics refers to actual numbering scheme used in literature for 
identical bonds being compared. 
Counter ion  and 
complex 
identification 
Cl-            (D)  PF6
-                  (E)  ClO4
-         (F)  Cl-                      (41) 
Bond lengths, Å       
Zn-Cl                                          
Zn-Na                                         
Zn-Nb                                        
Zn-Nc                                   





                  
2.2009(4)  
2.0429(13) (N1)   
2.0484(13) (N10)  
2.0363(13) (N11)                   
                      
2.196(2)   
2.042(4) (N1)             
2.058(4) (N3) 
2.042(4) (N4)          
                    
2.1949(14)        
2.053(4) (N3)              
2.070(4) (N7)           
2.053(4) (N10)         
Bond angles, ˚                         
Cl-Zn-Na                                  
Cl-Zn-Nb                                  
Cl-Zn-Nc                                
Na-Zn-Nb                    
Na-Zn-Nc                          
Nb-Zn-Nc                               
             
109.01(3) (N1) 
111.71(4) (N2) 
111.55(3) (N3)        
101.60(4)(N1,N2)    
98.83(4) (N1,N3)   
122.01(5)(N2,N3)          
                  
113.21(4) (N1)           
113.13(4) (N6)      
117.37(4) (N11)         
104.45(5)(N6,N11) 
104.76(5)(N1,N11) 
102.41(5)(N1,N6)                  
                 
116.2(1) (N1)          
124.4(1) (N3) 
117.4(1) (N4)        
105.1(2)(N1,N3)       
101.6(2)(N1,N4)  
86.8(2)  (N3,N4)         
                   
118.95(12) (N3)      
120.14(12) (N7) 













5.2.4. NMR spectroscopy 
 1H, 13C and 15N NMR spectra were acquired from 2D experiments as 
detailed in Chapter 2.  Chemical shifts and coupling constants for proton and 
carbon data are listed for each complex in the experimental section found in 
Chapter 7.  Ligands 35 and 39 were also characterised as part of this work.  
2D NMR was used to identify the configurations present in solution for four 
of the six structures in this chapter.  Analysis of the two phosphate 
complexes was problematic and details of the syntheses are given.  
 Zn-hexyl-Me2-cyclam(diacetate), 36:  NH protons from the 1D 
spectrum were identified using 2D [1H, 13C] HSQC, identified from the lack 
of crosspeak seen and [1H, 1H] COSY and TOCSY were recorded (Figure 
5.15).  Figure 5.16 highlights the assignments for all protons.  Chemical shifts 
are listed in the experimental section in Chapter 7 and assignments identified 
in Table 5.17 for the ligand 35 and complex 36.  Key signals for complex 36 
are summarised in Table 5.18. 







Figure 5.15   [1H, 1H] COSY spectrum of                     
Zn(II)-hexyl-Me2-cyclam(diacetate), 36 
 









   











































Table 5.17   [1H, 13C] NMR chemical shifts (δ ppm) of Hexyl-Me2-cyclam 35 (HMC), and              
Zn(II)-hexyl-Me2-cyclam(diacetate)] (Zn(HMC)), 36 recorded in CDCl3, 298 K 
Signal HMC, 35 Zn-HMC, 36 ∆δ ppm 
N1H 1.67 3.78  2.11 
N8H 3.65 4.51  0.86 


















































C11 3.34 3.49  0.15 
C12 0.96 1.20  0.24 
Δδ = [δ [Zn(II)-HMC(diacetate], 36 – δ HMC, 35]                                                                         
13C data for 36:  δ 17.0, 27.2, 28.1, 31.8, 32.3, 37.0, 43.0, 49.8, 53.5, 58.9, 62.6 
Table 5.18   1H NMR chemical shifts of Zn(II)-hexyl-Me2-cyclam(diacetate), 36 
δ 1H / ppm 
NCHCHN NCH2CH2CHN CHNCH2 CHNCH NH 
C2, 2.55      
C7, 2.51 
C10a, 2.07  
C10b, 1.68 
C9a, 2.75       
C9b, 3.08          


























 On identification of one of the NH protons, assignment of all peaks in 
the 1H NMR spectrum was aided by 2D [1H, 13C] HSQC and [1H, 1H] COSY 
NMR spectroscopy (Figure 5.15).  Protons N1H and N8H of complex 36 are 
in different environments and the 2D [1H, 13C] HSQC spectrum shows no 
coupling correlation for the signal at 3.65 ppm.  An assignment is made at 
3.65 ppm for the nitrogen proton (N8H) coupling to three protons from the 
2D [1H, 1H] COSY data.  The N1H proton is not clearly visible from the 1D or 
2D spectra but integration shows it is hidden under the large peak centred at 
1.70 ppm, and most likely between 1.60-1.65 ppm.  On complexing with zinc 
acetate, a downfield shift of around 2 ppm is seen and the N1H proton 
appears clearly in the spectrum at 3.75 ppm.  The N8H proton is hydrogen 
bonded to an acetate ligand that acts to deshield the proton and the signal is 
found shifted downfield to 4.50 ppm.  Signals for protons 3b and 10b move 
to a slightly lower chemical shift upon complexation.   
Zn-hexyl-Me2-cyclam(dichloride), 37:  2D [1H, 13C] data showed more than 
one species is present in solution.  2D [1H, 1H] TOCSY analysis showed that 
the free ligand was present giving rise to signals at 0.68, 0.75, 0.95, 1.20, 1.70, 
2.05, 2.12, 2.20, 2.29, 2.50, 2.85 and 3.35 ppm.  This made the interpretation of 
2D [1H, 1H] COSY very difficult as many overlapping signals were evident. 
2D [1H, 15N] gives rise to six signals.  If the structure of complex 37 is a             
6-coordinate zinc centre with axial chloride ligands, then the trans-III 
configuration would be expected to show two signals.  These are assigned as 
63.3 and 54.1 ppm.  If the structure of complex 37 is a 4-coordinate zinc 
centre bound to only three nitrogens of the macrocycle with a fourth bond to 
a chloride, three signals are expected for NH protons in the trans-I 
configuration.  Of the three bound NH protons, two are equivalent (diagonal 
protons across the cavity) and the fourth remains unbound.  A 4-coordinate 
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zinc centre in the trans-III configuration would give rise to four signals as 
each proton is in a different environment.  Signals observed in the [1H, 15N] 
HSQC spectrum for complex 37 are assigned as 63.1, 54.1 and 54.0 ppm for a 
4-coordinate 3N-bound zinc centre.  2D [1H, 13C] data also show that signals 
for the free ligand 35 overlap with at least one of the Zn-3N or Zn-4N bound 
species present.  The weak signal at 1.75 ppm in the [1H, 15N] HSQC 
spectrum is assigned to the free ligand, 35.  Integration of the signals 
indicates that the ratios of species present are in agreement with these 
assignments for the six signals.  Figure 5.20 shows the spectrum for the     




Zn-hexyl-Me2-cyclam(diphosphate), 38:  On acquiring a 1H spectrum of 
complex 38 before and after all 2D data was collected, there was evidence of 
new signals.  It is believed some decomposition of the product in the solution 
has occurred and may indicate that the phosphate complex is less stable than 







the acetate 36 and chloride 37 species.  Details of the synthesis are discussed 
more fully in Section 5.6.2. 
 Zn-naphthyl-hexyl-Me2-cyclam(diacetate), 40:  1H NMR chemical 
shifts are assigned for the free ligand 39 and listed in the experimental 
section in Chapter 7 and [1H, 13C] data for the acetate complex 40 showed 
very convoluted data.  Analysis by 2D [1H, 15N] HSQC was used to 
investigate configurations of the macrocycle using NH protons as probes for 
the identification of isomers in solution.    
 The 2D [1H, 15N] spectrum for ligand 39 is shown in Figure 5.22.  One 
signal is present due to the equivalence of both nitrogen protons on the 
macrocycle.  Figure 5.23 shows the 1D spectrum with the signal for the 
equivalent NH protons highlighted.   












Figure 5.22   [1H, 15N] HSQC NMR spectrum of 
constrained cyclam NHMC 39, in CDCl3, 298 K  
Figure 5.23   1H NMR spectrum of NHMC 39, 
in CDCl3, 298 K 
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2D [1H, 15N] data were acquired for complex 40 and compared with ligand 
39.  Two signals were observed (Figure 5.24) and the trans-III configuration is 
assigned to 40.  No other NH signals were seen and only one isomer appears 
to exist in solution.   
 In the absence of a crystal structure for complex 40, the NH proton at 
3.84 ppm is tentatively assigned as hydrogen bonded to the acetate ligand 
based on the downfield shift from the 2D [1H, 15N] HSQC data for ligand 39. 
The appearance of two signals indicates a trans-III configuration exists for 
complex 40 with each NH proton in different chemical environments.  
Exchange of NH protons with D2O was observed for ligand 39, but no 
exchange was seen for complex 40.  The NH protons are therefore not acidic 
indicating a strong Zn-N bond exists with high stability of the complex in 
solution.  Sodium hydroxide and hydrochloric acid were used to achieve 
pH10, pH7 and pH3 solutions of the complex.  D2O was added in 100 µL 
additions until the volume in the NMR tube contained 50% D2O.  No 
evidence of NH exchange was seen in the 1H spectra after 24 h.  
Figure 5.24   [1H, 15N] HSQC NMR 









Figure 5.25   1H NMR spectrum of Zn-NHMC 
40, in CDCl3, 298 K 
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 Zn(II)-naphthyl-hexyl-Me2-cyclam(dichloride), 41:  2D [1H, 15N] 
HSQC data were acquired for complex 41 to investigate configurations of the 
macrocycle using NH protons as probes for the identification of isomers in 
solution.  The data gave rise to five separate signals and upon integration the 
signals were assigned ratios relating to the probability of configurations 
present.  X-ray crystal data show that the structure is a 4-coordinate zinc 
centre bound to three nitrogens.  In solution, it appears there may be a 
mixture of 4-coordinate zinc with Zn-3N binding (species A) and either a     
5- or 6-coordinate zinc with Zn-4N binding (species B).  Species A has a  
trans-III (two cross peaks) configuration and appears to interconvert with 
species B.  It is unknown whether species B is a 5- or 6-coordinate zinc 
structure.  Signals are assigned to trans-I and trans-III configurations for 
species B.  Figure 5.26 shows spectra obtained at different time intervals and 
assigned signals for both species are labelled.  An additional [1H, 15N] signal 
is seen at 61.3 ppm in the spectrum after one week but does not relate to the 
free ligand, 39.  This may be another trans-I isomer but it is unknown which 







Figure 5.26   2D [1H, 15N] HSQC NMR of Zn(II)-naphthyl-hexyl-Me2-cyclam, 41 at                
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After two weeks the spectrum shows no change and no additional signals 
appear.  The same spectrum at a later point showed a new signal, further 
upfield from the existing signals at 2.53 (56.9) ppm.  This has not been 
assigned to any configuration and may be due to decomposition products 
although a signal for the free ligand 39 is not seen.  It may be possible the 
signal relates to an unbound NH proton if loss of a naphthyl ligand resulted 
in protonation of the free nitrogen.   
5.3. Antiviral Testing 
5.3.1. Anti-HIV 
 The ligand 35 and complex 36 were tested by Professor Dr Erik De 
Clercq, Rega Institute, Katholieke Universiteit Leuven, Minderbroedersstraat 
10, B-3000 Leuven, Belgium for anti-HIV activity.  Tests were carried out 
against a range of cell lines and both ligand and complex were found to be 
highly active against HIV.  Information and results of the anti-HIV and 
cytotoxicity tests are detailed in Table 5.27 and a graphical representation of 
the data is set out in Figure 5.28.  This bar chart compares levels of antiviral 
activity of the constrained cyclams with the oxovanadium(IV) complexes 








Table 5.27   Anti-HIV and cytotoxicity evaluation in IIIB and ROD cell cultures 
Ligand / 
complex 







av. IC50  µM 
(µg/mL) 
av. CC50 µM 
(µg/mL) 
SI 
HMC, 35 IIIB  10.33  
(3.47) 
 > 372          
(> 125) 
> 36 102    
   10.69     
(3.59) 
 > 372          
(> 125) 
> 35 145  10.51  
(3.53) 
 > 372           
(> 125) 
> 35 
 ROD  > 100    
(41.6) 
 > 372             
(> 125) 
> 3 71    
   > 100    
(48.3) 
  > 372         
(> 125) 
> 3 74  > 130    
(44.95) 





IIIB  3.73 
(1.94) 
 > 100           
(53.7) 
= 28 99    
   3.27 
(1.7) 
 > 129     
(67.4) 
= 40 114  3.50      
(1.82) 
 > 110   
(57.55) 
32 
 ROD  > 100   
(> 54.2) 
 > 100         
(54.2) 
< 1 42    
   > 100   
(> 54.9) 
 > 105           
(54.9) 
< 1 46  > 104        
(> 54.55) 











* av. IC50  highlighted in red shows concentration of compound required to effect 50% inhibition of virus.   
Figure 5.28   Bar chart representation of antiviral test results from Table 5.26.  The y-axis is purely 
qualitative for comparison purposes and does not have any units assigned. 








50% inhibition of viral replication in vitro

























 The bar chart representation of antiviral test results from Table 5.27 
shows higher bars for IC50 concentrations that represent higher activity, and 
higher bars for CC50 concentrations represent higher toxicity.  As cytotoxic 
concentration is determined to be < 40 µM, all complexes show high activity 
and low levels of toxicity to cells. 
It is difficult to see how these constrained macrocycles could adopt a 
cis-V configuration, previously shown to be important in the binding of 
antagonist molecules with CXCR4.[27]  The activity must arise from a different 
interaction and hydrophobic contributions may be more important for the 
constrained macrocycles.   
5.3.2. Antibody Binding Competition Tests 
 Investigations were carried out for the naphthylated constrained 
cyclam complexes (39-41) for anti-HIV activity by investigating antibody 
competition binding, but no antiviral activity was detected.  The antagonist 
molecules may be binding to CXCR4, but are easily displaced by the 
antibody.  These experiments were carried out by Dr Steve Archibald, 
Departments of Chemistry and Biological Sciences, University of Hull, Hull, 
U.K.    
 Figure 5.29 shows the plot obtained for complex 40 which is 
representative of all complexes tested. The plot shows the fluorescence lies in 
the region of the positive control meaning that none of the complex was 
found to be strongly bound to CXCR4.  The natural antibody was largely 


















5.4.   Discussion 
     Zinc complexes of two different constrained cyclams were 
synthesised and characterised using infrared spectroscopy and X-ray 
crystallography. The effect on configurational change for different axial 
ligands was investigated using 2D [1H, 13C] and [1H, 15N] solution NMR 
spectroscopy. 
5.4.1. Infrared spectroscopy 
 Infrared spectroscopy is frequently useful in determining structures 
and numbers of functional groups involved in coordination.  The relative 
Counts 
Figure 5.29   Fluorescence plot from antibody competition binding studies 
Key Name Parameter Gate
- control.001 FL1-H No Gate
ARVC(cGMP-2).011 FL1-H No Gate
+ control.019 FL1-H No Gate
102 101 100 
FL1-H 
100 
  80 
  60 
  40 
  20 
   0 
Key Name Parameter Gate 
- control.001 FL1-H No Gate
ARZnL3, 40 FL1-H No Gate
+ control.019 FL1-H No Gate
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position of a peak in a certain absorption band has shown to be dependent 
on the structure of the complex, and binding of acetate groups is compared 
between complexes 36 and 40.[15]   
 The infrared spectrum of Zn(II)-hexyl-Me2-cyclam(diacetate) 36 
recorded at room temperature shows three weak absorption bands (546, 526, 
488 cm-1) in the 400-600 cm-1 region, indicative of a trans- arrangement of the 
unidentate ligand.[15]  The cis- complex would be expected to show more 
bands and more splitting in this region because of lower symmetry.  These 
data appear to be consistent with the trans- configuration.  The spectrum for 
Zn(II)-naphthyl-hexyl-Me2-cyclam(diacetate) 40, shows similar weak 
absorbances in the 400-600 cm-1 region.  In complex 36, the asymmetric 
stretching vibration νas(COO) of the acetate ligand is observed at 1567 cm-1, 
while the symmetric stretching vibration νs(COO) appears at 1412 cm-1.  The 
difference between νas and νs of approximately 155 cm-1 is not consistent with 
a monodentate coordination mode for the acetato group.[15]  The lower value 
may be due to the presence of an intramolecular hydrogen bond formed by 
the carboxylate oxygen to an NH group of the constrained cyclam ligand.  In 
complex 40, the asymmetric stretching vibration νas(COO) is observed at   
1596 cm-1, while the symmetric stretching vibration νs(COO) appears at    
1395 cm-1.  The difference of approximately 201 cm-1 is higher than that of 
acetato ionic complexes but the lack of a strong band at 540 cm-1 [π(CO2)] 
would indicate that the acetato group is not monodentate.   
Data acquired for complex 36 show an absorption near 3405 cm-1 and 
the broadness of the band indicates there are hydrogen bonds in this 
complex.  The bands in the 3240-2850 cm-1 regions are due to symmetric and 
asymmetric NH and CH stretching modes, respectively.  The two bands of 
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ν(NH) observed at 3243 and 3180 cm-1 are responsible for the intramolecular 
hydrogen bond.  It is reported[28] that the cis- isomers of cyclam complexes 
exhibit at least three bands in the 890-830 cm-1 region due to the NH wagging 
modes, while the methylene vibration splits into two peaks in the               
830-790 cm-1 region.  The trans- isomers show two groups of bands, a doublet 
near 890 cm-1 arising from the secondary amine vibration, and only one band 
near 800 cm-1 due to the methylene vibration.[22, 28-31]  Complex 36 exhibits a 
strong band at 898 cm-1 and a much weaker band at 837 cm-1 in the NH 
wagging frequency region.  These vibrational modes are not significantly 
affected by differing counter anions or metal ions.  Metal-ligand stretching 
bands occur in the far infrared range.  Complex 40 exhibits two bands in the 
890-830 cm-1 region due to the NH wagging modes of the secondary amines;   
a doublet at 891 cm-1 suggests a trans- arrangement and an additional peak at 
851 cm-1 is seen.  Surprisingly, the methylene vibration splits into two peaks 
seen at 807 cm-1 and 785 cm-1 thought to be indicative of a cis- arrangement.[28]  
 For the chloride analogues, complex 37 shows two NH stretching 
bands at 3292 cm-1 (sharp) and 3367 cm-1 (broad), the latter indicative of 
hydrogen-bonding in the complex.  Weak signals below 400 cm-1 suggest a 
trans- geometry for axial ligands.  Complex 41 shows two NH stretching 
bands at 3244 cm-1 (sharp) and 3467 cm-1 (broad).  Again, evidence of 
hydrogen bonding is apparent by the broadness of the band at 3467 cm-1. 
 For the phosphate analogues, complex 38 shows very broad NH 
bands at 3450 cm-1 masked by water absorption as this complex is very 
hygroscopic.  A strong band at 739 cm-1 is due to NH deformation and any 
weak signals below 400 cm-1 are masked by a strong O-P-O stretch.  For 
complex 42, NH stretching bands are also broad at 3440 cm-1 and 3224 cm-1 
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and O-P-O and P=O stretches are evident at 557 cm-1 and 1400 cm-1 
respectively. 
5.4.2. NMR spectroscopy of Zn(II)-hexyl-Me2-cyclams 
 For complexes 36 and 40, the coupling constant between protons on 
carbons C2 and C7 could not be readily determined as the signals appear as a 
multiplet in the spectrum.  This made it difficult to assign a geometry for the 
protons although it is expected that a trans- arrangement exists with the 
cyclohexyl rings in the more energy favourable chair configuration due to the 
constraints provided by these rings.  A cis- arrangement of the two protons is 
unlikely as this would result in the higher energy twist-boat configuration 
for the cyclohexyl rings.  Assignment of all signals reveals that only one 
configuration is present in solution for both acetate complexes and is likely to 
be the trans-III configuration.    
 For the chloride complexes 37 and 41, different isomers exist in 
solution.  In complex 37 carbon data show two sets of signals and there may 
be a third isomer hidden.  2D [1H, 15N] data show signals assigned to a       
Zn-3N bound complex in the trans-I configuration (species A) and a Zn-4N 
bound complex in the trans-III configuration (species B) (Figure 5.25).  The 
zinc centre in the 3N-bound complex (species A) is tetrahedral and no 
evidence of a trans-III configuration is seen.  The zinc centre in the 4N-bound 
complex (species B) may not be octahedral and the difference in chemical 
shifts of the NH protons for species B suggest it may be square pyramidal 
with a chloride acting as counter ion.  If the zinc centre is 6-coordinate, it 
might be expected that the signals for species B would have a more similar 
chemical shift as the axial chloride has an equal effect on both NH protons.  
The difference observed in the chemical shift between the two signals may 
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imply that the zinc is in fact 5-coordinate and the chloride ligand is hydrogen 
bonding with only one NH proton shifting one further downfield than the 
other.   
 The phosphate complexes 38 and 42 were difficult to synthesise.  
Complex 38 was very hygroscopic and complex 42 could only be synthesised 
with very low yield.  The most problematic part of the synthesis was the 
removal of solvent from the phosphate complexes.  The solution foamed 
considerably under reduced pressure and much of the compound was lost at 
this stage.  Drying under vacuum resulted in a very thin layer of product that 
was difficult to retrieve.  The product was redissolved at this stage, 
transferred into a narrow sample vial used for recrystallisations and again 
dried under vacuum.  The yield for complexes 38 and 42 was not sufficient 
for NMR analysis due to the concentration required for [1H, 15N] HSQC.  The 
1H spectra cannot be assigned without 2D data and in the case of complex 38, 
decomposition products appeared before all of the 2D data could be 
collected.  It was decided to try and synthesise the phosphate complexes by a 
more direct method using zinc-phosphate.  This was not successful as it was 
discovered after the first attempt that zinc phosphate has extremely low 
solubility.  The compound is not a 1:1 salt as initially expected, but a 3:2 
compound of zinc and phosphate.   
5.5.   Conclusion 
    Zinc complexes of constrained macrocycles were synthesised and 
characterised.  The identification of different isomers in solution was 
investigated and NMR analysis showed evidence of both single and multiple 
configurations in solution for different axial ligands.  A possible intermediate 
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in the mechanism for uptake and release of metals by cyclams was isolated 
and complexes with both three and four nitrogens from the macrocyclic ring 
bound to zinc centres were observed.  It may be that the Zn-3N and Zn-4N 
species interconvert in solution.  The zinc centre in the 4N-bound species 
appears to be 5-coordinate and most likely adopts a square-pyramidal 
geometry.  In theory, this would allow the zinc centre to interact with 
carboxylate oxygens in the CXCR4 binding site through a vacant 6th axial 
ligand position.  From EPR studies for the oxovanadium(IV) bicyclams in 
Chapter 4, it is suggested that the axial ligand, and in particular chloride, is 
important for directing the macrocycle into a favourable configuration for 
binding to CXCR4.    
 Binding to CXCR4 was investigated through antibody competition 
binding studies and this showed that no binding occurred that could be 
sustained.  The chloride complexes 37 and 41 have not yet been tested for 
antiviral activity against the cell lines used for complex 36.  Complex 36 
showed activity at a concentration of 3 µM, but also failed to give a positive 
result using the antibody binding tests.  The mode of action relating to the 
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6. Conclusions and future work 
6.1.   Conclusions 
    The work contained in this thesis covers the synthesis and 
characterisation of potential oxovanadium(IV) bicyclam and zinc(II) 
constrained cyclam anti-HIV agents, with the synthesis and characterisation 
of oxovanadium(IV) cyclam complexes, shown in Chapter 3 to be inactive 
against HIV.  The complete inactivity of the cyclam complexes is intriguing 
and may be due to a combination of factors.  A facile exchange of the axial 
ligand trans- to the V=O group in solution is suggested and may result in a 
subsequent weak interaction between the V=O group and the protein 
backbone, forcing the macrocycle into an unfavourable position for binding 
to CXCR4 - an important receptor for HIV-1.  EPR measurements show 
identical spectra for all oxovanadium(IV) cyclam complexes in solution and 
results from conductivity tests and solution IR spectroscopy indicate that the 
axial ligand undergoes exchange in water. 
 In contrast to this, the bicyclams give markedly different EPR spectra 
and measurements suggest there may be more than one environment for 
vanadium in these complexes.  Retention of the axial ligand may be crucial in 
determining how the macrocycle binds to CXCR4 and could be an important 
component in directing optimum ring configurations for binding to the 
receptor.  The oxovanadium(IV) bicyclam chloride complex in particular 
showed high activity against HIV and is comparable with AMD3100.  Slight 
geometric differences were seen between the bicyclam and cyclam complexes 
on analysis by EXAFS/XANES and these differences may contribute to 
retention of the axial ligand in the bicyclams.  Alternatively, the bicyclams 
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may be displaying a much slower rate of exchange than the cyclams.  EXAFS 
data also showed that the bicyclam chloride complex may in fact be an 
oligomeric species, a possibility previously considered during synthesis as 
problems encountered with recrystallisation suggested either a polymer or 
bridged species had formed.  There may be different ring configurations 
present in solution for the bicyclams but no conclusive evidence could be 
obtained from the analyses carried out.  As both cyclam and bicyclam 
complexes contain identical chemical groups, it is likely that the aromatic 
linker plays an important role in the activity seen for the bicyclams. 
 X-ray crystallography showed interesting differences between the 
cyclam complexes, in particular where two complexes have the same 
chloride axial ligand but different counter ions.  By increasing the size of the 
counter ion, networks of hydrogen bonding between axial ligands, NH 
protons of the ring and solvent molecules were removed.  This in turn 
affected the angle sizes across the diagonal of the ring cavity.  
Oxovanadium(IV) cyclam also showed a high preference for hard ligands in 
accordance with Pearson’s Classification.[1] 
 A constrained cyclam and its zinc(II)-diacetate complex showed high 
activity against HIV when tested against the IIIB cell line, but antibody 
competition binding tests did not reveal any sustained binding to CXCR4.  
This may indicate that a different mechanism is involved for the constrained 
cyclams and needs to be investigated.  2D [1H, 13C] COSY NMR analysis 
revealed the complex adopted only one configuration in solution (trans-III) 
and is stable with no exchange of NH protons seen on deuteration of the 
solution.  On addition of naphthyl substituents to the constrained cyclam, no 
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change is seen for 2D NMR analysis of the zinc(II)-diacetate complex and this 
structure is also thought to be in the trans-III configuration in solution.   
 2D [1H, 15N] HSQC NMR analysis of a zinc(II)-dichloride constrained 
cyclam showed that an equilibrium mixture may exist between a                    
4-coordinate tetrahedral zinc bound to only three nitrogens of the ring with a 
fourth bond to chloride, and a 5-coordinate square-pyramidal zinc bound to 
all four nitrogens of the ring with a fifth bond to chloride.  The number of 
signals in the spectrum increased with time and a new signal for the 
uncomplexed ligand suggests demetallation occurred.  On addition of 
naphthyl substituents to the constrained cyclam, the same analysis revealed 
no additional signals over the same period of time and no signal was seen for 
the demetallated complex.  It would appear that the presence of the naphthyl 
substituents may serve to stabilise the structure. 
6.2.   Future Work 
6.2.1. Oxovanadium(IV) complexes 
 A promising result from this work was the high antiviral activity seen 
for the bicyclam sulfate and chloride complexes, with emphasis on the 
chloride structure warranting further investigation.  Solution chemistry of 
this particular structure may be complex, as possible demetallation and 
hydrolysis (or partial hydrolysis) of one or both rings may lead to several 
different species in solution.  The need for structural information on ring 
configurations in solution requires paramagnetic NMR analysis, and this 
presents its own challenges.  Recently, 2D IR spectroscopy has been used to 
demonstrate how the nitrile functional groups of an existing NNRTI are in 
different protein environments[2] and ion-mobility mass spectrometry in 
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conjunction with theoretical modelling has been used to evaluate the three-
dimensional structure of possible E- and Z- isomers of a copper(II)-
anthracenyl cyclam.[3]  Application of these techniques may provide further 
information on the structure of the oxovanadium(IV) bicyclam sulfate and 
chloride complexes. 
 It would also be useful to know whether zinc can displace vanadium 
in these complexes and kinetic studies may reveal important information in 
terms of uptake rates of vanadium in the presence of zinc.  Previous studies 
have shown how copper has a higher affinity for cyclam than zinc, but the 
uptake rate is slowed in the presence of zinc.[4]  These types of investigation 
would first require an improved synthesis and purification method for the 
bicyclam complexes to avoid precipitation in solution of possible oligomeric 
species.  Alternatively, synthesis could be concentrated on obtaining a 
different oxidation state for vanadium in these complexes, making analysis 
by NMR more accessible. 
 Molecular modelling could also be applied further to investigate 
amino acid residues near the aromatic linker of the bicyclam complexes to 
look at hydrophobic interactions that may play a part in directing the 
bicyclams into a favourable configuration within the CXCR4 binding site.  It 
would also be interesting to investigate whether the complexes synthesised 
in this thesis might bind with a different 7-helix transmembrane receptor, 
such as the D6 protein.  The promiscuous receptor D6 (or CCBP2) is now 
thought to be important for HIV pathogenesis in the brain and is shown to be 
a functional coreceptor for HIV-1 and HIV-2 on astrocytes which are glial 
cells found in the central nervous system.[5] 
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 The literature states that only two receptors are used by the HIV virus, 
CCR5 and CXCR4, and that the antagonist molecule AMD3100 is highly 
specific for CXCR4[6], but no published work appears to exist on attempts to 
test the viability of D6 as a target for zinc(II) xylyl-bicyclam and other 
metallo-macrocycles.  The receptor CXCR4 has 33% sequence identity 
agreement with bovine rhodopsin.  A 17% sequence identity agreement is 
found between D6 and bovine rhodopsin with 46% alignment agreement 
overall.  This is sufficient for homology modelling purposes confirmed in a 
critical assessment.[7]  The overlap is significant as the folding matches well in 
terms of topology.  More recently, a crystal structure for another GPCR, the 
human Β2-adrenergic receptor has been reported[8, 9] and may provide an 
alternative template for the engineering of new models. 
 Preliminary work has produced a model for D6 (Figure 6.1) using 
bovine rhodopsin as a template and the same programs used to construct the 
CXCR4 model in order to compare both location and distances between 
binding site residues.  It is hoped this model might be used to look at 
possible binding interactions with the complexes synthesised in this thesis, to 
see if and how they might bind with this receptor.  This investigation would 
be useful in conjunction with biological testing for uptake of the complexes 
by cell lines known to express the D6 receptor and may be the first step 
toward investigating a possible different mode of action for anti-HIV 
activity.   
 The D6 receptor displays a similar binding site to CXCR4 with the 
exception of one aspartate residue substituted by glycine.  This would 
remove what is thought to be an important acidic residue necessary for 
metal-carboxylate binding, but substitution by glycine may provide a 
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suitable environment for hydrogen bonding between the carbonyl and 
macrocycle backbone, seen previously in studies of metal cyclams with 
binding to lysozyme.[10] 
 
 From the homology model of D6, a histidine residue (His 186) is found 
in the binding site and this may be a possible candidate for metal binding.  
Investigation into whether tryptophan residues W195 and W283 (present in 
the CXCR4 binding site) are conserved may lead to the further possibility of 
D6 being a viable target for antagonist molecules with anti-HIV or other 
antiviral activity.   
 
6.2.2. Zinc(II) constrained cyclam complexes 
 The most interesting discovery from this thesis was the identification 
of possible intermediates in the uptake and release of metals by cyclams and 
Figure 6.1   Location of residues involved in Zn(II)2-xylyl-bicyclam binding is shown on 
the model of CXCR4 in the left-hand side panel.  The location of equivalent residues in D6 




the ability to retain a single configuration in solution.  This work requires 
more analytical investigation to look at how different steric substituents can 
improve stabilisation and possibly lead to the isolation of a particular species 
through the retention of one configuration in solution.  If significant energy 
differences exist between the Zn-3N and Zn-4N bound complexes, further 
[1H, 15N] NMR work at low temperatures may reveal the lowest energy 
configuration.   
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7.1.   General Experimental 
 
7.1.1. Materials 
 Cyclam (1,4,8,11-tetraazacyclotetradecane), α-α’-dibromo-p-xylene, 
ethyl trifluoroacetate, triethylamine, zinc acetate dihydrate, zinc chloride, 
barium chloride, vanadyl sulfate hydrate, vanadyl acetylacetonate, sodium 
bromide, potassium iodide, sodium thiocyanate, sodium ammonium 
phosphate tetrahydrate, silver hexafluorophosphate, guanosine                     
5’-monophosphate disodium salt hydrate (from yeast) guanosine 3’,5-cyclic 
monophosphate sodium salt and NMR solvents, deuterium oxide (99.9%) 
and chloroform-d (99.9%) were purchased from Aldrich Chemical Co., and 
were reagent grade unless otherwise stated.   
 
7.1.2. Infrared spectroscopy 
 Infrared spectra were recorded as detailed in Chapter 2 and data are 
listed as the wavenumber (νmax) in units of cm-1. 
 
7.1.3. Thin layer chromatography 
 Analytical thin layer chromatography (TLC) was performed using 
aluminium backed plates with a coating of Merck Kieselgel 60 F254 silica.  
Chromatograms were inspected under ultraviolet light at 254 nm. 
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7.1.4. Flash column chromatography 
 Flash chromatography was performed[1] using Chromatography 
Grade Silica 60A Particle size 35-70 micron (Silica 60A) from Fisher Scientific 
and Sephadex LH-20 (Amsersham Biosciences) with methanol as the eluent. 
 
7.1.5. Mass spectrometry 
 Mass spectral analyses were carried out by the service provided by 
University of St. Andrew’s as described in Chapter 2. 
 
7.1.6. Nuclear Magnetic Resonance Spectroscopy 
 All NMR spectroscopy was obtained in deuterated solvents and 
carried out as described in Chapter 2.  Data listed contains the following 
abbreviations:  J = coupling constant (Hz), s (singlet), d (doublet), t (triplet), q 
(quartet), m (multiplet).  
 
7.1.7. Evaporation of solvents 
 All solvents are reagent grade or ultra-dry purchased from Sigma 
Aldrich.  The term “removed under reduced pressure” means that the 
solvent or solvents were removed from solutes under reduced pressure using 
a Buchi Rotovapor R-200.  The term “further dried under vacuum” refers to 
the situation where the former procedure was insufficient to remove all 
traces of solvent.  A high vacuum (approximately 1 mm Hg) was used to 
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remove final traces of solvent.  Organic extracts were dried with powdered, 
anhydrous magnesium sulfate unless otherwise stated. 
 
7.1.8. Nomenclature 
 Compounds in the experimental section are named according to 
IUPAC rules.  Numbers in bold in brackets refer to the number given to the 
compound name in Chapters 3-5. 
 
7.1.9. Crystallographic data 


















7.2. Synthesis of oxovanadium(IV) and zinc(II) macrocycle 
complexes 
 
Oxovanadium(IV)-1,4,8,11-tetraazacyclotetradecane sulfate (21) 
Cyclam, (1,4,8,11-tetraazacyclotetradecane, 913.50 mg, 4.56 mmol) was 
dissolved in HPLC Grade methanol (35 mL) and refluxed under 
N2 for 10 min.  Vanadyl sulfate hydrate (1.072 g, 4.56 mmol, 1 
mol. equiv.) was added and the reaction refluxed for 24 h.  On 
stirring, a colour change was observed from blue to green after 1 
min and to grey after 3 min.  After 15 min the solution turned cloudy green 
and after 30 min was blue/grey in colour.  After 2½ h this colour deepened to 
a dark blue/grey.  The solution settled into two layers.  The top layer was a 
vivid green solution and a blue precipitate settled out as the bottom layer.  
The top layer was separated using centrifuge then filtration and the solvent 
removed under reduced pressure to give a green powder (1.5 g, 4.13 mmol, 
90.6% yield).  The product was further dried under vacuum and crystals for 
X-ray were formed by slow diffusion of ether into a methanolic solution of 
the product at 4 ˚C.  Anal. Calc. for C10H24N4VSO5·MeOH·0.5H2O: %C, 32.70; 
%H, 6.23; %N, 13.86.  Found %C, 32.43; %H 6.49; %N 14.46.  ESI-MS: m/z = 
363.90 [M+H]+; νmax (KBr)/cm-1 V=O, 974; SO4, ν3 1106, 1064, 1028; ν4 619, 598. 
Oxovanadium(IV)-1,4,8,11-tetraazacyclotetradecane dichloride (22) 
Oxovanadium(IV) cyclam 21 (72.66 mg, 0.21 mmol), was dissolved in 
distilled water (10 mL) and barium chloride (62.48 mg,          
0.3 mmol, 3 mol. equiv. excess) added as an aqueous solution 
(4 mL).  A white precipitate formed immediately and the 
mixture was stirred at room temperature in air for 16 h.  The 











solution filtered.  The solvent was removed under reduced pressure and 
further dried under vacuum to give a crystalline green powder.  Crystals for 
X-ray were formed by slow diffusion of ether into a methanolic solution of 
the product at 4 ˚C (26 mg, 0.08 mmol, 36.6%).  Anal. Calc. for 
C10H24N4VOCl2·H2O %C, 33.70; %H, 7.35; %N, 15.70.  Found %C, 34.04; %H, 
7.22; %N 16.05.  ESI-MS: m/z = 302.10 (Cl35), 304.00 (Cl37) [M]+; νmax (KBr)/cm-1 
V=O, 945. 
Oxovanadium(IV)-1,4,8,11-tetraazacyclotetradecane·2PF6 (23) 
Oxovanadium(IV) cyclam dichloride 22 (250 mg, 0.74 mmol) was dissolved 
in 15 mL distilled water and stirred at room temperature.  
Silver hexafluorophosphate (374.18 mg, 1.48 mmol, 2 mol. 
equiv.) was added and an instant precipitate formed in the 
solution.  The mixture was stirred at room temperature for 1 h 
and separated using centrifugal force (4000 rpm, 30 min).  The solvent was 
removed by freeze-drying to give a crystalline green powder (156.74 mg,  
0.59 mmol, 80%).  Anal. Calc. for C10H26N4VO2·2PF6·AgPF6·CH3OH %C, 15.36; 
%H, 3.52; %N, 6.51.  Found %C, 15.56; %H, 3.47; %N 6.49.  ESI-MS: m/z = 
265.9  [M-H2O]+; νmax (KBr)/cm-1 V=O 949. 
Oxovanadium(IV)-1,4,8,11-tetraazacyclotetradecane dibromide (24) 
Oxovanadium(IV) cyclam 23 (13.35 mg, 0.05 mmol), was dissolved in 10 mL 
distilled water.  Sodium bromide (5.15 mg, 0.05 mmol, 1 mol. 
equiv.) was added and stirred at room temperature for 16 h.  
The mixture was separated using centrifugal force          
(4000 rpm, 30 min) and solvent was removed under reduced 
pressure to give a crystalline green powder (5 mg, 0.01 mmol, 11.8 %).  



















solution of the product at room temperature.  Anal. Calc. for 
C10H24N4VOBr2·AgPF6·2CH3OH %C, 19.37; %H, 4.34; %N, 7.53.  Found %C, 
19.59; %H, 3.28; %N 7.40.  ESI-MS:  m/z = 346.1 (Br79), 348.1 (Br81) [M]+; νmax 
(KBr)/cm-1 V=O, 949. 
Oxovanadium(IV)-1,4,8,11-tetraazacyclotetradecane iodide·PF6 (25) 
Oxovanadium(IV) cyclam 23 (13.35 mg, 0.05 mmol) was dissolved in 10 mL 
distilled water.  Potassium iodide (8.30 mg, 0.05 mmol,         
1 mol. equiv.) was added and stirred at room temperature 
for 16 h.  The mixture was filtered and solvent was removed 
under reduced pressure with further drying under vacuum 
to give a crystalline green powder (12.75 mg, 0.03 mmol, 64.7%).  Crystals for 
X-ray were formed by slow diffusion of ether into a methanolic solution of 
the product at room temperature.  Anal. Calc. for C10H24N4VOI·PF6 %C, 
15.17; %H, 3.05; %N, 7.07.  Found %C, 15.18; %H, 2.64; %N 6.75.  ESI-MS:  m/z 
= 394.1 [M]+; νmax (KBr)/cm-1 V=O  948. 
Oxovanadium(IV)-1,4,8,11-tetraazacyclotetradecane thiocyanate·PF6 (26) 
Oxovanadium(IV) cyclam 23 (20.02 mg, 0.075 mmol) was dissolved in 10 mL 
distilled water.  Sodium thiocyanate (6.08 mg, 0.075 mmol,      
1 mol. equiv.) was added and stirred at room temperature for 
5 h.  The mixture was filtered and the solvent removed under 
reduced pressure with further drying under vacuum to give a 
green powder (25 mg, 0.05 mmol, 70.9 %).  Crystals for X-ray were formed by 
slow diffusion of ether into a methanolic solution of the product at room 
temperature.  Anal. Calc. for C11H24N5VOS·PF6·3AgPF6 %C, 10.75; %H, 1.97; 
%N, 5.70.  Found %C, 11.53; %H, 2.21; %N 6.49.  ESI-MS:  m/z = 325.1 [M]+; 



















Oxovanadium(IV)-1,4,8,11-tetraazacyclotetradecane phosphate (27) 
Oxovanadium(IV) cyclam 23 (13.35 mg, 0.05 mmol) was dissolved in 10 mL 
distilled water.  Sodium ammonium phosphate tetrahydrate 
(10.45 mg, 0.05 mmol, 1 mol. equiv.) was added and stirred at 
room temperature for 16 h.  The mixture was filtered and the 
solvent removed under reduced pressure with further drying 
under vacuum to give a pale green powder (10 mg, 0.03 mmol, 55%).  Anal. 
Calc. for C10H24N4VO5·NH4PF6·2CH3OH %C, 24.41; %H, 6.32; %N, 11.86.  
Found %C, 26.40; %H, 5.53; %N 11.97.  ESI-MS:  m/z = 364.0 [M+H]+; νmax 
(KBr)/cm-1 V=O,  933. 
Oxovanadium(IV)-1,4,8,11-tetraazacyclotetradecane guanosine 
monophosphate (GMP) (28) 
Oxovanadium(IV) cyclam 23 (13.35 mg, 0.05 mmol) was dissolved in 10 mL 
distilled water.  GMP (20.36 mg, 0.05 mmol, 1 mol. equiv.) 
was added and stirred at room temperature for 2.5 h.  The 
mixture was filtered and the solvent removed under 
reduced pressure to give a green powder (20 mg, 0.03 mmol, 
59%).   Anal. Calc. for C20H36N9VO8·PF6·AgCl·H2O %C, 26.15; 
%H, 4.17; %N, 13.72.  Found %C, 25.72; %H, 3.79; %N 13.60.  ESI-MS:  m/z = 
651.0 [M+Na]+; νmax (KBr)/cm-1 V=O 985, C=O 1695.  
Oxovanadium(IV)-1,4,8,11-tetraazacyclotetradecane cyclic guanosine 
monophosphate (cGMP) (29) 
Oxovanadium(IV) cyclam 23 (20.02 mg, 0.075 mmol) was dissolved in 10 mL 
distilled water.  cGMP (27.54 mg, 0.075 mmol, 1 mol. equiv.) 
was added and stirred at room temperature for 5 h.  The 

























removed by freeze-drying to give a green powder  (17 mg,  0.03 mmol, 
35.7%).  Anal. Calc. for C20H35N9VO8·PF6·AgCl %C, 26.70; %H, 3.92; %N, 
14.01.  Found %C, 26.85; %H, 3.74; %N 13.61.  ESI-MS:  m/z = 611.2 [M]+; νmax 
(KBr)/cm-1 V=O  968, C=O 1698. 
1-1’-[1,4-phenylenebis(methylene)]-bis(1,4,8,11-tetraazacyclo- 
tetradecane) (16) 
For the first step and protection of the NH groups, cyclam (2.02 g, 10.08 
mmol) was dissolved in methanol 
(8 mL) and stirred under an argon 
atmosphere.[2]  Triethylamine (1.4 
mL, 1 mol. equiv.) was added 
resulting in a pale yellow solution.  
The solution was cooled in an ice 
bath and ethyl trifluoroacetate (4 mol. equiv., 40.32 mmol, 4.82 mL) was 
added dropwise over 10 min.  After 1 h the ice bath was removed and the 
reaction was stirred at room temperature for a further 4 h.  The solvent was 
removed under reduced pressure and further dried under vacuum.  The 
resulting sticky residue was dissolved in ethyl acetate and passed through a 
silica plug (8 g) and the solvent removed under reduced pressure.  Further 
drying under vacuum resulted in a white foam (2.2 g, 4.5 mmol, 44.6%).  ESI-
MS: m/z = 489.2 [M+H]+.  1H NMR (250 MHz, CDCl3): 3.91-3.47 (m, 12H), 3.17-
2.65 (m, 4H), 2.30-1.73 (m, 4H).  
 For the second step and dimerisation with an aromatic linker, tri-
protected cyclam (2.2 g, 4.5 mmol) was dissolved in ultra-dry acetonitrile 
(100 mL) under an argon atmosphere and potassium carbonate (3 mol. 
















xylene (0.594 g, 2.25 mmol, 0.5 mol. equiv.) the reaction was refluxed for 24 h.  
The resulting cloudy mixture was filtered and the solvent removed under 
reduced pressure.  The product was paritioned with water (30 mL) and 
dichloromethane (100 mL) and the aqueous layer was washed with portions 
of dichloromethane (3 x 50 mL).  The combined organic layers were dried 
over MgSO4.  The solution was filtered and the solvent removed under 
reduced pressure to give an off-white powder.  The product was purified by 
column chromatography on silica gel using a 9:1 ratio of ethyl 
acetate:hexane.  The solvent was removed under reduced pressure to give a 
white solid (2.80 g, 2.6 mmol, 57.7%).  ESI-MS: m/z = 1079.8 [M+H]+.  1H NMR 
(250 MHz, CDCl3): 7.23-7.10 (m, 4H), 3.83-3.25 (m, 24H), 2.85-1.54 (m, 20H). 
 For the final step, deprotection was achieved by dissolving the hexa-
protected bicyclam (2.80 g, 2.6 mmol) in methanol (15 mL) and adding 10% 
NaOH (15 mL).  A white precipitate formed immediately that disappeared 
on stirring.  The solution was stirred for 6 h at room temperature to give a 
colourless solution.  The aqueous layer was extracted with chloroform          
(3 x 50 mL) and the organic layer dried with sodium sulfate.  After filtration, 
the solvent was removed under reduced pressure to give a white powder 
(1.90 g, 3.78 mmol, 68.8%).  ESI-MS:  m/z = 504.1 [M+H]+.  1H NMR (250 MHz, 
CDCl3): 7.50-7.32 (m, 4H), 3.83 (s, 4H), 3.32-2.70 (m, 32H), 2.18-2.08 (m, 4H), 
1.92-1.78 (m, 4H). 
Oxovanadium(IV)-1-1’-[1,4-phenylenebis(methylene)]-bis(1,4,8,11-
tetraazacyclotetradecane) disulfate (30) 
 Xylyl-bicyclam (16) (50.2 mg, 0.1 mmol) was dissolved in 5 mL 
anhydrous methanol and refluxed gently under argon for 5 min.  Vanadyl 
sulfate hydrate (47 mg, 0.2 mmol, 2 mol. equiv.) was added and a colour 
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change was observed, both in the solution and in the solid added.  After 3 
mins the initial clear solution 
began to turn green and the blue 
solid (vanadyl sulfate hydrate) 
turns grey.  After 15 min, the 
reaction becomes more 
homogenous and the colour 
darkens to brown.  On standing, 
the flask contents settled into two layers with a pale green solution forming 
on top of the dark solid.  The reaction was refluxed for 16 h and the solution 
on standing was green in colour.  The dark solid changed colour to light 
blue.  The green solution was separated from the blue solid under centrifugal 
force, 4000 rpm, 1 h and the solvent removed under reduced pressure and 
further dried under vacuum.  The product dried to give a dark green powder 
(51.3 mg, 0.06 mmol, 61.88%).  Anal. calc. for C28H54N8V2S2O10·MeOH·3H2O, 
%C 38.07, %H 7.05, %N 12.25, Found %C 37.53, %H 7.29, %N 11.67.  ESI-MS: 
m/z = 829.1 [M+H]+; νmax (K/Br)cm-1 V=O 945; SO42- ν3 1120, 1034; ν4 615. 
Oxovanadium(IV)-1-1’-[1,4-phenylenebis(methylene)]-bis(1,4,8,11-
tetraazacyclotetradecane) tetrachloride (31) 
Oxovanadium(IV)-(xylyl-bicyclam)-sulfate 16, (51.3 mg, 0.06 mmol) was 
dissolved in water (3 mL) and 
heated until fully dissolved.  
Barium chloride (24.99 mg, 
0.12 mmol, 2 mol. equiv.) was 
added as an aqueous solution 
(2 mL) and a cloudy solution 








































temperature then separated under centrifugal force to give a green solution 
and a blue solid.  The green solution was decanted, filtered and the solvent 
was removed by freeze-drying.  On drying, a colour change was noted from 
green to brown and on redissolving in water a green solution is obtained    
(35 mg, 4.5 mmol, 75%).  CHN analysis cannot be quoted as product is 
suspected to be an oligomer of varying polymer units.  ESI-MS: m/z = 705.4 




Oxovanadium(IV)-bicyclam chloride (31) (30.25 mg, 0.04 mmol) was 
dissolved in 8 mL HPLC Grade 
methanol at room temperature.  
An aqueous solution (2 mL) of 
silver hexafluorophosphate      
(40.45 mg, 0.16 mmol, 4 mol. 
equiv.) was added and an 
instant white precipitate was 
observed.  The reaction was stirred at room temperature for 16 h.  The 
solution was separated under centrifugal force (4000 rpm, 30 min) resulting 
in a green solution and white solid.  The green solution was filtered and the 
solvent removed under reduced pressure.  The product was further dried 
under vacuum and dried to a green powder (10 mg, 0.02 mmol, 40%).  Anal. 
Calc. for C28H58N4V2O4·4PF6·CH3OH %C, 27.11; %H, 4.86; %N, 8.72.  Found 

























 This ligand was prepared and kindly donated 
by Dr S J Paisey, University of Edinburgh.  νmax 
(K/Br)cm-1  NH 3423 (br); 1H NMR (250 MHz): 
1.90 (4H, m, 2 x CH2), 3.15 (16H, m, 8 x CH2), 
4.20 (2H, s, CH2), 7.40 (3H, m, 3 x CH), 7.83 




Naphthyl-cyclam 33 (48.55 mg, 0.1 mmol) was dissolved in HPLC Grade 
MeOH (20 mL) and refluxed under argon 
until dissolution was complete.  Vanadium 
acetylacetonate (26.52 mg, 0.1 mmol, 1 mol. 
equiv.) was added and the colourless 
solution turned green.  The mixture was 
refluxed for 16 h with no other colour 
changes observed.  The green solution was 
filtered and the solvent removed under 
reduced pressure with further drying under 
vacuum.  This resulted in a green, 
crystalline material (20 mg, 0.03 mmol, 33.7%).  ESI-MS: m/z = 481.54 [M-


























(5,16-dimethyl-2,6,13,17-tetraazatricyclo [14,4,01.18,07.12]docosane (35) 
Hexyl-Me2-cyclam 35, was synthesised as described in the literature [3, 4] and 
kindly donated by Professor Jong-Ha Choi, 
Department of Chemistry, Andong National 
University, Andong 760-749, South Korea.  
Anal. Calc. for C20H40N4 %C 71.37, %H 11.98, 
%N 16.65.  Found %C 71.54, %H 12.04, %N 
17.07.  1H NMR (600 MHz): 0.68 (2H, m, 2 x CH), 
0.75 (2H, m, 2 x NH), 0.90 (2H, m, 2 x CH), 0.95 (6H, s, 2 x CH3), 1.20 (4H, m, 
2 x CH2), 1.65 (4H, m, 2 x CH2), 1.70 (4H, m, 2 x CH2), 2.05 (2H, m, 2 x CH), 
2.12 (2H, d, J 13.22, 2 x CH), 2.20 (2H, d, J 13.60, 2 x CH), 2.29 (2H, m, 2 x CH), 
2.50 (2H, t, J 12.09, 2 x CH), 2.85 (2H, t, J 12.09, 2 x CH), 3.35 (2H, s, 2 x CH), 
3.65 (2H, bd, J 11.33, 2 x NH). 
Zinc(II)-(5,16-dimethyl-2,6,13,17-tetraazatricyclo [14,4,01.18,07.12]- docosane 
diacetate (36) 
Hexyl-Me2-cyclam 35 (33.76 mg, 0.1 mmol) was dissolved in HPLC Grade 
MeOH (20 mL) and stirred at room temperature.  
Zinc acetate dihydrate (30.73 mg, 0.1 mmol,        
1 mol. equiv.) was added and the resulting 
colourless mixture refluxed for 2 h.  The solution 
was filtered and the solvent removed under 
reduced pressure with further drying under 
vacuum.  The product was a white powder (16 mg, 0.03 mmol, 30.8%) and 
crystals formed from the slow evaporation of CHCl3 at room temperature.  
Anal. Calc. for C22H46N4O4Zn·0.5H2O %C 54.48, %H 8.90, %N 10.59.  Found 




























(100%); νmax (K/Br)cm-1: H-bonding 3405 (br); NH 3243, 3180; COOas 1567, 
COOs 1412.  1H NMR (600 MHz): 0.95 (2H, m, 2 x CH), 1.05 (2H, m, 2 x CH), 
1.20 (6H, d, J 6.80, 2 x CH3), 1.28 (4H, m, 4 x CH), 1.67 (2H, dt, J 4.53, 2 x CH), 
1.75 (4H, m, 4 x CH), 1.95 (6H, s, 2 x CH3), 2.08 (2H, t, J 14.35, 2 x CH), 2.18 
(2H, d, J 13.22, 2 x CH), 2.30 (2H, d, J 13.22, 2 x CH), 2.50 (2H, m, 2 x CH), 2.55 
(2H, m, 2 x CH), 2.75 (2H, q, J 12.09, 2 x CH), 3.10 (2H, d, J 11.71, 2 x CH), 3.49 
(2H, s, 2 x CH), 3.79 (2H, bd, J 10.58, 2 x NH), 4.51 (2H, bs, 2 x NH).  13C NMR 
(600 MHz): 17.0, 27.2, 28.1, 31.8, 32.3, 37.0, 43.0, 49.8, 53.5, 58.9, 62.6.   
Zinc(II)-(5,16-dimethyl-2,6,13,17-tetraazatricyclo [14,4,01.18,07.12]- docosane 
dichloride (37) 
Hexyl-Me2-cyclam 35 (33.66 mg, 0.1 mmol) was dissolved in HPLC Grade 
MeOH (20 mL) and refluxed under argon until 
dissolution complete.  Zinc chloride (13.63 mg, 
0.1 mmol, 1 mol. equiv.) was added and the 
mixture refluxed for 6 h.  The resulting clear 
solution was filtered and the solvent removed 
under reduced pressure with further drying 
under vacuum.  The product was a white powder (37.10 mg, 0.08 mmol, 
78.7%).  Anal. Calc. for C22H46N4O4ZnCl2·2H2O %C 47.20, %H 8.72, %N 11.01.  
Found %C 47.03, %H 8.56, %N 10.32.  ESI-MS: m/z = 435.2 [M-Cl]+; νmax 
(K/Br)cm-1: H-bonding (br) 3367; NH 3292, 3172.  13C NMR (600 MHz): 17.7, 
19.5, 27.1, 27.4, 27.9, 31.8, 32.4, 32.8, 33.3, 37.0, 38.4, 43.2, 45.3, 49.2, 50.2, 53.1, 





















Zinc(II)-(5,16-dimethyl-2,6,13,17-tetraazatricyclo [14,4,01.18,07.12]- docosane 
diphosphate (38) 
Zinc(II)-hexyl-Me2-cyclam dichloride 37 (37.10 
mg, 0.08 mmol) was dissolved in distilled 
water (10 mL) and stirred at room 
temperature.  Silver hexafluorophosphate  
(20.23 mg, 0.08 mmol, 1 mol. equiv.) was 
added and an immediate white precipitate 
was formed.  The mixture was stirred at room temperature for 1 h and the 
solution filtered to remove the precipitate. Sodium ammonium phosphate 
tetrahydrate was added (33.45 mg, 0.16 mmol, mol. equiv.) and stirred at 
room temperature for 16 h.  The solution was filtered and the solvent 
removed under reduced pressure with further drying under vacuum.  The 
product was a white powder (40.6 mg, 0.07 mmol, 68.5%) and crystals 
formed from a methanolic solution with diffusion of diethyl ether.  No CHN 
available due to decomposition.  ESI-MS:  m/z = 497.2 [M]+; νmax (K/Br)cm-1:  
H-bonding (br) 3421; NH 3224; P=O 1400; P-O 1084; P-F 841, 742; O-P-O 482.   
[2,13-N,N’-dinaphthyl 5,16-dimethyl-2,6,13,17-tetraazatricyclo- 
[14,4,01.18,07.12] docosane (39) 
Naphthyl-hexyl-Me2-cyclam 39, was synthesised according to a published 
procedure [5] and with addition of 1-
chloromethyl naphthalene.  The ligand was 
kindly donated by Professor Jong-Ha Choi, 
Department of Chemistry, Andong National 
University, Andong 760-749, South Korea.  
Anal. calc. for C42H56N4 %C 81.77, %H 9.15,  




























1H NMR (600 MHz):  0.9 (6H, s, 2 x 3H), 0.95 (2H, m, 2 x CH), 1.3 (6H, m, 6 x 
6H), 1.39 (2H, bd, J 11.71, 2 x CH), 1.72 (6H, m, 6 x CH), 2.06 (4H, m, 4 x CH), 
2.49 (2H, m, 2 x CH), 2.59 (2H, s, 2 x CH), 2.73 (2H, d, J 11.71, 2 x CH), 2.82 
(2H, d, J 9.06,  2 x CH), 3.1 (2H, d, J 11.33, 2 x NH), 3.27 (4H, d, J 10.58, 4 x 
CH), 4.48 (4H, d, J 11.33, 4 x CH), 7.4 (2H, m, 2 x CH), 7.49 (2H, s, 2 x CH), 
7.64 (2H, bs, 2 x CH), 7.81 (4H, m, 4 x CH), 9.60 (2H, m, 2 x CH).  13C NMR 
(600 MHz):  (aliph) 22.3, 22.9, 27.2, 28.1, 32.1, 36.0, 52.1, 52.7, 53.6, 55.5, 62.3, 
(arom) 127.7, 128.1, 129.0, 130.2, 130.4, 130.6, 132.0.  15N NMR (600 MHz):  
56.6. 
Zinc(II)-[2,13-N,N’-dinaphthyl 5,16-dimethyl-2,6,13,17-tetraazatricyclo- 
[14,4,01.18,07.12] docosane diacetate (40) 
 Naphthyl-hexyl-Me2-cyclam 39 (123.38 mg, 0.2 mmol) was dissolved in 
ultra-dry acetonitrile (35 mL) and refluxed 
under argon until dissolution complete.  The 
compound is not fully soluble at this stage.  
Zinc acetate dihydrate (43.90 mg, 0.2 mmol,  
1 mol. equiv.) was added to the flask and the 
mixture refluxed for 16 h.  The solution was 
filtered and the solvent removed under 
reduced pressure with further drying under 
vacuum (65 mg, 0.08 mmol, 40.67%). Anal. calc. for 
C44H62N4O4Zn·2ZnOAc·CH3OH %C 56.65, %H 6.71, %N 5.18.  Found %C 
56.14, %H 6.01, %N 5.27.  ESI-MS: m/z = 739.2 [M-OAc]+; νmax (K/Br)cm-1:  H-




















tricyclo[14,4,01.18,07.12] docosane dichloride (41) 
 Naphthyl-hexyl-Me2-cyclam 39 (61.69 mg, 0.1 mmol) was dissolved in ultra-
dry CH3CN (30 mL) and refluxed under 
argon until dissolution was complete.  Zinc 
chloride (13.63 mg, 0.1 mmol, 1 mol. equiv.) 
was added and the mixture refluxed for 3 h.  
The resulting clear solution was filtered and 
the solvent removed under reduced pressure 
with further drying under vacuum.  The 
product was a pale pink/white powder       
(60 mg, 0.08 mmol, 79.9%) and colourless block crystals formed from a 
methanolic solution diffused with diethyl ether.  Anal. calc. for 
C42H56N4ZnCl·PF6 %C 58.47, %H 6.54, %N 6.49.  Found %C 58.48, %H 6.63, 
%N 6.54.  ESI-MS: m/z = 717.4 [M+H]+.  νmax (K/Br)cm-1:  H-bonding (br) 3467; 
NH 3244, 3157, 3057.  15N (600 MHz):  47.9, 55.9, 56.9, 58.8, 62.6.       
Zinc(II)-[2,13-N,N’-dinaphthyl 5,16-dimethyl-2,6,13,17-tetraaza-tricyclo-
[14,4,01.18,07.12] docosane diphosphate (42) 
Zinc(II)-naphthyl-hexyl-Me2-cyclam dichloride 41 (30 mg, 0.04 mmol) was 
dissolved in HPLC Grade MeOH (5 mL) and 
stirred at room temperature.  Silver 
hexafluoro-phosphate (10.12 mg, 0.04 mmol, 
1 mol. equiv.) was added and an immediate 
white precipitate was formed.  The mixture 
was stirred for 1 h and the resulting pink 
solution was separated under centrifugal 































phosphate tetrahydrate was added (7.0 mg, 0.04 mmol, 1 mol. equiv.) and 
refluxed under argon for 16 h.  The solution was separated under centrifugal 
force, 4000 rpm, 10 min, then decanted and filtered.  The solvent was 
removed under reduced pressure with further drying under vacuum.  The 
product was a white powder (11 mg, 0.01 mmol, 31.5%) that quickly 
decomposed in air, so no CHN analysis is available.  ESI-MS: m/z = 763.2 
[M+2H]+; νmax (K/Br)cm-1: H-bonding (br) 3440; NH 3224; P=O 1400; P-O 1205, 
1142, 1082; P-F 839; O-P-O 557.  
 
7.3. Antibody Competition Binding Tests 
 These experiments were carried out by Dr Steve Archibald, 
Departments of Chemistry and Medical Biology, University of Hull, Hull, 
UK.  Cell cultures, assays and flow cytometry were carried out by Mr Abid 
Khan, a PhD student of Dr Steve Archibald. 
 
7.3.1. Cell cultures 
 Human leukaemia T cell lymphoblasts (Jurkat) were obtained from 
the MRL (University of Hull, Hull, UK).  These cells were cultured in RPMI 
1640 medium (Invitro technologies, UK) containing 10% (v/v) heat 
inactivated fetal bovine serum (FBS)(Biowest, France), 1% glutamate (2mM), 
1% (v/v) penicillin and streptomycin (100 units/mL) antibiotics.  The cell 
cultures were maintained at 37oC in a humidified, CO2 (5%) controlled 
atmosphere with subculturing done every 2-3 days as appropriate.  
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7.3.2. Antibodies, chemokines and fluorescent dyes  
 Unconjugated mouse anti-human CXCR4 mAb clones 44708.111, 
44716.111, 44717.111 and 12G5 were purchased from R & D systems Europe, 
Abingdon, UK.  Negative control mouse IgG and the secondary fluorescein 
isothiocyanate conjugated anti-mouse antibody (IgG-FITC) were purchased 
from Serotec, UK.  Dilutions of mAbs were prepared using PBS 
supplemented with 0.25% (v/v) BSA and 0.01 M NaN3.  All reagents, 
antibodies, chemokines and fluorescent dyes were reconstituted and stored 
according to the manufacturer’s instructions unless otherwise stated. 
7.3.3. Assay to measure displacement of antagonist with anti-CXCR4       
 antibodies by flow cytometry 
 Cell cultures were centrifuged (180 x g for 3 min), re-suspended in    
10 mL PBS and centrifuged (180 x g, 3 m).  The cell pellet was re-suspended 
in 1.0 mL PBS and counted using the Trypan-blue test.  Cells at a density of 
2.0 – 2.5 x 105 cells were aliquoted into polypropylene FACS tubes (Falcon 
2054 tubes), the cell solution was then incubated with 10 µL of the antagonist 
compound (20 µM) (or PBS for the controls) for 30 min at 4oC.  The cells were 
washed with 1.0 mL PBS (centrifuged at 180 x g, 3 m) to remove excess 
compound.  They were then incubated with 10 µL of the appropriate 
concentration of antibody (10 & 1 µg/mL) for 1 hr at 4oC.  Cells were again 
washed (centrifuged at 180 x g, 3 m) with 1.0 mL PBS/0.25% BSA/0.01 M 
NaN3 and incubated with the secondary fluorescein isothiocyanate 
conjugated anti-mouse antibody (IgG-FITC) (diluted 1:100 in PBS/0.25% 
BSA/0.01 M NaN3), 30 m, 4oC.  After further washing (centrifuged at 180 x g, 
3 m) with 1.0 mL PBS/0.25% BSA/0.01 M NaN3, cell samples were fixed in  
300 µL of PBS/0.25% BSA/0.01 M NaN3 and analysed on a FACScan flow 
cytometer (BD Biosciences Europe, Erembodegem, Belguim).  Data were 
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acquired and analysed with CellQuest software (Becton Dickinson) on an 
Apple Macintosh computer.  As a negative control for non specific 
background staining, the cells were stained in parallel with the negative 
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